Contents Section I: Embryology Chapter 1. Gametogenesis .............................................. 3 Chapter 2. Fer...
122 downloads
1979 Views
10MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Contents Section I: Embryology Chapter 1. Gametogenesis .............................................. 3 Chapter 2. Fertilization ................................................. 7 Chapter 3. First Week .................................................. 9 Chapter 4. Second Week .............................................. 11 Chapter 5. Third Week ................................................ 15 Chapter 6. Fourth to Eighth Weeks ...................................... 19 Chapter 7. Ninth Week to Parturition .................................... 25 Chapter 8. Fetal Membranes and Placenta ................................ 29 Chapter 9. Body Cavities and Mesenteries ................................ 35 Chapter 10. Pharyngeal Arches and Their Derivatives ....................... 39 Chapter 11. Congenital Abnormalities .................................... 45
Section II: Histology Chapter 1. Epithelium ................................................. 53
Section III: Pathology Chapter 1. General Pathology .......................................... 61
KAPLAlf I me d lea
vii
Section IV: Pharmacology Chapter 1. Pharmacodynamics and Pharmacokinetics ..................... 85 Chapter 2. Autacoids ............................................... 95 Chapter 3. Lead Toxicity and Chelating Agents .......................... 113 Chapter 4. Antineoplastic Agents ..................................... 117
Section V: Behavioral Sciences Chapter 1. The Basics of Behavioral Sciences ........................... 139 Chapter 2. Brain-Behavior Correlations ................................ 145 Chapter 3. Defining the Mind ....................................... 157 Chapter 4. Human Development and Sociocultural Issues ................. 163 Chapter 5. Medical Ethics .......................................... 193 Chapter 6. Psychopathology ........................................ 199
Section VI: U.S. Health Care Chapter 1.
u.s. Health Care ......................................... 241
Section VII: Biostatistics and Epidemiology Chapter 1. Biostatistics ............................................. 249 Chapter 2. Epidemiology ........................................... 263
Index .................................................................... 269
•••
VIII
KAPLA~. I meulca
SEmoN I
Embryo ogy
Gametogenesis
Gametogenesis is the process whereby specialized sex cells (gametes) are produced. Spermatogenesis refers to a series of changes through which spermatogonia differentiate into spermatozoa in the seminiferous tubules of the testes. Oogenesis refers to the series of changes through which oogonia differentiate into oocytes in the ovaries. During gametogenesis, there are changes in DNA content and cellular morphology; these changes are the result of two processes: meiosis and morphologic maturation. During meiosis, the chromosome number and DNA content of the cell are reduced by half, and genetic recombination occurs. During morphologic maturation, the sperm prepares for its motile role, and the egg prepares to support embryologic development. This chapter reviews the processes of meiosis, spermatogeneis, and oogenesis.
MEIOSIS A. Gonocyte primordia. The primitive germ cells contain a 2n (diploid) complement of DNA, consisting of 44 autosomes and two sex chromosomes. 1. Before the onset of meiosis, the DNA replicates, and the cell contains twice the normal
amount of DNA (4n complement). 2. Each of the 46 chromosomes is present as a pair of chromatids joined together at the centromere. B. First meiotic division 1. During prophase of the first meiotic division, homologous chromosomes pair with each
other (synapsis); each homologous pair consists of four chromatids. a. While the homologous chromosomes are paired, there is an interchange of chromatid segments between the two paired chromosomes (crossing over) that leads to genetic recombination. b. In contrast, during mitosis, homologous chromosomes do not pair, and genetic recombination does not occur. 2. The first meiotic division results in a pair of daughter cells, each containing 23 chromosomes (i.e., one member of each homologous pair) but a 2n amount of DNA because each chromosome consists of two chromatids. C. Second meiotic division occurs without prior DNA synthesis. During this process, each of
the 23 chromosomes divides at the centromere and gives rise to two haploid (n) daughter cells, each containing 23 chromosomes and a haploid amount of DNA.
KULA!._
I
meulC8
1
Embryology
) (23,2n) ("P
/
l!
\*
"'".v
Cell division '! Alignment and
, disjunction Centromeres split
Gamete
Figure 1-1-1. Meiosis.
Clini(al Correlate Down syndrome (trisomy 21) is caused by nondisjunction, resulting in three copies of chromosome 21. Common clinical features include mental retardation, short stature, flat nasal bridge, and epicanthal folds.
4
KAPLA~. I meulca
D. Nondisjunction refers to an abnormality in either the first or second meiotic division that is characterized by a failure of a homologous pair of chromatids to separate. 1. The result is the production of gametes containing 22 and 24 chromosomes instead of the normal 23. 2. Nondisjunction appears to be a more common abnormality in germ cells of women than in those of men.
Gametogenesis
SPERMATOGENESIS Spermatogenesis is the process of male gamete formation-from spermatogonia to spermatozoa. A. Primordial germ cells (46 chromosomes, 2n) migrate during embryonic life from the yolk sac wall into the primitive testes, where they become surrounded by the primitive supporting Sertoli cells.
B. Spermatogonia and spermatocyte formation 1. Just before puberty, the primordial germ cells (now called gonocytes) differentiate to form the spermatogonia (46 chromosomes, 2n) in the seminiferous tubules of the testes.
2. The spermatogonia divide by mitosis and ultimately give rise to the primary spermatocytes, which undergo meiosis. a. Early in the formation of primary spermatocytes, DNA is replicated; spermatocytes then contain 46 chromosomes and a 4n amount of DNA. b. After a prolonged prophase, spermatocytes complete their first meiotic division, giving rise to a pair of approximately equal-sized secondary spermatocytes (23 chromosomes,2n). C. Spermatid formation. Secondary spermatocytes quickly begin the second meiotic division. 1. Each cell gives rise to two approximately equal-sized spermatids (23 chromosomes, n).
2. Thus, a single primary spermatocyte gives rise to four approximately equal-sized spermatids. D. Spermiogenesis is the process in which the spermatids undergo morphologic differentiation to form spermatozoa. 1. This process includes loss of most of the spermatid cytoplasm, condensation of the nucleus in the sperm head, formation of the acrosome cap over the nucleus, and movement of the centrioles opposite to the acrosomal cap.
2. The spermatozoon consists of a head, neck, and tail. a. The head is formed by the nucleus and is covered by the acrosome and cell membrane. b. The neck contains two centrioles. c. The tail (flagellum) consists of a central axoneme composed of a pair of central microtubules and surrounded by a concentric ring of nine doublets (9 x 2 + 2 arrangement).
In a Nutshell The process of spermiogenesis includes loss of most of the cell cytoplasm, condensation of the nucleus to form the sperm head, formation of the acrosome cap over the nucleus, and movement of the centrioles opposite the acrosomal cap.
( 1) Proximally in the middle piece of the tail, the axoneme is surrounded by an inner
layer of dense fibers and an outer layer of mitochondria arranged in a circular helix. (2) Distally in the principal piece of the tail, the axoneme is surrounded by dense fibers and an outer fibrous sheath. (3) At the terminal end of the tail, a short end piece consists only of the axoneme covered by the cell membrane. 3. Spermatozoa are released from the Sertoli cells and enter the lumina of the seminiferous tubules. a. Spermatozoa are transported from the testis via the straight tubules, rete testis, and efferent ductules to the duct of the epididymis. This process occurs as a result of the combination of fluid production by the testis, contractile elements in the testes, ciliated cells in the efferent ductules, and smooth muscle in the epididymis. b. Spermatozoa in the epididymis undergo further maturation and acquire their potential for motility and fertilization.
KAPLAtf I me illea
5
Embryology
In a Nutshell
OOGENESIS
In males, spermatogenesis does not begin until puberty; in females, oogenesis begins before birth, enters a stage of arrested development until puberty, and is not fully completed unless fertilization occurs.
Oogenesis is the process of female gamete formation-from oogonia to oocytes. A. Primordial germ cells. By the fifth week of fetal life, primordial germ cells migrate from the yolk sac wall into the primitive ovaries and contain 46 chromosomes and a diploid amount of DNA. B. Oogonia and oocyte formation l. In the gonad, the primordial germ cells differentiate into oogonia (46 chromosomes, 2n).
a. By the end of the first trimester, the oogonia undergo several mitotic divisions in the ovarian cortex. b. After the mitotic divisions, oogonia differentiate to form the primary oocytes. 2. The DNA of the primary oocytes is then replicated, resulting in tetraploid cells (46 chromosomes, 4n). a. The oocytes then begin the prophase of their first meiotic division, which is nearly complete at about the time of birth.
Note Prophase I can be further divided into the following stages: preleptotene, leptotene, zygotene, pachytene, diplotene, and diakinesis.
b. Instead of continuing on into metaphase, all of the female gametes at birth are primary oocytes arrested in late prophase I of meiosis, and crossing over has already occurred. c. Primary oocytes remain in the diplotene stage of prophase I in primordial follicles until puberty.
c. Maturation of primordial follicles 1. At puberty, a few primordial follicles begin to mature during each ovarian cycle, although only one usually fully matures. 2. Once the follicle is mature, the primary oocyte re-enters the first meiotic division, which it completes shortly before ovulation. This division leads to the formation of two unequal cells: the secondary oocyte and the first polar body. a. Although both cells contain an equal number of chromosomes (46) and DNA content (2n), the secondary oocyte receives almost all of the cytoplasm. b. The fate of the first polar body remains uncertain. 3. As soon as the secondary oocyte is formed, it enters the second meiotic division and is released from the ovary during ovulation as soon as it shows spindle formation. a. This division is completed only if fertilization occurs. If fertilization does not occur, the secondary oocyte will begin to degenerate within 12-36 hours after ovulation. b. Division of the secondary oocyte after fertilization produces the second polar body and the ovum (23 chromosomes, n), which contains the female pronucleus and almost all of the cytoplasm from the secondary oocyte.
6
IlPLA!._
I
meulC8
Fertilization
Fertilization is the fusion of the male and the female gametes. It usually occurs in the widest portion (ampulla) of the uterine tube (oviduct, fallopian tube). Once shed, the ovum is viable for about 24 hours; therefore, the fusion of sperm and egg must occur within 1 day of ovulation for fertilization to occur. Fertilization is a complex process that involves preparatory phases for spermatozoa, which are incapable of fertilization when they arrive in the female tract, entry of the sperm into the egg, and fusion of the male and female genetic material. This chapter reviews the events that lead up to and complete the process of fertilization.
CAPACITATION AND ACROSOME REACTION For a spermatozoon to fertilize the ovum, it must undergo capacitation and the acrosome reaction. A. Capacitation is the removal, in the female reproductive tract, of various factors that coat and cover the acrosomal portion of the sperm plasma membrane. B. Acrosome reaction is the process of acrosome enzyme release that occurs when the sper-
matozoon binds to the zona pellucida of the female gamete. This reaction is required for the spermatozoon to penetrate the zona pellucida.
ENTRY OF THE SPERMATOZOON A. Inhibition of polyspermy. After the entry of one sperm into the zona pellucida and fusion of the sperm and egg cell membranes, important enzymatic events prevent polyspermy (i.e., fertilization by more than one spermatozoon). 1. Cortical reaction. Enzymes that prevent additional spermatozoa from penetrating the
oocyte membrane are released from granules in the egg cortex. 2. Zona reaction. Cortical granule enzymes alter the zona pellucida, making the zona
impenetrable to additional spermatozoa. B. Continuation of meiosis. Fusion of the sperm and egg cell membranes also induces the resumption of meiosis in the oocyte. 1. The oocyte now completes the second meiotic division, which results in what is called the
definitive oocyte as well as the second polar body. 2. The genetic material of the sperm and oocyte are enclosed within structures called the male pronucleus and female pronucleus.
meClical
7
Embryology
Second meiotic metaphase
Figure 1-2-1. Fertilization.
FUSION OF THE MALE AND FEMALE PRONUCLEI A. Genetic composition of the pronuclei. The female pronucleus contains 22 + X chromosomes, and the male pronucleus contains either 22 + Y or 22 + X chromosomes. B. Zygote formation. Fusion of the pronuclei to produce the zygote is considered the beginning of embryonic development and entails the following: 1. It restores the diploid number of chromosomes (46) in the zygote. 2. It determines the sex of the embryo. An X-bearing sperm produces an XX (female)
individual, whereas a Y-bearing sperm produces an XY (male) individual. 3. It triggers a series of rapid mitotic divisions called cleavage.
8
KAPLAffdme leaI
First Week
After fertilization and formation of the zygote, designated as day 1 of embryogenesis, the first week is characterized by the mitotic divisions of cleavage, formation of the blastocyst, and implantation. This chapter discusses the events that occur during the first week of zygote development.
CLEAVAGE Cleavage is the series of cell divisions that occur as the zygote passes down the uterine tube on its way to the uterus. Cleavage begins within 24 hours of zygote formation. With each division, the daughter cells, called blastomeres, become smaller because these divisions are not accompanied by cell growth. A. Compaction begins with the eight-cell stage. 1. In compaction, the loosely organized blastomeres flatten and are held together by tight
junctions. 2. This process also segregates inner blastomeres from outer blastomeres. Inner blastomeres communicate closely via gap junctions. B. Morula. By the third or fourth day, the compacted embryo contains 16-32 cells and is
Note Although uterine tube is the Termino/agio Anotamico term, the synonyms oviduct and fallopian tube are commonly used.
referred to as the morula. 1. The inner cells of the morula give rise to the inner cell mass. 2. The outer cells give rise to the outer cell mass.
BLASTOCYST FORMATION A. Blastocele. Once the morula is inside the uterus, fluid begins to accumulate in the intercellular spaces in the morula and forms a central cavity known as the blastocele. B. Blastocyst (Figure 1-3-0. The zygote, now free of its zona pellucida, is called a blastocyst and
consists of two cell groups. 1. The embryoblast (inner cell mass) projects into the cavity. The embryoblast gives rise to
the embryo proper. 2. The trophoblast (outer cell mass) forms an outer epithelial layer that surrounds the embryoblast and blastocele. The trophoblast gives rise to the fetal portion of the placenta.
KAPUff I me illea
9
Embryology -----
Blastocyst
Uterine epithelium
Trop h0 bl ast
Syncytiotrophoblast { Cytotrophoblast '-\t)'lI---Outer cell mass or trophoblast
Figure 1-3-1. Blastocyst at 5 days.
IMPLANTATION A. Normal 1. Implantation begins by the end of the first week, when the trophoblast cells over the
Clinical Correlate The presence of hCG in urine or serum is a commonly used method for pregnancy testing.
embryo blast pole invade the endometrial epithelium of the uterine body. After the embryoblast is embedded within the endometrial stroma, the surface is repaired by a blood clot, which is later replaced by epithelial overgrowth.
2. When the embryo implants, the trophoblast produces human chorionic gonadotropin (heG). This is a hormone that maintains the corpus luteum, and its progesterone secretion until the placenta begins to produce its own progesterone. B. Abnormal 1. The blastocyst may implant in an abnormal site in the uterus near the internal os or
cervix.
2. Implantation outside the uterus is referred to as an ectopic pregnancy.
Clinical Correlate Due to the narrowness of the uterine tube, ectopic tubal pregnancies that persist beyond the fifth week can rupture the tube.
a. Implantation of this type usually results in abortion and severe hemorrhaging during the second month of pregnancy. b. Ectopic sites of implantation occur in the uterine tube (tubal pregnancy), on the surface of the ovary, or in the abdomen, where they often are found in the rectouterine (Douglas) pouch. C. Proliferation of the trophoblast
1. The trophoblast proliferates and differentiates into two cell layers. a. The cytotrophoblast is the single-celled layer adjacent to the embryoblast. b. The syncytiotrophoblast is a thick outer layer that lacks cell boundaries and grows into the endometrial stroma. 2. Excessive growth of the trophoblast may result in proliferation of vesicular masses called
hydatidiform moles. Moles secrete hCG and may give rise to benign or malignant tumors.
10
mectical
Second Week
The second week of development is characterized by continued implantation and expansion of the syncytiotrophoblast until it surrounds the entire embryo and the uteroplacental circulation is established. During this period, the embryoblast splits into two germ layers: the epiblast and hypoblast. The blastocyst cavity is replaced first by the primary yolk sac and then by the secondary yolk sac, and the amniotic and chorionic cavities appear.
FORMATION OF BILAMINAR DISC At the beginning of the second week, the cells of the embryoblast begin to differentiate into two layers, the epiblast and hypoblast, forming a bilaminar disc (Figure 1-4-1). A. Epiblast (primary ectoderm) consists of high columnar cells that separate from the cytotrophoblast to form the amniotic cavity. The roof of this cavity is lined by the ectodermal amnioblasts, which are adjacent to the cytotrophoblast. The remaining portion of the epiblast layer lines the floor of the cavity. During the third week, the epiblast gives rise to two germ layers: the embryonic ectoderm and mesoderm. B. Hypoblast (primary endoderm) consists of low cuboidal cells adjacent to the blastocyst
cavity. This layer contributes to the lining of the primary yolk sac.
TROPHOBLAST DEVELOPMENT A. Extraembryonic mesoderm
1. On days 11 and 12, the trophoblast gives rise to the extraembryonic mesoderm, which is loosely arranged around the amnion and primitive yolk sac.
KAPLAff I medlea
11
Embryology
Cytotrophoblast
Syncytiotrophoblast Enlarged blood vessels (sinusiods)
~~~~~~~;:(~.~. Amnioblasts
I
piblast S·,I ammar . . Hypoblast em. bryonic ~!':SI;':~JirJ:·.:;~";·~~·.:: ; (embryonic disk . ~ntoderm)
Amniotic cavity
Figure 1-4-1. Blastocyst at 10 days.
2. Cavities within the extraembryonic mesoderm quickly fuse to form the extraembryonic coelom. The coelom divides the mesoderm into the extraembryonic somatic mesoderm, which covers the cytotrophoblast and amnion, and the extraembryonic splanchnic mesoderm, which covers the yolk sac. B. Uteroplacental circulation 1. The trophoblast and extraembryonic somatic mesoderm lining comprise the chorion.
2. Trophoblastic erosion of maternal blood vessels allows blood to flow from sinusoids (enlarged, congested capillaries of the endometrium) into the lacunar or intervillous spaces that have formed in the embryonic syncytiotrophoblast. When this occurs, the primitive uteroplacental circulation is established. C. Chorionic cavity 1. The expanded extraembryonic coelom forms the chorionic cavity on day 13.
2. The bilaminar embryo, amnion, and yolk sac are suspended in this cavity by the connecting stalk, which is a condensation of extraembryonic mesoderm that later develops into the umbilical cord. 3. At this time, the secondary (definitive) yolk sac is pinched off from the primary yolk sac (Figure 1-4-2).
12
iiieclical
Second Week
Lacunar network
Amniotic cavity
Extraembryonic somatic mesoderm --===:;li.W-AlEi(;li?
~~~~_ Secondary yolk sac
Chorion--------~~~~~·)
of primitive yolk sac
'R,... mn~l"lt
Figure 1-4-2. Blastocyst at 14 days.
D. Decidual reaction. During week 2 of development, cells of the decidua, the functional layer of the pregnant endometrium, respond to implantation and progesterone secretion by enlarging and accumulating glycogen and lipid. The entire tissue becomes edematous. This response is known as the decidual reaction.
UPLA~. I meulca
13
Third Week
The third week of development is characterized by the formation of all three germ layers during the process known as gastrulation. Thus, the bilaminar disc is converted into the triiaminar disc. It is during this period that the cephalocaudal, left-to-right, and anteroposterior axes of the body are established. In addition, the notochord develops, the allantois appears as a posterior diverticulum of the yolk sac, and the trophoblast expands rapidly to form a complex set of villi that ensure the exchange of gases and nutrients between maternal and embryonic tissues.
FORMATION OF TRILAMINAR DISC A. Primitive streak 1. During the third week of development, the cephalocaudal axis of the embryo becomes
defined by the primitive streak, which is a linear thickening of the ectoderm cells on the caudal part of the dorsal embryonic disc. The streak is delimited rostrally by the primitivenode. 2. The epiblast cells of the primitive streak proliferate and migrate inward (invagination)
between the epiblast and hypoblast layers. Initially, they replace the original hypoblast with the definitive endoderm. Migrating epiblast cells then form a third germ layer, the intraembryonic mesoderm. The remaining epiblast cells are the ectoderm. Thus, the three definitive germ layers are derived from the epiblast. B. Intraembryonic mesoderm 1. Mesodermal cells form a loosely arranged tissue known as mesenchyme. The lateral
extension of mesoderm establishes direct contact with the extraembryonic mesoderm that covers the yolk sac and amnion. 2. Ectodermal and endodermallayers fuse at the cephalic and caudal ends of the embryonic
disc to form the buccopharyngeal and cloacal membranes, respectively (Figure 1-5-1). Migrating mesodermal cells do not penetrate these areas but pass on either side to surround them. Rostral to the buccopharyngeal membrane, the mesoderm forms the cardiogenic plate that will give rise to the heart.
I KAPLArf medlea
15
Embryology
Amniotic ectoderm
Embryonic ectoderm
Hensen node (primitive knot)
Notochord Cephalic end
Intraembryonic mesoderm
Cloacal membrane
Figure 1-5-1. Longitudinal section of embryo at 17 days.
C. Fate of the primitive streak. The primitive streak usually degenerates and disappears. However) in abnormal cases, some remaining multipotent ceJls of the streak may give rise to sacrococcygeal teratomas, which are tumors of many cell types, found on or near the midline. More common in females than in males, these tumors may become malignant.
FORMATION OF NOTOCHORD A. Day 16. About this time, cells of the primitive streak migrate rostrally and form the tube-like notochordal process. B. Day 17. By this time, the mesoderm layer and notochordal process (a mesodermal deriva-
tive) separate the ectoderm and endoderm layers entirely, with the exception of the buccopharyngeal and cloacal membranes. C. Day 18. By this time, disintegration of the floor of the notochordal process and the fused underlying endoderm opens a transient passage, the neurenteric canal, which connects the yolk sac cavity and the amniotic cavity.
FORMATION OF ALLANTOIS On about day 16, the allantois forms as a diverticulum of the posterior wall of the yolk sac, which extends into the connecting stalk. Both the allantois and the yolk sac are responsible for early blood formation, which previously took place extraembryonically. At the beginning of the third week, angioblasts in the visceral mesoderm of the yolk sac wall form clusters and cords that become canalized. Centrally located cells give rise to primitive blood cells and cells on the periphery flatten to form endothelial cells that line blood islands.
16
ii1.Ctical
Third Week
TROPHOBLAST DEVELOPMENT The chorion differentiates to form chorionic villi during the third week of development (Figure 1-5-2).
A. Primary villi are formed when cords of cytotrophoblast cells migrate into the irregular processes of the syncytial layer. B. Secondary villi are formed when the extraembryonic mesoderm of the chorion invades the
cytotrophoblastic core of the primary villi. C. Tertiary villi are formed by organization of the core mesoderm into capillaries. These cap-
illaries make contact with vessels of the connecting stalk and chorion, which, in turn, make contact with the intraembryonic circulatory system to connect the placenta to the embryo.
Cytotrophoblast core "
"
Extraembryonic somatic mesoderm
",:. :" '.>'- ".
Primary villous
Maternal blood
Chorionic cavity
Trophoblastic lacunar (intervillous) network
Figure 1-5-2. Diagram of trophoblast with embryo (left) and longitudinal section of villus (right) during the third week.
UPLllf I me d1C8
17
Fourth to Eighth Weeks
Beginning approximately in the third week and extending through the eighth week is the interval known as the embryonic period. This period of embryogenesis and organogenesis is characterized by the cephalocaudal and lateral folding that transforms the embryonic disc into a tube and by the formation of the organs and systems of the body from derivatives of the three germ layers. At the end of this period, major external body features are recognizable. The subsequent interval from the beginning of the third month until parturition is known as the fetal period, a period of organ system maturation and body growth. This chapter reviews the processes that occur during the embryonic period.
ECTODERMAL DERIVATIVES A. Central nervous system (CNS) (Figure 1-6-1) 1. Neural plate. At the cephalic region of the embryo, the notochord induces a thickening of ectoderm, which becomes the neural plate. The neural plate increases in length as the primitive node and primitive streak move caudally.
2. Neural groove and neural crest. Invagination of the neural plate by day 18 results in the formation of the neural groove. The lateral edges of the plate form neural folds, which join in the midline as the neural groove deepens. The edge of each fold is known as the neural crest. 3. Neural tube. The neural tube is formed as the neural folds fuse in the midline. Fusion begins in the region of the future neck (fourth somite) and proceeds in cephalic and caudal directions.
upurr I meillea
19
Embryology
Neural plate
Neural told
Notochordal process Ectoderm
Neural told
~V~
~~:::::~
A --
Neural groove
Day 18
Neural told Rostral neuropore
B ---
Neural crest
In a Nutshell
Caudal neuropore (closes at 27 days)
Ectodermal Derivatives • Nervous system • Otic and lens placode
• Pituitary and mammary glands
Ectodermal Neural Crest Derivatives • Dorsal root ganglia • Sensory ganglia of cranial nerves • Autonomic ganglia
Neural crest
Failure to close results in ancephaly, causing polyhydraminos and increased alpha-teto protein.
C ---
• Skin, hair, nails, tooth enamel
Neural tube
Day 22
Failure to close results in spina bitida Alphateto protein.
Figure 1-6-1. Neural tube development (cross-section).
4. Brain and spinal cord. The cephalic end of the neural tube eventually dilates to form the
forebrain, midbrain, and hindbrain. The spinal cord is formed from the remainder of the tube. Neural crest cells form the dorsal root ganglia, sensory ganglia of the cranial nerves, autonomic ganglia, meninges, Schwann cells, adrenal medullary cells, melanocytes, and ectomesenchyme of the head and neck. B. Otic placode and lens placode. Subsequent to neural tube closure, two additional ectoder-
mal thickenings, the otic placode and the lens placode, appear in the cephalic region of the embryo. 1. The otic placode invaginates to form the otic vesicle, which gives rise to the organs of
• Meninges • Schwann cells • Adrenal medulla • Melanocytes
20
meilical
hearing and equilibrium. 2. The lens placode invaginates to form the lens vesicle, which forms the lens during the fifth
week of development.
c. Other ectodermal derivatives include skin, hair, nails, subcutaneous glands, mammary glands, pituitary gland, and tooth enamel.
Fourth to Eighth Weeks
MESENCHYMAL DERIVATIVES By day 17, the originally diffuse intraembryonic mesoderm becomes differentiated into three distinct regions. Paraxial mesoderm forms tissue columns on either side of the embryonic midline. This region is contiguous laterally with the intermediate mesoderm, which, in turn, is contiguous with the lateral mesoderm (Figure 1-6-2). A. Paraxial mesoderm 1. On day 20, the paraxial mesoderm tissue begins division into segmental blocks or somites. The first pair of somites appears in the cervical region. Subsequent pairs appear in a craniocaudal sequence, approximately three per day, until 42 or 43 pairs are present by the end of the fifth week. 2. Beginning in the fourth week, each somite becomes differentiated into a ventromedial sclerotome and a dorsolateral dermamyotome. The dermamyotome further differentiates into dermatome and myotome regions (Figure 1-6-2). a. Sclerotome cells migrate medially to the notochord and differentiate to form the bones, cartilage, ligaments of the vertebral column, and part of the base of the skull. b. Dermatome cells migrate laterally under the ectoderm to form the dermis and subcutaneous tissues of the skin. c. Myotome cells give rise to skeletal muscles. B. Intermediate mesoderm. Cephalic intermediate mesoderm becomes arranged in cell clusters, which are the future nephrotomes. Caudal intermediate mesoderm forms an unsegmented mass of tissue known as the nephrogenic cord. This tissue will give rise to portions of the urogenital system.
In a Nutshell ~_ _ _ L.dlt:l·dl
mesoderm
Mesodermal Derivatives • Connective tissue (bone, cartilage) • Muscle
Figure 1-6-2. Development of mesoderm.
• Dermis • Urogenital system
C. Lateral mesoderm tissues divide into two layers. 1. The somatic (parietal) mesoderm is continuous with the mesoderm covering the
amnion. The somatic mesoderm and overlying ectoderm form the lateral and ventral body wall. 2. The splanchnic (visceral) mesoderm is continuous with the extraembryonic coelom on either side of the embryo. The splanchnic mesoderm and underlying endoderm form the wall of the gut. Cells facing the coelomic cavity form serous (mesothelial) membranes that line the pericardial, pleural, and peritoneal cavities.
• Serous membranes lining the pericardial, pleural, and peritoneal cavities • Vascular structures, including lymphatics • Adrenal cortex • Spleen KAPUff . ._ I me lea
21
Embryology
D. Other mesodermal derivatives include striated, cardiac, and smooth muscle; connective tissue, including cartilage and bone; blood cells and vessels; lymph cells and vessels; kidneys, gonads, and their ducts; the cortical portion of the adrenal gland; and the spleen.
ENDODERMAL DERIVATIVES A. Gastrointestinal tract. The endodermal germ layer gives rise to the gastrointestinal tract. This formation depends on the cephalocaudal and lateral folding of the embryonic disc into a tube-like gut. 1. Head and tail folds. Rapid longitudinal growth of the eNS causes the cephalic and cau-
dal ends of the embryonic disc to bend and form the head and tail folds. a. Head fold. As a result of the head fold, the brain comes to lie cranial to the cardiogenic area and septum transversum, which contributes to the formation of the diaphragm. Part of the yolk sac becomes incorporated into the embryo as the foregut. This cavity opens into the midgut via the anterior intestinal portal and is bordered anteriorly by the buccopharyngeal membrane. This membrane forms the back of the stomodeum, or primitive mouth, which appears as a depression in the surface ectoderm. The buccopharyngeal membrane ruptures at the end of the third week to establish communication between the amniotic cavity and the primitive gut (Figure 1-6-3). b. Tail fold. As a result of the tail fold, the proximal part of the allantois is incorporated into the cloaca. The distal part of the allantois remains in the connecting stalk, which fuses at the end of the fourth week with the yolk sac stalk to form the umbilical cord. Part of the yolk sac is incorporated into the hindgut. The hindgut connects to the midgut at the posterior intestinal portal and is bordered posteriorly by the cloacal plate, which is known as the cloacal membrane at this stage. This membrane forms the floor of the proctodeum, a depression in the surface ectoderm, which divides into the urogenital and anal membranes (Figure 1-6-3).
Septum transversum
Allantois
Tail fold
Figure 1-6-3. Longitudinal section of embryo showing head and tail folds at 26 days.
11
meilical
Fourth to Eighth Weeks
2. Midgut. Continued growth of the somites causes the expanding lateral margins of the embryonic disc to bend ventrally, forming lateral folds. As a result of this folding, part of the yolk sac is taken into the embryo to form the midgut. In addition, this folding constricts the initially wide communication between the embryo and yolk sac to a narrow, long vitelline duct, which eventually lies within the umbilical cord. B. Other endodermal derivatives include the epithelial lining of the primitive gut and the intraembryonic portions of the allantois and vitelline duct. Derivatives also include the epithelial linings of the respiratory tract, urinary bladder, urethra, tympanic cavity, and eustachian tube, as well as the parenchyma of the thyroid, parathyroids, thymus, liver, and pancreas.
In a Nutshell Endodermal Derivatives • Gastrointestinal system • Thyroid • Parathyroids
DEVELOPMENTAL CHANGES DURING THE EMBRYONIC PERIOD
• Thymus
A. Fourth week
• Liver
1. Most body systems, as well as the eyes, nose, and ears, appear in rudimentary form.
• Pancreas
2. Four pairs of branchial (pharyngeal) arches develop.
• Lining of respiratory tract, bladder, and urethra
3. Arm and leg buds form small surface projections. 4. The heart begins beating, and a primitive circulatory system connects the capillary
plexuses of the yolk sac and chorion with the embryo. Partitioning of the atrium begins. Hematopoiesis still occurs in the yolk sac. 5. The crown-rump length of the embryo is approximately 5 mm. B. Fifth week 1. Parathyroids, spleen, genital ridges, and external genitals form. 2. The stomach starts to rotate, and the midgut forms a loop. 3. Hand plates are distinguishable on the forelimbs. 4. Cardiac septa form, and atrioventricular (AV) cushions fuse.
5. Cartilage and muscle begin to form. 6. The crown-rump length is approximately 8 mm.
e. Sixth week 1. Limbs subdivide into limb, forelimb, and hand or foot. Finger rays arise in the hand plate. 2. The heart is almost fully formed. The foramen primum closes, and the aorticopulmonary
septation is complete. Hematopoiesis occurs in the liver. 3. Paramesonephric ducts are present, and sex cords start to develop. 4. Chondrification and intramembranous ossification occur in the skeletal system. 5. The crown-rump length is approximately 14 mm.
D. Seventh week 1. Notches appear between the rays of the hand plate.
2. The ventricular septum is fully formed. 3. The crown-rump length is approximately 22 mm.
KAPLA~. I meulCa
23
Embryology
E. Eighth week 1. The head increases in size and is as large as the rest of the body. The neck region develops.
The forebrain vesicle expands, and neuromuscular development permits fetal movement. 2. The body is covered with thin skin. 3. The eyes are directed forward instead of laterally. 4. Digits appear first on the hands and later on the feet.
5. The mesonephros is fully formed, and the metanephric duct is branching. 6. Testes and ovaries are visible, but external genitalia are not distinguishably different. 7. The crown-rump length is approximately 30 mm.
ESTIMATION OF EMBRYONIC AGE Methods of estimating embryonic age are based upon the mother's memory of specific reference points or upon the external appearance of the embryo. A. Specific reference points. Estimations are made from 14 + 2 days after the onset of the mother's last menstrual period or from the day of fertilization. B. External appearance of the embryo
1. The number of somites can be counted. An embryo has approximately 28 somites by the
end of the fourth week. As somites become less conspicuous during the second month of development, this method becomes less reliable. 2. Crown-rump length, which is measured from the vertex of the skull to the midpoint
between the apices of the buttocks; the crown-heel length, which is measured from the vertex of the skull to the heel of the foot; and external features, such as the development of limbs and digits, are other measures used to estimate embryonic age.
24
m.ilical
Ninth Week to Parturition
Beginning at the ninth week and extending until birth is the interval called the fetal period. During this period little new differentiation occurs, but maturation of the organs and systems occurs. It is also during this time that the body experiences rapid growth. In the 30-week fetal period, the fetus grows from approximately 8 g to a birth weight of about 3,400 g. The first portion of this period is characterized by a rapid growth in length; the latter portion is characterized by a growth in weight. This chapter reviews the developmental processes that occur during the fetal period as well as the processes that occur during parturition.
FETAL PERIOD A. Third lunar month 1. The fetus nearly doubles in length, but growth of the head slows relative to the rest of
body. The eyes and ears come to be located near their final positions, and the eyelids fuse. Lanugo (soft, downy hair) appears on the head and at the eyebrows. 2. The upper limbs nearly attain their final proportioned length, and nails begin to form. The lower limbs are less well developed. 3. The intestinal loops of the midgut withdraw from the umbilical cord into the abdominal cavity. The kidneys have begun to secrete urine, and the fetus is swallowing amniotic fluid. 4. The external genitalia are sexually distinguishable. B. Fourth and fifth lunar months 1. The fetus has a well developed chin. 2. Lanugo covers the entire body, and hair appears on the head. 3. The skin is covered with vernix caseosa, a whitish mixture of fetal sebum and dead epidermal cells that is thought to act as protection against the amniotic fluid. The vernix may be held in place by the lanugo. 4. Brown fat, important in heat production, is formed. 5. The mother can recognize fetal movements, or quickening, and the fetal heart beat may be heard.
UPU~.
I
meulC8
25
Embryology
c.
Sixth lunar month 1. The skin is wrinkled. The lack of subcutaneous fat gives the skin a red color, which is due to underlying muscle and capillary blood. 2. Eyebrows and eyelashes are present, and the eyelids have opened.
D. Seventh lunar month 1. Deposition of subcutaneous fat begins. 2. Until late in this period, the fetus would have difficulty surviving extrauterine life because the respiratory system is not fully developed and the CNS is just becoming able to regulate breathing.
E. Eighth lunar month 1. The subcutaneous fat increases, and the skin appears smoother and pinker. 2. Lanugo hairs begin to be shed.
F. Ninth lunar month 1. The fetus appears plump.
2. In males, the left testis has descended into the scrotum. G. Tenth lunar month 1. More fat is deposited, bringing the percentage of white fat in the body from 3.5% at 6 months to 16% at full term.
2. In males, both testes have descended. 3. The fetus has attained a crown-rump length of 360 mm and a weight of 3,000-3,400 g; half of the weight is gained in the last 3 months.
BIRTH Birth usually occurs within 10-14 days of the expected date, which is considered to be 280 days from the first day of the last menstrual period in women with regular menstrual cycles or 266 days after fertilization.
A. Fetal position at birth 1. At the time of birth, the fetus is usually in a flexed position, its long axis parallel to that of the uterus and its head lowermost. Normally, the fetus is in a transverse position. In breech presentation, the breech, or rump, is lowermost.
2. The enlarged uterus, which previously had risen from the symphysis pubis to the level of the xiphoid process, has again moved downward to a position between the umbilicus and the xiphoid. The height of the uterus during pregnancy is approximately as follows: a. Four months at the symphysis pubis b. Five months between the symphysis and umbilicus c. Six months at the umbilicus d. Eight months between umbilicus and xiphoid e. Nine months at the xiphoid process
26
meClical
Ninth Week to Parturition
B. Labor. The precise mechanism(s) that trigger(s) labor is (are) not fully understood. It is
likely that a wide variety of hormones and other factors are involved. For example, increases in local prostaglandin levels as well as an increase in the local estrogen-to-progesterone ratio increase uterine contractions. In addition, oxytocin-like substances produced by the placenta upon signals from the fetal adrenal cortex, or oxytocin released from the maternal neurohypophysis, can also stimulate contractions. These contractions are not dependent upon extrinsic innervation and are not disturbed by spinal anesthesia. Their strength and duration, however, may be regulated by oxytocin from the maternal neurohypophysis. Labor, or parturition, continues through three stages. 1. First stage extends from onset of regular contractions until dilation of the cervix is com-
plete. During this stage, the amniotic fluid and fetal membranes serve as a hydrostatic wedge in the cervical canal. Late in this stage, the membranes are ruptured and amniotic fluid is released. The average duration is 10-12 hours for first pregnancies (primigravidas) and 7 hours for later pregnancies (multiparas). 2. Second stage is from full dilation of the cervix to complete delivery of the conceptus by combined action of uterine contractions and reflexive abdominal contractions. The average duration is 50 minutes for primigravidas and 20 minutes for multiparas. 3. Third stage is from the birth of the infant to the expulsion of the placenta, which separates from the uterine wall through the decidua basalis and attached membranes. The maternal surface of the expelled placenta is characterized by grooves of the placental septa that divide the placenta into cotyledons. The fetal surface is characterized by the umbilical cord attachment and vessels associated with it. Contractions of the uterus constrict the spiral arteries and prevent excessive bleeding. The average duration is less than 30 minutes. C. Abnormal fetal growth 1. Premature infants are characterized by a birth weight of 2,500 g or less and a gestation of 28-38 weeks. 2. Small-for-dates infants are full-term, low-weight infants. They have wrinkled skin due to a lack of subcutaneous fat, which may be caused by placental dysfunction. 3. Infants of diabetic mothers may be abnormally heavy and large. Maternal hyperglycemia and fetal insulin secretion are thought to stimulate the growth of the fetus.
IIP~~.
I
mvulC8
27
Fetal Membranes and Placenta
The four extraembryonic membranes are the chorion, yolk sac, allantois, and amnion. The placenta is a compound organ that incorporates the fetal chorion frondosum and the maternal decidua basalis. This chapter reviews the different extraembryonic membranes and their functions.
CHORION A. Chorion frondosum and chorion laeve 1. In early development, secondary and tertiary chorionic villi cover the entire surface of the
chorion. However, as pregnancy advances, the villi on the embryonic pole enlarge to form the chorion frondosum, whereas those on the opposite (abembryonic) pole degenerate by the third month to form the chorion laeve. 2. The decidua over the chorion frondosum is called the decidua basalis; it is tightly connected to the chorion. The decidual layer over the abembryonic pole is the decidua capsularis; this layer stretches as the chorion enlarges and subsequently degenerates. 3. The chorion laeve fuses with the decidua parietalis, on the opposite side of the uterus, and the uterine cavity is obliterated. B. Placenta. The placenta is established by the end of the third month. It has two components: a fetal portion formed by the chorion frondosum (including vascularized allantoic mesoderm) and a maternal portion formed by the decidua basalis.
meClical
29
Embryology
cavity Chorion frondosum (bushy)
Internal os
Amnion
cavity
Figure 1-8-1. Fetal membrane development.
1. Placental circulation
a. Maternal blood enters the intervillous spaces under pressure through 80-100 spiral endometrial arteries. The blood then flows over the surface of villi of the chorion frondo sum and is drained by endometrial veins.
b. Deoxygenated fetal blood is brought to the chorionic villi by the two umbilical arteries and their branches. Oxygenated blood from the placenta is returned to the fetus by venules that join to form the umbilical vein. 2. Placental functions
a. A gas exchange of oxygen and carbon dioxide as well as nutrient and electrolyte exchange are important functions of the placenta. b. Excretion of embryonic wastes including CO 2 , urea, uric acid, and bilirubin occurs. c. Antibody transmission in which the fetus acquires maternal IgG antibodies occurs.
The fetus obtains passive immunity against some diseases such as diphtheria, smallpox, and measles, but not against chickenpox and whooping cough. d. Hormone production, including estrogens, progesterone, hCG, and chorionic somatomammotropin (hCS), is also an important function.
30
meClical
Fetal Membranes and Placenta
YOLK SAC A. Description. At the end of the second month, the yolk sac is a small, pear-shaped structure, which continues to shrink during development. 1. The dorsal part of the yolk sac is continuous with the primitive gut, from which the epithelium of the trachea, bronchi, lungs, and digestive system is derived. 2. The vitelline duct connects the yolk sac to the midgut. This duct and the yolk sac come to lie within the umbilical cord. 3. In approximately 2% of adults, the yolk sac stalk persists as an outpouching of the ileum called Meckel diverticulum. B. Functions of the yolk sac 1. During the second and third week of development, a function of the yolk sac is the trans-
fer of nutrients to the embryo from the trophoblast via the extraembryonic coelom and mesoderm. 2. The primordial germ cells originate from the yolk sac during the third week. 3. There is formation of blood cells and formation of blood vessels that join with the vitelline arteries and veins. The arteries arise from the dorsal aorta and eventually fuse to form the single superior mesenteric artery to the midgut.
ALLANTOIS A. Description. The allantois arises as a diverticulum from the posterior yolk sac that forms the hindgut. It grows into the body stalk and, thus, is incorporated with the body stalk into the umbilical cord. The intraembryonic allantois persists as the urachus, which runs from the urinary bladder to the umbilicus. After birth, this becomes the median umbilical ligament. B. Functions of the allantois. Although the allantoic sac is vestigial in humans, its abundantly vascularized mesoderm provides the blood vessels for the chorion to establish the definitive chorioallantoic placenta. The allantois is responsible for the formation of the umbilical blood vessels (two arteries, one vein).
AMNION A. Description. The amnion is the thin, nonvascular membrane that lines the amniotic cavity. It is formed from an internal ectoderm layer and an external extraembryonic mesoderm layer. B. Amniotic fluid. The amniotic cavity is filled with fluid derived from the maternal blood, but in late pregnancy, it also contains some fetal urine. Amniotic fluid is rapidly turned over via the placental membrane. Beginning in the fifth month, it is also swallowed and returned to the circulation via the fetal gastrointestinal tract. 1. Hydramnios, or excessive amniotic fluid, is a condition often associated with twins, maternal diabetes mellitus, anencephaly, and esophageal atresia. In the latter two cases, it may be related to the inability of the fetus to swallow. 2. Oligohydramnios, or insufficient amniotic fluid, is almost always associated with absent fetal renal function and is the cause of deformities of the skull, limbs, and trunk.
IIAPLl~. I meulca
31
Embryology
C. Amniocentesis. The amniotic fluid contains fetal cells, which may be sampled by amniocentesis. Karyotyping of these cells allows detection of chromosomal abnormalities. Cell culture may be used to diagnose inborn errors of metabolism. Examination of the amniotic fluid also allows determination of the amount of fetal blood cell destruction by maternal antibodies in cases of Rh incompatibility.
D. Umbilical cord. As the embryo develops, it bulges into the amniotic cavity and is cushioned by the amniotic fluid. Growth of the embryo causes expansion of the amniotic cavity and the obliteration of the extraembryonic coelom. As a result, the amnion and chorion fuse, while the body stalk and yolk sac become incorporated into the umbilical cord. 1. The umbilical cord initially contains the vitelline vessels, allantois, umbilical vessels, remnants of the chorionic cavity, mesenchyme of the body stalk (which is rich in glycosaminoglycans and is called Wharton jelly), and the intestinal loops (which cannot be accommodated by the abdominal cavity and are extruded in a physiologic umbilical hernia). 2. Later, the yolk sac, vitelline vessels, allantois, and remnants of the chorionic cavity are obliterated and the intestinal loops are withdrawn, leaving only the umbilical vessels and Wharton's jelly in the umbilical cord (Figure 1-8-2).
Amniotic cavity Connecting
Primitive umbilical
Figure 1-8-2. Umbilical cord at 10 weeks.
32
meclical
Fetal Membranes and Placenta
TWINS A. Dizygotic (fraternal) twins represent two thirds of the total number of twins. They arise from two ova, each fertilized by a sperm, to give two zygotes. Each zygote forms its own fetal membranes, and the twins are no more similar than any pair of siblings. The placentas and chorions mayor may not fuse. B. Monozygotic (identical) twins arise from a single fertilized ovum or zygote that splits.
They are genetically identical, and, except in cases of the "fetal transfusion syndrome" where blood is shunted from one twin to the other through placental vessel anastomoses, they are physically and mentally similar. 1. If splitting occurs at the two-cell stage, the twins have two amnions, two chorions, and two placentas that mayor may not fuse. 2. Splitting at the inner cell mass stage, which occurs most frequently, results in twins that have their own amnion but share chorions and placentas. 3. Splitting during later stages of development results in twins that also share an amnion. These often become entangled in their umbilical cords and die. 4. Incomplete splitting causes conjoined twins. Twins that share no major organ systems may be separated surgically.
KAPLAlf I medlea
33
Body Cavities and Mesenteries
Three potential cavities surrounded by serous membranes result from the partitioning of the embryonic coelom: pericardial, pleural, and peritoneal. When the continuity between the extra- and intraembryonic coelom is lost the somatic mesoderm gives rise to the parietal layers of the serous membranes, and the splanchnic mesoderm gives rise to the visceral layers. The formation of the diaphragm separates the coelom into thoracic and peritoneal portions, and subsequently the pleuropericardial membranes separate the thoracic cavity into pleural and pericardial cavities. Double layers of the peritoneal serous membrane develop into the mesenteries. This chapter reviews the formation of the mesenteries and the body cavities that they define.
FORMATION OF COELOMIC CAVITY At the end of the third week, the lateral plate mesoderm divides into two layers: the somatic (parietal) mesoderm and the splanchnic (visceral) mesoderm. These two layers border a space known as the intraembryonic coelom. With cephalocaudal and lateral folding of the embryonic disc, the intraembryonic coelom loses its connection with the extraembryonic coelom and extends from the thoracic to the pelvic regions. Mesothelial cells of the somatic mesoderm give rise to the parietal serous membranes lining the outside of the coelomic cavities. Splanchnic mesoderm gives rise to the mesothelial covering of the abdominal organs, lungs, and heart.
DIAPHRAGM The diaphragm divides the coelom cavity into the thoracic cavity and the peritoneal cavity. A. Development. The adult diaphragm develops from the following four structures: 1. Septum transversum is a mesodermal plate between the pericardial cavity and the vitelline duct. It forms in the neck region and moves caudally with its nerve supply as the
heart descends from neck to thorax. It fuses dorsally with the mediastinum and pleuroperitoneal membranes to form the muscle and central tendon of the diaphragm. 2. Pleuroperitoneal membranes. By the seventh week, these membranes are fused with the dorsal mesentery of the esophagus and the dorsal portion of the septum transversum to form a partition between the thoracic and abdominal portions of the coelom. 3. Dorsal mesentery of foregut forms the left and right crura of the diaphragm. 4. Muscular components of lateral and dorsal body walls form the peripheral portions of the diaphragm.
KAP LA If I me d lea
35
Embryology
Mnemonic 0, (4, (5 keep the diaphragm alive.
B. Innervation. The diaphragm receives innervation from the third, fourth, and fifth cervical segments of the spinal cord. With the descent of the diaphragm to the level of the first lum-
bar vertebra, the phrenic nerves lengthen. The peripheral muscular elements of the diaphragm are innervated by intercostal nerves. However, the bulk of diaphragmatic muscle receives its motor supply via the phrenic nerves.
THORACIC CAVITY A. Pericardioperitoneal canals. The thoracic and peritoneal cavities are initially continuous via paired pericardioperitoneal canals on either side of the foregut. B. Pleuropericardial membranes. Lung buds grow into the canals and subsequently expand
into the body wall mesenchyme. In this manner, the body wall is split into two components: the thoracic wall and the pleuropericardial membrane (a thin layer of mesoderm that contains the common cardinal vein and the phrenic nerve). Right and left pleuropericardial membranes fuse at the midline to divide the thoracic cavity into a pericardial cavity and two pleural cavities. 1. The pleuropericardial membranes form the adult fibrous pericardium.
2. The connection between the thoracic and abdominal portions of the coelomic cavity is closed by the pleuropericardial membranes.
MESENTERIES The lateral folding of the embryonic disc causes the lateral edges of the intraembryonic coelom to fuse in the midline, which partitions the peritoneal cavity into two halves. Splanchnic mesoderm encloses the primitive gut and is suspended from the dorsal body wall as a double-layered membrane, the dorsal mesentery. The ventral mesentery is formed from the mesoderm of the septum transversum and, thus, extends for only a short distance along the gut, leaving the left and right halves of the peritoneal cavity in free communication. A. Dorsal mesentery extends from the lower end of the esophagus to the cloacal region of the hindgut. It serves as a pathway for blood vessels, nerves, and lymphatics supplying the in testinal tract. 1. Dorsal mesogastrium is the mesentery of the stomach region. a. During the fourth week, clefts appear in the mesentery dorsal to the stomach. These clefts fuse to form the omental bursa (lesser peritoneal sac) behind the stomach. b. During the fifth week, the spleen develops between the layers of dorsal mesentery behind the stomach. The spleen maintains connections to the dorsal body wall in the region of the left kidney (lienorenal ligament) and to the stomach via dorsal mesentery derivatives (gastrolienal ligament ).
c. Positional changes of the stomach cause the dorsal mesentery forming the left wall of the omental bursa to grow downward and extend over the transverse colon and small intestine as the apron-like greater omentum. The posterior layer of the omentum fuses with the anterior surface of the transverse colon. 2. Dorsal mesoduodenum is the mesentery of the duodenal region. The rotation of the stomach and duodenum and the rapid growth of the head of the pancreas cause the duodenum and the head of the pancreas to be pressed against the right dorsal body wall. The surface of the dorsal mesoduodenum fuses with the adjacent peritoneum and disappears. Therefore, the duodenum and pancreas lie retroperitoneally.
36
meclical
Body cavities and Mesenteries
3. Mesentery proper is the mesentery of the primitive intestinal loop. a. It originally is attached to the posterior abdominal wall in the midline. Rotation of the midgut causes the mesentery to twist around the origin of the superior mesenteric artery. The mesenteries of the ascending and descending portions of the colon press against the peritoneum of the posterior abdominal wall and fuse. These structures lie in a retroperitoneal position. The appendix and cecum retain their free mesentery. b. The transverse mesocolon fuses with the posterior wall of the omental bursa, remaining intraperitoneal, and is attached from the hepatic flexure of the ascending colon to the splenic flexure of the descending colon. B. Ventral mesentery. The hepatic bud, an endodermal derivative from the foregut, grows into the ventral mesentery, which forms the fibrous capsule and connective tissue of the liver. 1. As the liver grows into the abdomen, the ventral mesentery between the liver and ventral body wall becomes stretched and membranous and forms the falciform ligament. The
free margin of the falciform ligament contains the umbilical vein, which, after birth, is obliterated to form a fibrous cord called the ligamentum teres. 2. Similarly, the ventral mesentery between the liver and the ventral stomach-duodenal border forms a membrane called the lesser omentum. The free margin of the lesser omentum contains the bile duct, portal vein, and hepatic artery.
CONGENITAL ANOMALIES A. Diaphragmatic hernia, a relatively common anomaly, is caused by failure of the pleuroperitoneal membranes to close the pericardioperitoneal canals. It occurs more frequently on the left side than on the right and may herniate through the diaphragm into the pleural cavity, which, in some cases, retards growth of the lungs, displaces the heart and mediastinum to the right, and impairs initiation of respiration at birth. 1. Parasternal hernia occurs more often in the anterior portion and is caused by failure of some diaphragmatic muscle fibers to develop. 2. Esophageal hernia is a protrusion of the stomach into the thorax and its subsequent constriction by the diaphragm. It is probably caused by a shorter length of the esophagus than normal. B. Mobile cecum and colon caused by to incomplete fusion of the ascending mesocolon with the peritoneum of the posterior abdominal wall. If a long mesocolon remains, intestinal twisting (i.e., volvulus) and obstruction of the ascending colon may result. It is treated by fixation of the ascending colon to the posterior abdominal wall.
IIIPLA~.
meulca
I
37
Pharyngeal Arches and Their Derivatives The pharyngeal (branchial) arches contribute to the formation of the lower head and neck. In the fourth and fifth weeks of development, these structures appear as condensations of mesenchymal tissue on the lateral walls of the foregut at the level of the pharynx. The arches are demarcated internally by the endodermally lined pharyngeal pouches and externally by the ectodermally lined pharyngeal clefts (Figure 1-10-1). The mesenchyme of the arches is derived from mesoderm and neural crest.
Pharyngeal clefts
Pharyngeal pouches
Mandibular process ----~~~~ Pharyngeal arches
Caudal
A
8 Figure 1-10-1. Fetus at 32 days showing (A) pharyngeal clefts outside embryo and (8) pharyngeal pouches inside embryo.
KAPLA~. I meulca
39
Embryology
PHARYNGEAL ARCHES Note Remember that the terms "pharyngeal" and "branchial" mean the same thing. You may see the term "branchial" used in some review books. Another term that is used synonymously is "visceral" arches.
The mesenchyme core of the pharyngeal arches gives rise to the musculature of the face and neck. Each arch has its own cranial nerve and arterial components. A. First pharyngeal (mandibular) arch 1. Musculature
a. Muscles of mastication: temporalis, masseter, and pterygoids b. Anterior belly of the digastricus c. Mylohyoideus d. Tensor tympani e. Tensor veli palatini 2. Skeletal component. The mesenchyme divides into a dorsal maxillary process and a ventral mandibular process. a. The maxillary process extends anteromedially beneath the eye to give rise to the maxilla' zygomatic, palatine, and squamous temporal bones through intramembranous ossification. b. The mandibular process gives rise to the mandible; its dorsal end (Meckel cartilage) becomes ossified to form the malleus and incus. 3. Cranial nerve component of the first pharyngeal arch gives rise to the maxillary and mandibular divisions of the trigeminal nerve (cranial nerve V). B. Second pharyngeal (hyoid) arch 1. Musculature
a. Muscles of facial expression: orbicularis oris and occuli, platysma, auricularis, buccinator, occipitofrontalis b. Stapedius c. Stylohyoid
d. Posterior belly of the digastricus 2. Skeletal components. The mesenchyme forms a cartilaginous bar, called Reichert's cartilage. a. The dorsal part of Reichert cartilage forms the styloid process of the temporal bone. b. The intermediate part forms the stylohyoid ligament. c. The ventral part of Reichert's cartilage forms the superior part of the body of the hyoid
bone. 3. Cranial nerve component is the facial nerve (cranial nerve VII) C. Third pharyngeal arch
1. Musculature includes the stylopharyngeus 2. Skeletal components. The ventral portion persists to form the greater cornu of the hyoid bone and the inferior part of the body of the hyoid bone.
40
meClical
Pharyngeal Arches and Their Derivatives
3. Cranial nerve component is the glossopharyngeal nerve (cranial nerve IX). 4. Arterial component of the third pharyngeal arch is the common carotid and roots of the internal carotid arteries. D. Fourth pharyngeal arch 1. Musculature includes the constrictors of the pharynx, the cricothyroid, and the levator
In a Nutshell
veli palatini. 2. Skeletal component includes the thyroid cartilage. 3. Cranial nerve component is the superior laryngeal branch of the vagus nerve (cranial nerve X). 4. Arterial component is the right subclavian artery and the arch of the aorta.
Cranial Nerve Innervation of Arches • 1st arch = CN V (maxillary and mandibular divisions of the trigeminal nerve)
= CN VII (facial
E. Fifth pharyngeal arch. In human embryos, the fifth arch is either short lived or does not develop.
• 2nd arch nerve)
E Sixth pharyngeal arch
• 3rd arch = CN IX (glossopharyngeal nerve)
1. Musculature includes the intrinsic laryngeal muscles. 2. Skeletal components include the laryngeal cartilages. 3. Cranial nerve component is the recurrent laryngeal branch of the vagus nerve (cranial nerve X). 4. Arterial component includes the roots of the right and left pulmonary arteries and the ductus arteriosus.
• 4th arch = CN X (superior laryngeal branch of the vagus nerve) • 6th arch = CN X (recurrent laryngeal branch of the vagus nerve)
PHARYNGEAL POUCHES A. First pharyngeal pouch forms a diverticulum, called the tubotympanic recess, that contacts the epithelial lining of the first pharyngeal cleft, which is the future external auditory meatus. The distal portion of outpocketing widens to form the middle ear cavity, and the proximal portion remains narrow to form the eustachian tube. Its lining forms the inner epithelial covering of the tympanic membrane. B. Second pharyngeal pouch. The epithelial lining buds into the mesenchyme to form the
palatine tonsil. Part of the pouch remains in the adult as the tonsillar fossa.
e. Third pharyngeal pouch. The ventral wings of the paired third pharyngeal pouches give rise
In a Nutshell Pouch Derivatives • Middle ear = 1st pouch • Eustachian tube = 1st pouch
= 2nd pouch
to the thymus, and the dorsal wings differentiate into the inferior parathyroid glands.
• Palatine tonsil
1. Thymus arises as a bilateral diverticulum, which grows inferiorly to the superior medi-
• Thymus = 3rd pouch
astinum, solidifies, and fuses. a. Endodermal cells multiply to give rise to the epithelial reticulum of the thymus as well as Hassall's (thymic) corpuscles. b. Lymphoid tissue invades the thymus by the fourth week. 2. Inferior parathyroid glands develop as a proliferation of endodermal cells and travel with the thyroid to lie on the dorsal surface of this gland.
• Inferior parathyroids = 3rd pouch • Superior parathyroids = 4th pouch • C cells of thyroid = 5th pouch
D. Fourth pharyngeal pouch. The endodermal proliferation of the dorsal wing cells gives rise to the superior parathyroid glands, which come to lie on the posterior surface of the thyroid gland. E. Fifth pharyngeal pouch is the last of the pharyngeal pouches to develop. It forms the ultimobranchial bodies, which give rise to the calcitonin-secreting parafollicular (C) cells of the thyroid.
meClical
41
Embryology
PHARYNGEAL CLEFTS Four pharyngeal clefts are present in the 5-week-old embryo. Only the first pharyngeal deft contributes to embryonic structures. It penetrates the underlying mesoderm, forming the external auditory meatus and the outer epithelial lining of the tympanic membrane.
OTHER PHARYNGEAL DERIVATIVES A. Tongue 1. Development a. During the fourth week, three swellings originate from the first pharyngeal arch: two lateral lingual swellings and one medial swelling, called the tuberculum impar. b. Another median swelling, the hypobranchial eminence (copula), is formed from the mesoderm of the second through fourth arches. c. The posterior part of the fourth arch gives rise to a third median swelling, which develops as the epiglottis. d. The lateral lingual swellings grow over the tuberculum impar and fuse in the midline, forming the anterior two thirds of the tongue. 2. Innervation a. The first pharyngeal arch mucosa is innervated by the lingual nerve, which is a branch of the mandibular division of the trigeminal nerve. b. The posterior third of the tongue arises from the second through fourth arches. The sensory innervation of this part of the tongue is from the glossopharyngeal nerve. c.
The epiglottis and the extreme posterior part of the tongue, fourth-arch derivatives, are innervated by the superior laryngeal nerve.
d. The musculature of the tongue is innervated by the hypoglossal nerve. 3. Tongue musculature is mainly derived from occipital somites. B. Thyroid gland originates as an endodermal mass at the level of the foramen cecum, a
pharyngeal diverticulum between the tuberculum impar and the copula. 1. As the thyroid descends in front of the pharynx, it maintains its connection to the tongue by the thyroglossal duct, which normally disappears. 2. Ectopic thyroid tissue may occasionally be found along the path of its descent. 3. The thyroid gland lies in front of the trachea during the seventh week and produces colloid by the end of the third month. C. Face, jaws, palate, and nose
1. Face and palate are formed by mesenchymal swellings, which grow and fuse during the second month.
a. Mandibular processes, caudal to the stomodeum, meet in the midline to form the lower jaw, lip, and part of the face. b. Frontal prominence, at the upper border of the stomodeum, forms the forehead and apex of the nose. Two ectodermal invaginations, the nasal pits, divide this single mesenchymal prominence into two lateral and two medial nasal swellings. The lateral swellings become the sides of the nose. The medial swellings form the mid part of the
42
meclical
Pharyngeal Arches and Their Derivatives
nose, the midpart, or philtrum, of the upper lip, the middle portion of the upper jaw and associated gingiva, and the primary palate. c. Maxillary processes move medially to form the lower border of the developing orbit and push the medial nasal processes to the midline. The latter then merge with each other and the maxillary processes. The lateral nasal swellings extend from the eye to the mouth and form the nasolacrimal duct. d. Secondary palate forms from the palatine shelves, which grow out of the maxillary processes. These fuse in the midline above the tongue and anteriorly with the primary palate, which carries the incisors. Posterior outgrowths of these shelves give rise to the soft palate. Simultaneously, the nasal septum, a downgrowth of the merged medial nasal swellings, fuses with the cephalic aspect of the palate. 2. Conchae, or lateral elevations, are formed in the nasal cavities. Specialized olfactory epithelium, which sends fibers to the olfactory bulbs within the cranial cavity, is formed in the roof of each cavity. The paranasal air sinuses form as outgrowths of the lateral nasal wall into the maxilla, ethmoid, frontal, and sphenoid bones. D. Teeth 1. Dental lamina. Teeth develop from outbuddings of the dental lamina, located in the epithelial lining of the upper and lower jaws. a. Epithelium from the outer dental layer differentiates into ameloblasts, which form tooth enamel. b. Mesenchyme cells adjacent to the inner dental layer differentiate into odontoblasts, which form dentin. c.
Mesenchyme cells outside the tooth differentiate into cementoblasts, which produce cementum.
d. The periodontal ligament, another mesenchymal derivative, anchors the tooth into position on the alveolar bone. 2. Deciduous "milk" teeth appear 6-24 months after birth. Buds for the permanent teeth are
formed during the third month.
CONGENITAL ANOMALIES A. Branchial fistula allows remnants of the second through fourth clefts to maintain surface connection through this canal. B. Mandibulofadal dysostosis is a syndrome of malformations mainly caused by abnormal development of derivatives of the first arch. Insufficient migration of neural crest cells is an important factor. Symptoms include: 1. Bony defects of malar bone and mandible 2. Malformed ears and palate
Bridge to Immunology
3. Defects of lower eyelid
The immunologic consequences of DiGeorge syndrome are discussed in detail in the Clinical Immunology chapter of General Principles Book 1 (Volume I).
C. DiGeorge syndrome is characterized by the poor development or absence of several struc-
tures, including the thymus and parathyroids. This condition is caused by abnormal development of the third and fourth pharyngeal pouches and associated neural crest.
meClical
43
Embryology
D. Thyroglossal cyst is a remnant of the thyroglossal duct. It is found anywhere along the migratory path of this structure but is usually close to the midline. It may be connected externally by the thyroglossal fistula.
E. Cleft lip and cleft palate are relatively common abnormalities resulting from a variety of environmental as well as genetic factors. They may be bilateral or unilateral. l. Cleft lip is caused by failure of the maxillary processes to fuse with the medial nasal
swellings. It most often occurs on the upper lip. 2. Cleft palate is usually associated with cleft upper lip. It is caused by the failure of the palatine shelves to fuse. Severe cleft palate may not allow the infant to suckle properly, and milk may be regurgitated through the nose or aspirated into the lungs.
44
iM&ical
Congenital Abnormalities
Congenital malformations are structural abnormalities present at birth. Although accurate comparative intemational statistics about the incidence of various malformations do not exist, it is generally thought that 2-3% of liveborn infants demonstrate one or more anomalies at birth and that an additional 2-3% of abnormalities are detected during the first year. Although a small percentage of congenital defects are known to be genetically determined, and others have been shown to be caused solely by environmental factors, the majority probably result from an interplay of factors. This chapter reviews some of the most common congenital anomalies.
TERATOGENIC AGENTS Teratogenic agents are factors that cause abnormal development and congenital anomalies. In addition to the types of factors involved, the time of exposure is also important. These agents are most harmful during periods of intensive differentiation. A. During the pre-embryonic period, teratogenic agents usually cause death or abortion by impeding implantation or killing all the cells. Less likely effects are the death of a few cells followed by complete compensation of the remaining, still multipotent, cells. Interference with meiotic disjunction is another less common indirect cause of congenital anomalies. B. Teratogens are most likely to produce major malformations during the embryonic period of organogenesis. Within this period, each organ goes through its most critical stage of early differentiation. C. During the fetal period of organ growth, susceptibility decreases, and teratogens are most likely to produce minor defects. Because parts of the brain and urogenital system continue to differentiate late in pregnancy, they remain sensitive to the actions of teratogens.
CHROMOSOMAL AND GENETIC FACTORS A. Numerical chromosomal abnormalities are usually caused by nondisjunction, that is, failure of one or more pairs of homologous chromosomes to separate during meiosis. This situation typically results in germ cells of 22 and 24 chromosomes, which form monosomic and trisomic zygotes of 45 and 47 chromosomes, respectively. Becaused increased maternal age increases the frequency of autosomal trisomies, they are thought to be due primarily to nondisjunction during oogenesis. Some trisomies, as well as monosomy of a sex chromosome, are compatible with life. Monosomy of an autosome is uniformly fatal.
IIlP~~.
I
m.,.,.lC8
45
Embryology
1. Trisomy 21 (Down syndrome)
a. In some cases, the extra chromosome 21 is translocated or attached to another chromosome. A carrier parent (clinically normal) with 45 chromosomes who has a translocated chromosome 21 has an increased chance of having a child with the syndrome. b. Trisomy 21 is characterized by mental deficiency, small skull size, upwardly slanting palpebral fissures, and a deep transverse crease across each palm. c. It is associated with an increased incidence of congenital heart defects, umbilical her-
nia, and duodenal atresia. 2. Trisomy 18 (Edward syndrome) is characterized by mental retardation, receding chin, abnormal skull shape, low-set ears, and flexed fingers. It is often associated with syndactyly, cardiac anomalies, and skeletal defects. 3. Trisomy 13 (Patau syndrome) is characterized by mental retardation, malformed ears, a small head, congenital heart defects, renal anomalies, cleft lip and palate, deafness, and eye defects. 4. Klinefelter syndrome (most commonly XXY) a. This syndrome is characterized by sterility, small testes, degeneration of seminiferous tubules, gynecomastia, tallness, and, sometimes, mental retardation. b. Within the nucleus, a darkly staining chromatin region, or Barr body, can be found. The presence of this sex chromatin is due to the random condensation and "shutdown" of all X chromosomes except one. The Barr body is usually present only in normal females. 5. Turner syndrome (XO) or ovarian dysgenesis a. This syndrome is characterized by the absence of ovaries, dysmenorrhea, and infantile external genitalia and mammary glands. b. No sex chromatin is present. c. Turner syndrome is often associated with short stature, webbed neck, lymphedema of
the extremities, skeletal defects, no or mild mental retardation, and congenital heart defects.
B. Structural chromosomal abnormalities are usually due to chromosomal breakage caused by environmental factors. 1. Chromosomal deletions occur when a portion of the chromosome is lost. An example of
this abnormality is the cri-du-chat syndrome that results from a partial deletion of the short arm of chromosome 5. Affected children have a high-pitched, cat-like cry, mental retardation, microcephaly, and congenital heart defects. 2. Fragile chromosomal sites are portions of chromosomes that are unusually susceptible to breakage. An example of this abnormality is the fragile X syndrome, in which a fragile site on the X chromosome is associated with an altered phenotype. Affected individuals are mentally retarded. C. Single gene mutations 1. Autosomal dominant mutant gene anomalies include:
a. Huntington disease b. Marfan syndrome c. Osteogenesis imperfecta
46
meClical
Congenital Abnonnalities
d. Adult polycystic kidney disease e. Familial adenomatous polyposis f. Familial hypercholesterolemia g. von Recklinghausen disease 2. Autosomal recessive mutant gene anomalies include: a. Cystic fibrosis b. Hemoglobinopathies c. Phenylketonuria d. Thalassemias e. Albinism f. Juvenile polycystic kidney disease g. Congenital adrenal hyperplasia 3. Sex-linked mutant genes involve abnormal recessive genes on the X chromosome and consequently are expressed in males. Anomalies include: a. Hemophilia b. Duchenne muscular dystrophy c. G6PD deficiency d. Color blindness
ENVIRONMENTAL FACTORS
BridJe to Miaobiology
A. Infectious agents can cross the placental barrier and enter the fetal bloodstream.
Rubella, CMV, and herpes are discussed in detail in the Virology chapter of General Principles Book 1 (Volume I). Syphilis is discussed in the Spirochetes chapter, and Toxoplasma is reviewed in the Protozoa chapter of this same volume.
1. Rubella (German measles) causes malformations, which are usually the result of maternal infection during the first trimester. It may cause:
a. Cataracts and glaucoma b. Cardiac septal defects and persistence of patent ductus arteriosus c. Destruction of the organ of Corti in the ear, leading to deafness d. Microcephaly and mental retardation 2. Cytomegalovirus (CMV). The mother is usually asymptomatic. It is thought that only fetuses infected during late pregnancy survive and exhibit anomalies, which include: a. Microcephaly, hydrocephalus, mental retardation, and cerebral calcifications b. Chorioretinitis and microphthalmia c. Hepatosplenomegaly 3. Herpes simplex virus can be acquired by the fetus at birth if the mother has a genital infection. This condition leads to abnormalities, including chorioretinitis. Congenital anomalies, which result from infection in utero, include:
iii8C1ical
47
Embryology
Mnemonic
a. Microcephaly and mental retardation
Transplacental infections are sometimes referred to as "ToRCHes" organisms:
b. Microphthalmia and retinal dysplasia c. Hepatosplenomegaly
4. Toxoplasma gondii, a protozoan infection, can result in anomalies such as:
• Toxoplasma
a. Cerebral calcification, microcephaly, hydrocephalus, and mental retardation
• Rubella
b. Microphthalmia and chorioretinitis
• CMV • Herpes, HIV
5. Syphilis is caused by Treponema pallidum. Congenital syphilis can result in growth retardation and abnormal brain and skeletal development. B. Irradiation. Although the evidence regarding the hazards of diagnostic levels of radiation is
• Syphilis
not definitive, large doses of radiation or exposure to atomic fallout are known to be teratogenic. Anomalies include skull defects, skeletal defects, spina bifida, microcephaly, mental retardation, cleft palate, and mutations on germ cells, which lead to congenital anomalies in future generations. C. Drugs
1. Alcohol. Exposure to alcohol can result in fetal alcohol syndrome. It is associated with a number of fetal defects, including growth retardation, abnormal brain development and CNS dysfunctions, cardiac abnormalities, facial dysmorphism, and joint defects.
2. Thalidomide is a sedative that was used widely by pregnant women from 1960 to 1962 until it was withdrawn from market. It causes anomalies such as absent or defective long bones, resulting in amelia or meromelia (i.e., total or partial absence of extremities), gastrointestinal defects, and cardiac defects. 3. Tetracycline exposure can result in teeth and skeletal abnormalities. 4. Isotretinoin exposure can result in ear, brain, and heart malformations. 5. Chloramphenicol exposure can cause gray baby syndrome. 6. Aminopterin and its derivative methotrexate, antitumor agents and folic acid antagonists, cause anomalies including: a. Skeletal defects b. Anencephaly, hydrocephalus c. Cleft lip and palate d. Abortion 7. Antithyroid drugs (thiouracil, iodides, radioactive iodine) can cause goiter. 8. Environmental chemicals, such as organic mercury present in fish from polluted waters or certain fungicides sprayed on grain, cause anomalies including neurologic symptoms resembling cerebral palsy and blindness. D. Hormones 1. Progestins (e.g., ethisterone and norethisterone) may produce vanous degrees of masculinization of the genitalia in female embryos, including:
a. Clitoral hypertrophy b. Labial fusion c. Hypoplasia of uterus and vagina in severe cases
48
meclical
Congenital Abnormalities
2. Cortisone. Although this steroid has been shown to cause cleft palate in laboratory animals, its potential teratogenic effect in humans remains to be determined. E. Nutritional deficiencies 1. Maternal diabetes. Abnormal changes in the carbohydrate metabolism of the mother is
often the cause of abortions, stillbirths, neonatal deaths, and abnormally large infants. 2. Maternal iodine deficiency causes cretinism.
KArLA!!._ I meulca
49
SECTION II
Histology
Epithelium
Epithelial tissue consists of a variety of cell types with a minimal amount of extracellular material, which together line and cover virtually all free surfaces of the body. Epithelia are derived from all three germ layers and form sheets composed of groups of cells, in one or more layers, joined by specialized adhesions. The apical surfaces of epithelia face the free surface of the body or lumen of an organ or gland, and the basal surfaces rest on the basement membrane. Epithelial tissues are avascular so that nutrients and blood gases must diffuse from blood vessels located in the underlying connective tissues to the more superficially located epithelial cells. This chapter reviews the different types of epithelium and their functions within the body.
CLASSIFICATION OF EPITHELIA A. Surface epithelia are classified on the basis of two major characteristics: the number of cell layers in the epithelium (i.e., simple or stratified) and the shape of the cells in the surface layer (i.e., squamous, cuboidal, columnar). 1. Simple epithelia are defined as a single layer of cells in which all cells rest on the basement membrane. a. Simple squamous epithelium is one layer of flattened, scale-like cells (e.g., alveoli of lungs). In two locations, this epithelium has particular names: (1) Endothelium lines the cardiovascular and lymph vessels. (2) Mesothelium lines the pleural, pericardial, and peritoneal cavities.
Flashback to Embryology Both endothelium and mesothelium are derived from mesoderm.
b. Simple cuboidal epithelium is one layer of cells that are usually as tall as they are wide, as seen in vertical section (e.g., ducts of many glands). c. Simple columnar epithelium is one layer of cells that are taller than they are wide, as seen in vertical profile (e.g., intestinal absorptive cells). 2. Pseudostratified epithelium is often considered as a variant of simple epithelium because all of the cells rest on the basement membrane, despite the fact that their nuclei appear to be stratified because some of the cells do not reach the free surface. Two important pseudostratified epithelia are: a. Respiratory epithelium is pseudostratified, ciliated, and columnar with goblet cells, as found in the conducting airways of the respiratory tract (e.g., trachea). b. Urothelium transitional epithelium, found in the urinary system, is also pseudostratified. 3. Stratified epithelia are defined as two or more layers of cells where only the basal layer rests on the basement membrane. IIlPLAlf I meillea
53
Histology
a. Stratified squamous epithelium consists of multiple layers of cells and a surface layer of flattened, squamous cells.
Note Stratified epithelia are poorly suited for functions of absorption and secretion due to their thickness. They are well suited for protective function instead.
(1) Stratified squamous keratinizing epithelium occurs in the epidermis of the skin.
(2) Stratified squamous nonkeratinizing epithelium occurs in such areas as the oral cavity, esophagus, and vagina. b. Stratified cuboidal epithelium exhibits cuboidal-like surface cells (e.g., in the ducts of salivary glands). c. Stratified columnar epithelium exhibits columnar surface cells (e.g., in portions of the male urethra). B. Glandular epithelia consist of single cells or groups of cells specialized for secretion. They are
classified as exocrine (i.e., their secretions enter into a duct system) or endocrine (i.e., their secretions enter blood vessels). Exocrine glands are generally classified on the basis of the following four factors: 1. Number of cells a. Unicellular glands are defined as single cells interspersed among other epithelial cells of different functions (e.g., goblet cells). b. Multicellular glands occur as many adjacent secretory cells within the epithelium (e.g., surface mucous cells of stomach) or as complex glands with ducts (e.g., pancreas). 2. Duct system and secretory portion a. Simple glands have a simple, unbranched duct with tubular or acinar (alveolar) secretory pieces. b. Compound glands have a branched duct system with tubular, acinar, or tubuloacinar secretory units. 3. Type of secretion a. Mucous glands secrete a variety of viscous mucins rich in protein and polysaccharides. b. Serous glands secrete a watery fluid containing proteins. c. Mixed glands contain both mucus and serous secretory units.
In a Nutshell • Merocrine-involves exocytosis; most common form of secretion • Apocrine-discharge of the portion of the cell with secretory product included; e.g., lipid products of mammary gland • Holocrine-discharge of whole cell; e.g., sebaceous gland
54
meClical
4. Mechanism of secretion a. Merocrine secretion involves exocytosis. The membrane of the secretory granule fuses with the plasma membrane to release the contents of the granule. b. Apocrine secretion is the mechanism by which both the secretory product and a portion of the apical secretory cell cytoplasm are pinched off and released. c. Holocrine secretion is the mechanism by which entire cells and their contained secretory product are released. Cellular death occurs in this process.
5. Myoepithelial cells are myoid (muscle-like) cells that contain contractile filaments and assist in the secretion of certain glands (e.g., sweat, salivary, mammary). Derived from ectoderm, they are situated between the secretory cells and their basement membranes.
Epithelium
EPITHELIAL SPECIALIZATIONS A. Apical (free) surface specializations
1. Microvilli are apical cell surface evaginations of cell membrane with cores of microfilaments that function to increase the cell surface area available for absorption. They are covered by a thick glycocalyx coat, which gives a positive periodic acid-Schiff (PAS)
appearance under the light microscope. The core of each microvillus is anchored in the apical cell cytoplasm to the terminal web, which itself is anchored to the zonula adherens of the cell membrane (Figure II -1-1). 2. Stereocilia are elongated microvilli found at the apices of cells lining the epididymis, ductus deferens, and hair cells of the inner ear where they playa role in auditory sensation. 3. Cilia are apical cell surface projections of cell membrane that contain microtubules. a. Longer and coarser than microvilli, cilia are inserted on centriole-like basal bodies present below the membrane surface at the apical pole. b. Electron microscopy reveals the structure of cilia. They contain a central pair of microtubules, which are encircled by nine pairs of microtubules that all run in the direction of the long axis of the cilia. c. The cilia move back and forth to propel fluid and particles in one direction.
4. Flagella are longer than cilia but have the same microstructure; a prominent example is in the sperm, where the single flagellum provides motility. B. Lateral surface specializations 1. Zonula occludens (tight junction) occurs on the lateral cell surfaces just beneath the api-
Note
cal poles. a. Formed by the interactions of specific integral membrane proteins of apposed cell membranes, these junctions serve as permeability seals of the paracellular compartment. b. Each contact point represents a tiny ridge that, together with other ridges, form an anastomosing network that interlocks tightly across the intercellular gap. c. The zonula occludens network extends completely around the apical cell borders to
seal the underlying intercellular clefts from contact with the outside environment. d. In addition, it prevents leakage of materials, including ions, bidirectionally between epithelial cells.
In some epithelia (e.g., intestinal absorptive cells),
junctional complexesconsisting of occluding junctions, adhering junctions, and desmosomes-bridge the gap between the lateral surfaces of contiguous epithelial cells to seal and attach adjacent epithelial cells.
2. Zonula adherens (adhering junction) lies basal to the zonula occludens. It is also a bandlike junction but serves in the attachment of adjacent epithelial cells.
I IlAPLAlf medlea
55
Histology
3. Macula adherens (desmosome) is formed by the juxtaposition of two disk-shaped plaques contained within the cytoplasm of each adjacent cell and joined via specific attachment proteins.
Zonula occludens --+-----'+ Zonula adherens --+---
r\
Desmosome !}""'.' 1 (macula --+------;-\:.) L) adherens) Gap junction (nexus)
~ --%
Figure 11-1-1. Surface specializations found on simple columnar epithelial cells.
In a Nutshell Basement membranes provide elastic support, attach epithelia to the underlying connective tissues, and act as selective diffusion barriers.
a. Intermediate ftlaments (tonofIlaments) radiate away from the plaques. b. Desmosomes are most common in lining membranes, are subject to wear and tear, and are considered spot welds that hold cells together. 4. Macula communicans (gap junction) is an area of communication between adjacent cells that allows the passage of very small particles and ions from one cell to another. a. The junction consists of a hexagonal lattice of tubular protein subunits called connexons, which form hydrophilic channels connecting the cytoplasm of adjacent cells. b. The communicating channels through the gap junction permit the direct passage of ions and small molecules between cells to conduct electrical impulses or other signals. c.
56
meClical
Gap junctions are the sites of intercellular communication between epithelial cells as well as between cells of other tissues that require direct communication (e.g., impulses for smooth muscle contraction).
Epithelium
C. Basal surface specializations 1. Basement membrane is a sheet-like structure that underlies virtually all epithelia. It con-
sists of the following: a. Basal lamina is composed of type N collagen, glycoproteins (e.g., laminin), and proteoglycans (e.g., heparan sulfate). b. Reticular lamina is composed of delicate reticular fibers. 2. Hemidesmosomes resemble half-desmosomes and are found at sites where epithelial cells are attached to extracellular material, like the basement membrane. A complete desmosome, therefore, is found only on surfaces facing contiguous epithelial cells. In addition, intercellular attachment within desmosomes involves adhesion proteins of the cadherin variety, whereas hemidesmosomes use integrins.
IlAPLAff I medlea
57
SECTION III
Pathology
General Pathology
Cellular injury and inflammation are basic processes underlying all cellular and tissue changes in health and disease. These disease states may result from neoplasms, genetic or metabolic disorders, or from the introduction of exogenous toxic materials. This chapter focuses on the underlying processes causing cellular disease states, and on the mechanisms by which the cell adapts to its external stimuli.
CELLULAR INJURY AND ADAPTATION
In a Nutshell
Pathologic processes are manifested at the cellular, organ, and whole body levels. Cell survival depends on the maintenance of homeostasis, a stable internal environment, which requires a constant supply of metabolic energy and active transport processes. Before the microscopic appearance of cell injury, critical alterations of basic biochemical pathways must occur. When this homeostatic state is disrupted sublethally, the cell first adapts to the change. If the cell is unable to fully adapt, cell injury ensues. Injury at first causes reversible changes but may progress ultimately to irreversible injury and cell death. The ability of the cell or organ to tolerate injury depends on the severity, duration, and type of insult and on the adaptive capacity of the tissue.
Homeostatic cell
I Metabolic changes Ischemia Toxins, etc.
/\ /\
Adaptation A. Causes of cellular injury 1. Hypoxia, a lack of oxygen, leads to the inability of the cell to synthesize sufficient ATP.
The loss of ATP production results in a failure of the membrane sodium pump, increased glycolysis, and progressive detachment of the ribosomes from the rough endoplasmic reticulum. Hypoxia can result from:
Reversible changes
Injury
Irreversible changes
a. Loss of blood supply (ischemia) due to decreased arterial flow b. A decrease in the oxygen-carrying capacity of the blood due to anemia or carbon monoxide poisoning; CO produces a stable complex with hemoglobin, blocking 02 transport. c. Poisoning of the enzymes of oxidative phosphorylation by toxins such as cyanide, rotenone, and antimycin A 2. Chemical injury can lead to a disruption of the physical structure of the cell or to a breakdown of the biochemical processes of the cell. For example, chemicals can alter membrane permeability or block the action of an enzyme by binding either to the enzyme or to its cofactor. 3. Physical injury, such as crush injuries, gunshot wounds, burns, frostbite, radiation, and pressure changes, can lead to cell death and inflammation.
KAPLAlf I medlea
61
Pathology
4. Infections. Virtually all aspects of cellular metabolism are affected by biologic agents infecting the cell. a. Viruses invade cells, commandeer synthetic machinery, and may release proteins that are toxic to host cells and cellular metabolism. b. Bacteria release exotoxins (e.g., phospholipases) or produce endotoxins (e.g., lipopolysaccharides) from their cell walls. Both cause cell injury and possihly death. c. Viruses, bacteria, parasites, and fungi can cause the host to initiate a cellular (e.g., macrophages, T cells) or humoral (e.g., IgG, IgM) immunologic reaction to the invader.
5. Immunologic reactions. Although the immune response is tightly regulated, it can result in injury as manifested by an anaphylactic reaction or autoimmune diseases. Direct injury to an organism can result from the absence of an immune reaction. 6. Genetic disorders, which can present as biochemical abnormalities, can lead to the accumulation of toxic products or the inability to metabolize various compounds due to enzyme defects, such as cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. Acquired genetic defects (mutations) in genes that govern cell growth and differentiation (oncogenes) may lead to the development of cancer. 7. Nutritional or vitamin deficiencies, hypervitaminosis, inadequate calorie intake, or inadequate protein intake may all lead to cellular atrophy or even death. 8. Aging can lead to the breakdown of normal cellular machinery, ultimately leading to death of the cell. Some cells, such as gut epithelium or bone marrow stem cells, continuously renew, whereas others, such as neurons and skeletal muscle, may age and die. B. Cellular changes during injury 1. Cloudy swelling results from disruption of the integrity of the plasma membrane. By
inhibiting oxidative phosphorylation, hypoxia results in decreased ATP production. The loss of ATP affects the ouabain-ATPase, causing a failure of the membrane Na' pump. Disruption of the cells' osmotic pumps leads to an influx of Ca h and water and an efflux of Ki. The cells swell, and the endoplasmic reticulum becomes dilated. Although initially reversible, ultimately injury to the cell becomes irreversible if ATP is not restored.
In a Nutshell Cellular Changes During Injury • Cloudy swelling from cell membrane disruption
2. Membrane damage plays a central role in the pathogenesis of irrevenible injury. The membrane can be damaged from the loss of membrane phospholipids, breakdown of the cytoskeleton, production of toxic oxygen intermediates, and the production of lipid products, which by themselves can have a detergent-like effect on the plasma membrane. 3. Dilation and swelling of the endoplasmic reticulum lead to detachment of ribosomes, which leads to a decrease in protein synthesis.
• Membrane damage
4. Mitochondrial swelling results in an accumulation of Ca 2l , which uncouples oxidative phosphorylation.
• Endoplasmic reticulum swelling
5. Lysosomes rupture releases digestive enzymes into autophagic vacuoles or into the cytosol.
• Mitochondrial swelling • Lysosomal swelling • Nuclear changes • Apoptosis
6. Nuclear changes proceed from chromatin clumping to pyknosis with degeneration and condensation of nuclear chromatin. This can be followed by karyorrhexis (i.e., nuclear fragmentation) or karyolysis (i.e., dissolution of the nucleus). C. Expected pathologic changes in cell death and injury 1. Coagulative necrosis is the most common form of necrosis in cells without large num-
bers of lysosomes. The cell is converted into a homogeneous, eosinophilic mass with loss of the nucleus but preservation of cellular shape. Coagulative necrosis typically occurs
62
meClical
General Pathology
after sudden ischemia, thermal injury, or toxin injury. The heart is the most common example of an organ undergoing coagulative necrosis after an injury. 2. Liquefaction necrosis results from cellular destruction by hydrolytic enzymes involved in autolysis and heterolysis. Typically, liquefaction necrosis occurs in brain infarcts and pancreatic necrosis. Liquefaction by leukocytic enzymes is called suppuration, and the resultant fluid is called pus. 3. Caseous necrosis is a combination of coagulation and liquefaction necrosis, which produces tissue that is grossly soft, friable, and "cheese-like." Caseous necrosis is characteristic of tuberculosis, some granulomas and fungal infections, and the center of certain malignancies. 4. Enzymatic fat necrosis is caused by the action of lipases on fatty tissue. It is characteristic of tissues adjacent to acute pancreatic necrosis.
Note Squamous carcinomas often necrose in the center of invasive nodules due to their rapid growth.
5. Gummatous necrosis is seen in the late stage of syphilis; grossly, it differs from coagulative and liquefactive necrosis by its gelatinous appearance. 6. Apoptosis is a specialized form of programmed cell death that is characterized by: a. Chromatin condensation and formation of cytoplasmic membrane blebs (cell surface deformities caused by cytoskeletal disruption) b. Breakdown of DNA into nucleosome-sized fragments c. RNA and protein synthesis
d. A minimal inflammatory response D. Other cellular alterations during injury 1. Intracellular accumulations a. Lipids (1) Triglycerides (e.g., fatty change in liver cells)
(2) Cholesterol (e.g., atherosclerosis) (3) Complex lipids (e.g., sphingolipid accumulation) b. Proteins (e.g., renal epithelial cells in proteinuria) c. Glycogen and complex carbohydrates (e.g., glycogen storage diseases, mucopolysac-
charidoses) d. Pigments are colored substances, either normal cellular constituents or abnormal constituents, that lead to deposits. (1) Exogenous pigments. Anthracotic pigmentation of the lung is secondary to
inhalation of carbon dust. (2) Endogenous pigments. Lipofuscin (wear and tear pigment), melanin, hemosiderin, and bilirubin all may accumulate either in the cells that made them or in macrophages. 2. Calcification a. Dystrophic calcification appears in areas of necrosis due to precipitation of calcium phosphate in low pH. b. Metastatic calcification caused by hypercalcemia (malignancy, hyperparathyroidism) is due to precipitation of supersaturated solutions of calcium phosphate.
meClical
63
Pathology
E. Adaptive cellular responses to injury 1. Atrophy is a loss of cells or cell substances, resulting in a decrease in cell and organ size. The causes of atrophy are disuse, ischemia, aging, malnutrition, and lack of hormonal or neural stimulation. Atrophy of an organ may be caused by loss of cells, a decrease in cell size, or both. 2. Hypertrophy is an increase in both cell and organ size. It is caused by an increased mechanical demand, such as that seen in striated muscle of weight lifters or cardiac muscle in hypertension. It can also be seen with an increased endocrine stimulation. Hypertrophy can be physiologic or pathologic. Hypertrophy of an organ may be caused by an increase in cell number (lactating breast), an increase in cell size (skeletal muscle), or both (many cancers). 3. Hyperplasia is an increase in the number of cells. It is often associated with hypertrophy. Some cell types are unable to exhibit hyperplasia (e.g., nerve, cardiac, skeletal muscle cells). It can be physiologic or pathologic. Physiologic causes include compensatory (e.g., after partial hepatectomy), hormonal stimulation (e.g., breast development at puberty), or antigenic stimulation (e.g., lymphoid hyperplasia). 4. Metaplasia is a reversible change of one cell type to another, usually in response to irritation. It has been suggested that the replacement cell is better able to tolerate the environmental stresses. For example, bronchoalveolar epithelium undergoes squamous metaplasia in response to chronic irritation of tobacco smoke.
INFLAMMATION AND REPAIR Inflammation enables the body to resist infection. Inflammation occurs in response to injury, which can result from hypoxia, chemicals, drugs, physical agents, microbial agents, immunologic reactions, nutritional imbalances, genetic defects, or aging. The acute inflammatory response occurs over seconds, minutes, hours, and days after the initial insult, whereas the chronic inflammatory response can continue for weeks, months, and even years after the primary injury. A. Acute inflammation 1. Cardinal signs of inflammation a. Rubor (redness) b. Calor (heat)
Note
c. Tumor (swelling)
Transudate is a protein-free fluid leaked to the extravascular space; exudate is fluid containing proteins and cells leaked to the extravascular space. Transudate is usually caused by pressure differences between the vasculature and intracellular space (e.g., pulmonary edema in CHF). Exudate is usually caused by increased permeability of endothelial cell barriers and chemotactic factors attracting white blood cells (e.g., lung cancer, infection, toxins).
64
KAPLAN'iIme leaI
d. Dolor (pain) e. Loss of function 2. Pathophysiology. The acute inflammatory response begins with changes in the vasculature. There is a transient vasoconstriction followed by vasodilatation of the affected area. Ultimately, the blood flow slows as the vasculature becomes leaky. First, there is a transudate of comparatively protein-free fluid into the extravascular space, followed by an exudate of proteins, cells, and plasma, depending on the severity of the injury. a. Vascular changes (1) There is a transient vasoconstriction of arterioles followed by vasodilatation with
opening of supplementary capillary beds, which leads to an increased blood flow. Vasodilatation can be mediated by histamine, bradykinin, and, prostaglandins. (2) Increased vascular permeability or vascular leakage is caused by endothelial cell and pericyte contraction, transiently affecting venules; direct endothelial cell injury, affecting all microvessels; leukocyte-dependent injury to vessels; and later, regenerating endothelium.
General Pathology
(3) Chemical mediators of increased vascular permeability include the vasoactive amines, histamine and serotonin, which are stored in the granules of mast cells, basophils, and platelets. They act exclusively on venules (not capillaries). The complement components C3a and C5a are both anaphylatoxins and cause the release of more vasoactive amines. Bradykinin, an end-product of the kinin cascade, can also cause pain. Leukotrienes (i.e., LTC4 , LTD 4 , LTE 4 ) also individually produce increased vascular permeability. (4) Slowing of the circulation, resulting from increased blood viscosity due to extravasation of fluid, allows leukocytes to marginate, roll, and then adhere to endothelium via specific receptors. These include the integrin family of glycoproteins (LFA-l, CDlla/18) on the neutrophil and intercellular adhesion molecule (ICAM-l, CD54) on the endothelial cell. Adhesion is Ca 2+ dependent. (5) Leukocytes emigrate from the vasculature. The marginated, adherent cells extend pseudopods between the endothelial cells. They then move between the endothelial cells, migrating through the basement membrane toward the inflammatory stimulus. (6) Chemotaxis is the attraction of cells toward a chemical mediator that is released in the area of inflammation. Important chemotactic factors include bacterial products, such as N-formylmethionine (a prokaryotic product), LTB 4 , many factors liberated from leukocytes, and IL-8. The two most important chemotactic factors for neutrophils are C5a and IL-8. (7) Phagocytosis. Neutrophils and macrophages engulf and destroy foreign material. The particle to be phagocytosed can be coated with serum opsonins, such as IgG and C3b. These facilitate phagocytosis by allowing the particle to bind to complement receptor 1 (CRl) and the Fc receptor on the surface of the cell. After the particle is engulfed, the phagocytic vacuole fuses with a lysosome, forming a phagolysosome complex. The lysosome disgorges its contents into the fused vacuole. The offending particle (e.g., a bacterium) is then broken down via the action of reactive oxygen species, acid hydrolases, neutral proteases, and lysozyme. b. Chemical mediators of inflammation. Metabolites of arachidonic acid metabolism mediate many of the important aspects of the inflammatory response. The processing of arachidonic acid occurs via two pathways:
Bridge to Biochemistry Linoleic acid
(1) Cydooxygenase pathway, leading to prostaglandin formation; certain
I
prostaglandins (i.e., PGI 2, PGD 2, PGE 2, PGF 2a ) mediate vasodilatation and pain. (2) Lipoxygenase pathway, leading to leukotriene synthesis; certain leukotrienes (i.e., LTB 4 ) are involved in chemotaxis and increasing vascular permeability. c. Actions of anti-inflammatory drugs (1) Aspirin and the nonsteroidal anti-infammatory drugs (NSAIDs) exert their anti-
inflammatory effect by inhibiting prostaglandin synthesis (cyclooxygenase). (2) Corticosteroids most likely act by preventing the transformation of phospholipid into arachidonic acid by inhibiting the membrane enzyme phospholi-pases. Therefore, they inhibit both prostaglandin and leukotriene synthesis. Corticosteroids also impair leukocyte migration toward an inflammatory focus and stabilize lysosomal membranes.
Arachidonic acid
(Lipoxyge~ ~ /
(CYdOTgenaSel
LTC4 LTD4 LTE4
PGG 2 I PGH 2
(Leukotr~
\
TXA2
PGF2a (thromboxane) PGE2 PGD 2 PGI 2 (prostacyclin)
meclical
65
Pathology
Note The main cellular component in acute inflammation is the neutrophil; the main cellular component in chronic inflammation is the monocytemacrophage.
B. Chronic inflammation. Acute inflammation can be resolved completely or progress to chronic inflammation. The activated monocyte-macrophage plays a central role in chronic inflammation. It secretes enzymes such as neutral proteases (i.e., elastase, collagenase) and acid hydrolases (i.e., phospholipases), which can digest connective tissue. The activated monocyte-macrophage acquires the capability in a few days of secreting various plasma proteins, such as complement components C1 to C5, reactive metabolites of oxygen, leukotrienes, prostaglandins, cytokines (i.e., IL-1, tumor necrosis factor), and various growth factors (i.e., fibroblast growth factor, epidermal growth factor, platelet-derived growth factor). Chronic inflammation occurs if the offending agent cannot be removed (e.g., nondegradable foreign bodies, parasites) or if the tissue is subjected to repeated episodes of acute inflammation, such as recurrent cholecystitis. 1. Composition of the cellular infiltrate a. Cellular inftltrate is primarily mononuclear with proliferation and maturation of monocytes into macrophages (e.g., interferon-y). b. Fibroblasts are recruited and proliferate; small vessels proliferate and subsequent collagen deposition results in fibrosis and scarring.
c. Lymphocytes, plasma cells, and eosinophils are also present in sites of chronic inflammation. d. Neutrophils are occasionally continuously attracted in chronic inflammation associated with pus. 2. Chronic granulomatous inflammation occurs if a substance cannot be completely removed (e.g., asbestos, silica, tuberculous bacilli) or if a cell-mediated reaction is initiated against an agent. It is most frequently seen in tuberculosis (caseating granulomas), sarcoid (noncaseating granulomas), or with foreign bodies. Granulomas are also seen in Crohn disease, gout, rheumatoid arthritis, and in fungal and parasitic infections. a. Granulomas are small (0.5-2 mm) and consist of aggregations of macrophages, which can be transformed into epithelioid cells with occasional multinucleated giant cells. They are often surrounded by lymphocytes as well as plasma cells and fibroblasts. b. Epithelioid cell-modified macrophages with abundant eosinophilic cytoplasm contain large amounts of endoplasmic reticulum, Golgi, and vesicles, which indicate a secretory rather than a digestive function. C. Repair. Almost as soon as the inflammatory process begins, the repair of the damaged cells
and tissues starts. Repair involves two separate processes: regeneration of the damaged tissue by cells of the same type and replacement by connective tissue. Together they constitute wound healing. 1. Regeneration. Different tissues have different regenerative capacities. a. Labile cells regenerate throughout life. This cell type includes surface epithelial cells, such as those lining the skin, oral cavity, vagina, and cervix; hematopoietic, splenic, and lymphoid cells; and the mucosal cells of all excretory organs. b. Stable cells replicate at a low level throughout life but are dormant unless stimulated by some initiating event; these include the liver, pancreas, kidney, vascular endothelium, and smooth muscle.
c. Permanent cells cannot replicate and include neurons, skeletal muscle, and cardiac muscle. 2. Replacement of a damaged area by connective tissue involves migration and proliferation of fibroblasts into the damaged area, deposition of extracellular matrix, formation of new
66
KAPLA~.
meulCa
I
General Pathology
blood vessels, and reorganization of the connective tissue into a scar. Macrophages are usually present initially as the area is being remodeled. Neutrophils, eosinophils, lymphocytes, and mast cells can also be present. 3. Wound healing involves collagen synthesis and degradation. Various growth factors (such as PDGF, transforming growth factors [TGF] ex and ~, and FGF) and cytokines (such as tumor necrosis factor [TNF] and IL-1) stimulate collagen synthesis. Collagen can be broken down by various proteases such as collagenase, which can be secreted by macrophages and neutrophils migrating into the damaged area. Wound healing may be prolonged by foreign bodies, infection, ischemia, diabetes, malnutrition, or scurvy. a. Primary union by first intention occurs when there has been little surrounding tissue damage. The wound is clean, and the wound edges are closely approximated. (1) The wound fills with clotted blood, forming a scab.
Clinical Correlate Scurvy is caused by vitamin C deficiency; because vitamin C is a necessary cofactor for the cross-linking of collagen, scurvy can result in impaired wound healing because the cross-linking of collagen is essential for its tensile strength.
(2) Neutrophils line the wound edge within 24 hours. (3) A thin, continuous epithelial cover appears within 24-48 hours. (4) Macrophages replace neutrophils, and granulation tissue fills in the wound; the epithelial covering thickens. (5) By day 5, collagen fibers laid down by fibroblasts cross the incision following fibrin and fibronectin matrices. (6) Collagen continues to be synthesized, and the scar becomes increasingly avascular. (7) Full maturation of a scar requires up to 1 year.
b. Secondary union by secondary intention occurs when the two skin edges are not in contact. It requires larger amounts of granulation tissue to fill in the defect; it is characterized by significant wound contraction and is mediated by myofibroblasts.
CIRCULATORY DISTURBANCES A. Edema is the presence of excess fluid in the intercellular space. It can be localized or generalized and is caused by: 1. Increased hydrostatic pressure due to venous thrombosis (local) or congestive heart failure (generalized)
2. Hypoalbuminemia, resulting in a decreased colloid osmotic pressure 3. Lymphatic obstruction 4. Renal retention of salt and water B. Congestion is an excessive amount of blood in an area secondary to diminished venous outflow. With increasing stasis, the area acquires a purplish hue. C. Thrombosis is the solidification of a formed mass of blood components. It requires the interaction of all cells within the vasculature and endothelial cells, as well as circulating elements, such as platelets and the clotting cascade. Clotting is a balance between two opposing forces: those favoring the formation of a stable thrombus and those factors causing breakdown of the clot.
Clinical Correlate Congestion may be seen in purple-discolored legs with chronic venous stasis due to circulatory failure.
1. Pathophysiology of thrombosis formation. Injury to the vascular endothelium releases factors that both facilitate and inhibit thrombosis.
meClical
67
Pathology
a. Facilitation (1) Exposure of tissue factor from injured cells activates factor VII. (2) Exposure of thrombogenic subendothelial collagen activates factor XlI. (3) Platelets deposit and aggregate due to collagen exposure and generation of thrombin. b. Inhibition (1) Increased prostacyclin (PGI) and nitryl (N0 2 ) inhibit platelet aggregation.
(2) Synthesis of plasminogen activator promotes fibrinolytic activity.
Clinical Correlate Classic hemophilia (hemophilia A) is caused by a deficiency or reduced activity of factor VIII; it is characterized by excessive bleeding after trauma and bleeding into the joints (hemarthrosis). PTT is prolonged, but bleeding time and PT are normal. A deficiency in von Willebrand factor causes von Willebrand disease, characterized by spontaneous bleeding from mucous membranes and excessive bleeding after trauma. Bleeding time is prolonged, but platelet count and PT are normal. PTT is also prolonged because von Willebrand factor serves as a carrier for factor VIII; von Willebrand disease therefore results in a functional factor VIII deficiency.
2. Sequence of events in thrombogenesis a. Endothelial injury exposes subendothelial collagen. b. Platelets adhere, requiring von Willebrand factor and factor VIII; stimulation of the clotting cascade requires thromboplastin release from the endothelium (tissue factor). c. Platelets degranulate, releasing ADP and fibrinogen, and synthesize thromboxane ~.
d. Platelets aggregate, forming a temporary hemostatic plug. Later, there is formation of a secondary plug enmeshed in fibrin, requiring ADP, thrombin, and thromboxane. e. The thrombus retracts and organizes with proliferation of capillaries, fibroblasts, and infutration by neutrophils and macrophages. f. Canalization or formation of a new path for blood flow through the thrombus is accomplished by endothelial growth over the surface and through the thrombus, resulting in incorporation of the thrombus into the vessel. 3. Additional factors favoring thrombogenesis a. Endothelial injury releases abundant tissue factor. b. Changes in blood flow cause turbulence and stasis. Predisposing factors are sites of turbulence (i.e., vessel bifurcations, valves, past stenoses), atherosclerotic plaques, trauma, certain malignancies, and inflammation. c. State of hypercoagulability where there is increased thrombogenesis due to an alteration of the clotting mechanisms (e.g., nephrotic syndrome where more inhibitors than activators are lost) 4. Morphology of the thrombus. The head of the thrombus is composed of platelets and fibrin. The tail of the thrombus grows downstream. It consists of red blood cells and fibrin. Lines of Zahn are alternating layers of fibrin, platelets, and RBCs within the tail of the thrombus. a. Mural thrombi are adherent to the vessel wall. They are not occlusive and affect large vessels, such as the heart and aorta. b. Occlusive thrombi restrict blood flow most frequently in coronary, cerebral, femoral, iliac, popliteal, and mesenteric vessels. They often overlie an atherosclerotic plaque. Arterial thrombi are often occlusive and result in infarct (e.g., myocardial infarct, strokes), whereas venous thrombi rarely occlude vessels and tend to embolize. c. Postmortem clot can be differentiated from a thrombus by the absence of lines of Zahn and by its appearance as a rubbery, coagulated mass that is not attached to the vessel wall but forms a cast of the wall.
68
meCtical
General Pathology
5. Disseminated intravascular coagulation (DIe) begins with extensive formation of thrombi in the microcirculation, causing consumption of components necessary for hemostasis (i.e., platelets, fibrin, coagulation factors) and activation of the fibrinolytic pathways, leading to a bleeding diathesis. DIC is associated with a diverse array of clinical circumstances, such as amniotic fluid emboli, pre-eclampsia, gram-negative sepsis, cancer, trauma, surgery, and burns. D. Embolism is the occlusion of a vessel (either artery or vein) by a mass. Often emboli are thrombi that have dislodged from their site of formation and have lodged in a distal site occluding blood flow. 1. Pulmonary emboli often originate from deep vein thrombosis in the lower legs and less often from deep pelvic veins. 2. Systemic emboli are formed in the arterial circulation; most arise in the heart.
Clinical Correlate Die can be diagnosed by the presence of fibrin split products in the blood, low platelets, and prolonged PT and PH
Note An embolus is most likely a thrombus that has dislodged from its site of formation and has traveled to another site.
3. Paradoxical emboli cross over from the right side to the left side of the heart through septal defects and gain access to the systemic circulation. 4. Other types of emboli include gas emboli (e.g., Caisson disease), fat emboli (e.g., associated with bone fractures), amniotic fluid emboli, bone chips, and tumor cells. E. Infarction. If an artery or vein becomes occluded, then the acute loss of blood supply to the area can result in ischemic necrosis of the tissue. Most infarcts (99%) result from thrombotic or embolic occlusion of an artery or vein. Clinically, common sites of infarction are myocardial, pulmonary, brain, and intestinal tissue. Factors that affect the development of an infarct include: 1. Vascular supply, including collateral circulation
2. Rate of occlusion 3. Vulnerability of the tissue to hypoxia 4. Oxygen-carrying capacity of the blood F. Shock is characterized by vascular collapse. There is a greatly decreased perfusion of both
cells and tissue due to reduced blood volume, cardiac output, or vascular tone. Cellular injury is initially reversible, but if anoxia persists, cellular injury becomes progressive, leading to the death of cells and the patient. 1. Cardiogenic shock results from myocardial infarction (pump failure).
2. Hypovolemic shock results from reduced blood volume from any cause (hemorrhage, fluid loss). 3. Septic shock results from bacterial infection, such as gram-negative septicemia, which causes the release of vasodilatory mediators into the vasculature (lipopolysaccharides). 4. Neurogenic shock results from anesthesia or spinal cord injury.
NEOPLASMS A neoplasm is a mass of abnormal tissue whose growth exceeds and is uncoordinated with that of the normal tissues and continues in the same excessive state after cessation of the stimuli that evoked the change. A. Definitions 1. Anaplasia is loss of cell differentiation and tissue organization.
IlAPLA~. I meulca
69
Pathology
~~--------------------------------------------------------------------------------
2. Metaplasia is replacement of one type of adult cell or tissue by another not normally present in that site. 3. Desmoplasia is excessive fibrous tissue formation in tumor stroma. 4. Dysplasia is abnormal atypical cellular proliferation. 5. Carcinoma is malignant tumor of epithelium. 6. Carcinoma in situ is malignant tumor of epithelium that shows no invasion of underlying tissue. 7. Sarcoma is nonepithelial (mesenchymal) malignant tumor. 8. Metastasis is secondary, discontinuous malignant growth, such as a lung metastasis of a colon carcinoma. 9. Grade is an estimate of the cytologic malignancy of a tumor, including the degree of anaplasia and number of mitoses. Nuclear size, chromatin content, nucleoli, and nuclearto-cytoplasmic ratio are all used. 10. Stage is the clinical estimate of the extent of spread of a malignant tumor. Low stage means a localized tumor. Stage rises as tumors spread locally then metastasize.
B. Tumor markers 1. Alpha-fetoprotein (AFP) is expressed in hepatoma, embryonal cell tumor of the testis, and malignant teratoma. 2. Carcinoembryonic antigen (CEA) can be seen in any tumor derived from gut epithelium or in intra-abdominal inflammation (e.g., ulcerative colitis). It is most often elevated in colon and pancreatic cancers. It is also elevated in smokers in the absence of tumor and may be elevated in some carcinomas of the lung. 3. Beta human chorionic gonadotropin (I3hCG) is elevated in choriocarcinoma, hydatidiform mole, and germinoma. It is also elevated in pregnancy, forming the basis of the common pregnancy test. 4. Prostatic acid phosphatase elevations are seen in prostate tumors extending outside the capsule of the prostate (stage C or D). 5. Prostate-specific antigen (PSA) is also elevated in prostate cancer and in some cases of benign prostatic hyperplasia. 6. CA-125 is elevated in ovarian cancer.
In a Nutshell • Carcinoid tumor --? 5-HIAA • Oat cell tumor --? ADH, AGH • Squamous cell tumor --? PTH
7. CA 19-9 is elevated in pancreatic, gastric, and colon cancer. C. Ectopic hormone production causes a paraneoplastic syndrome.
1. Carcinoid tumors may produce S-hydroxyindoleacetic acid (S-HIAA), a metabolite of serotonin. 2. Oat cell tumors of the lung, derived from neuroendocrine cells, may produce ectopic hormones, most frequently antidiuretic hormone (ADH) or adrenocorticotropic hormone (ACTH). Many other small peptide hormones associated with oat cell carcinoma have been described. 3. Squamous cell carcinoma of the lung sometimes produces hypercalcemia by releasing a PTH-like molecule. D. Metastasis 1. Multiple routes to metastasis
70
liieClical
General Pathology
a. Body cavities and surfaces (e.g., peritoneal, pleural, pericardial) may be directly seeded by tumor cells floating in fluid such as ascites or a pleural effusion. b. Hematogenous spread is also quite common for most neoplasms, making the lung a common site for metastases of all kinds of cancer. c. Lymphatic spread is the most common route of spread for epithelial carcinomas.
d. Transplantation via mechanical manipulation (e.g., surgical incision, needle tracts) may occur but is relatively rare. 2. Sequence of lymphohematogenous spread a. Penetration of blood or lymphatic vessels requires detachment from neighboring cells, amoeboid movement, digestion of basement membranes, and crawling between endothelial cells. b. Release and embolization of tumor cells requires detachment from vessel walls and other tumor cells. c. Adherence of tumor cells, which become anchored in fibrin mesh, requires cell surface
receptors that bind to extracellular matrix proteins. d. Penetration of vessel walls in the metastatic site (i.e., lung) also requires altered adhesion molecules and amoeboid movement. e. Once tumor cells have crawled out of blood vessels in a new organ, they must survive in a new environment of hormones dissimilar to the cell's original environment. Although millions of cells may be shed from a primary tumor, successful metastasis is relatively rare. E. Theories of carcinogenesis 1. Essentially all malignant tumors have genomic alterations at the time of diagnosis. 2. Somatic mutation refers to structural changes at the gene or chromosomal level that occur spontaneously or in response to carcinogens after germ cell line maturation. Somatic mutation produces neoplasms that are more often monoclonal than polyclonal. 3. Aberrent differentiation in cancer cells occurs in the absence of structural changes, indicating abnormalities of gene regulation affecting growth and differentiation. This may occur regardless of the stimulus inciting malignant change: chemical, viral, radiation, or spontaneous. 4. Viral infection and consequent integration of viral DNA into the host genome may lead to malignant transformation (e.g., hepatitis B genome has been found in hepatoma cells, and RNA retroviral DNA copies have been found in some lymphomas). 5. Cell selection. Carcinogens favor the expression of a pre-existing population of transformed cells that would not be clinically evident otherwise. F. Cytology is the analysis of individual or clumps of cells to determine the degree of anaplasia. Cytology may be used to analyze cells from any source: uterine, cervix, sputum, plural fluid, ascites, fine needle aspiration, joint fluid, and others. Besides staining cells on slides, cells may be analyzed by flow cytometry, a procedure in which fluorescent antibodies are reacted with cells to determine the surface markers they express. This is most often done in the case of lymphomas and leukemias. Karyotype analysis of tumors is also helpful in showing which chromosomal regions of tumors are abnormal. Gene probe analysis defines specific gene rearrangements and can show gene expression patterns in tumors. These help in classification.
KAPLAlf I medlea
71
Pathology
G. Carcinogenic agents 1. Chemical carcinogens may be divided into two broad groups:
a. Direct-acting chemical carcinogens are mutagens that cause cancer directly, usually by modifying DNA (e.g., alkylating agents). b. Procarcinogens require metabolic conversion to form active carcinogens. Many strong chemical agents are procarcinogens. (1) They require an initiating agent and a promoter. Exposure to the initiating agent results in an irreversible cellular change, which allows the cells to produce a tumor. The promoter is an agent that increases the tumorigenic process in initiated cells. Cells may not be tumorigenic without previous exposure to an initiating agent. An initiator may cause a mutation, whereas a promoter causes increased growth rates. (2) Potential carcinogens are screened by the Ames test, which detects any mutagenic effects on bacterial cells in culture. Mutagenicity in vitro correlates well with carcinogenicity in vivo. 2. Radiation a. Ultraviolet radiation produces pyrimidine dimers in DNA, leading to transcriptional errors. b. Ionizing radiation by x-rays and gamma rays causes chain breaks in nucleic acids. When critical genes are mutated, cancer may result. 3. Oncogenic viruses a. RNA oncogenic viruses produce a viral-coded reverse transcriptase allowing synthesis of DNA from a viral RNA template. The DNA can then be integrated into the host genome. b. DNA oncogenic viruses include papovavirus, adenovirus, and herpesvirus. Infection does not necessarily result in the release of infectious virus. For example, EBV is associated with Burkitt lymphoma in Africa; HBV is associated with hepatocellular carcinoma. In both cases, viral DNA integrates into the host genome. 4. Loss of immune regulation. In patients with immune system dysfunction, an increased number of neoplasms develop, suggesting loss of the surveillance mechanism, which normally destroys neoplastic cells via recognition of "nonself" antigens.
TOXIC AND ENVIRONMENTAL CAUSES OF DISEASE A. Lead (plumbism) 1. Etiology. Plumbism is most often caused by chronic gradual accumulation; children absorb lead more readily than adults. In children, it may result from ingesting lead-based paint chips, chewing on painted furniture or painted lead pencils, and inhaling highway exhaust. Other sources oflead include improperly glazed ceramic dishes, home-fermented liquor, and contaminated drinking water. The use of lead-free paint and unleaded gasoline is reducing the incidence and severity of plumbism. 2. Pathogenesis. Lead inhibits enzymes involved in hemoglobin synthesis (including the inhibition of iron incorporation in tetrapyrrole rings) and inhibits adenyl cyclase activity in the brain and pancreas. 3. Clinical features. There is an insidious onset.
72
meClical
General Pathology
a. Anemia is characterized by increased hemolysis, coarse basophilic stippling, and elevated free erythrocyte protoporphyrin. The anemia is hypochromic and microcytic. b. Encephalopathy is caused by diffuse edema, demyelination, and neuronal degeneration, which causes delirium, seizures, and coma. c. Peripheral neuropathy is caused by myelin degeneration, which predominantly affects motor neurons. The radial nerve is most often affected, leading to wrist drop. d. Renal lesions feature proximal tubular dysfunction, causing glycosuria, aminoaciduria, and hyperphosphaturia (Fanconi syndrome). It is associated with mineral-containing intranuclear inclusions in proximal tubular cells.
In a Nutshell Key features of lead poisoning include: • Basophilic stippling of RBCs • Peripheral neuropathy • Lead lines in bones • Abdominal colic
e. Abdominal colic is chronic and often severe. f. Lead lines refer to an accumulation of lead sulfide on the gingival mucosa and epiphyseal radio densities on x-ray. B. Carbon monoxide 1. Pathogenesis. Carbon monoxide combines with hemoglobin to form carboxyhemoglobin, which cannot carry oxygen. The affinity of carbon monoxide for hemoglobin is more than 200 times greater than that of oxygen. Once formed, carbon monoxide is displaced from hemoglobin very slowly.
2. Types a. Acute toxicity. Symptoms of hypoxia are apparent when 30% of hemoglobin is carboxyhemoglobin; coma and death ensue when 60% is carboxyhemoglobin. The blood is cherry red, turning the lips cherry red as well. Carbon monoxide poisoning causes CNS hyperemia, edema, and focal hemorrhages with symmetric degeneration of the basal ganglia. There is loss of consciousness, coma, and death within minutes. b. Chronic toxicity. Slow poisoning causes systemic pathology with milder CNS changes. Fatty change occurs in the heart, liver, and kidney. The patient can usually recover completely. C. Acetaminophen. Because of its widespread availability, acetaminophen has become a commonly ingested substance in accidental childhood poisonings and in suicide attempts.
Note Cigarette smoke contains carbon monoxide; the percentage of carboxyhemoglobin in smokers is proportionate to the number of cigarettes smoked per day.
1. Pathogenesis. Hepatotoxicity is mediated by a toxic reactive metabolite, which, after depleting glutathione stores, binds to hepatocyte macromolecules.
2. Pathology. Acetaminophen toxicity causes severe centrilobular hepatic necrosis. The severity correlates with the serum drug level. 3. Clinical features. Patients experience nausea, vomiting, abdominal pain, and shock. Hepatic failure is not evident until 2-6 days after ingestion. 4. Treatment is gastric lavage and supportive measures; N-acetylcysteine may counteract the effects by replenishing glutathione stores. Blood levels should be followed, and early intervention is critical. D. Salicylates are another commonly ingested toxin. They may be ingested accidentally or in suicide attempts. 1. Pathogenesis. Initially, direct respiratory stimulation produces a respiratory alkalosis. In addition, the metabolic effects of salicylates cause a metabolic acidosis. Vomiting complicates fluid and electrolyte disturbances. Fatalities are most often due to dehydration and hypokalemia.
Bridge to Pharmacology Becaused there is delayed hepatic failure, acetaminophen overdoses ca n be treated with su Ifu r agents to restore reduced glutathione in the liver.
meClical
13
Pathology
2. Pathology. Hemorrhagic gastritis, petechiae, systemic hemorrhages, and necrosis of lymphoid germinal centers occur. 3. Treatment is gastric lavage (to remove any toxin still in the stomach), activated charcoal (to neutralize toxin still in the GI tract), and hemodialysis (to directly remove excess toxin from the blood). E. Mercury poisoning is rare. 1. Pathogenesis. Mercury inactivates enzymes (particularly cytochrome oxidases) and dam-
ages cell membranes. 2. Types
a. Acute toxicity causes necrosis of gastric and colonic epithelium, acute renal tubular necrosis, and, possibly, cerebral edema. b. Chronic toxicity causes excessive salivation, gingivitis, gastritis, renal tubular basement membrane thickening (which causes proteinuria and eosinophilic inclusions), and cerebral (particularly occipital) and cerebellar atrophy.
GENETIC DISORDERS A. Autosomal dominant disorders (Table III -1-1) 1. Phacomatoses. Tuberous sclerosis and von Hippel-Lindau disease are transmitted by auto-
Bridge to Pharmacology
somal dominant inheritance. Neurofibromatosis is transmitted in an autosomaldominant fashion in 50% of cases, and 50% of cases are sporadic mutations. 2. Familial hypercholesterolemia
Heterozygotes are treated with HMG-CoA reductase inhibitors (e.g., lovastatin) and bile acidbinding resins (cholestyromine), which partially act through the indirect increase of liver LDL receptors, which help to clear LDL from the blood. Homozygotes cannot be treated as heterozygotes because there are no functional LDL receptors. Therefore, they are treated with probucol, whose mechanism of action is unclear.
Clinical Correlate Nearly 100% of patients with FPC will get carcinoma of the colon by the fifth decade of life. The treatment of choice is to surgically remove the entire colon, usually in the second or third decade of life.
74
meClical
a. Clinical features. Homozygotes have more severe symptoms than heterozygotes, including xanthomas and extensive, early atherosclerosis often resulting in myocardial infarction in the second or third decade of life. b. Pathogenesis. There is a loss of feedback inhibition of cholesterol synthesis caused by decreased or defective low-density lipoprotein (LDL) receptors. 3. Marfan syndrome is a connective tissue abnormality; approximately 85% of cases are autosomal dominant. The incidence of sporadic cases increases with increasing paternal age. a. Pathogenesis is unclear. There is probably a defect in collagen structure and possibly defective elastin or mucopolysaccharide ground substance due to mutations in the fibrillin glycoprotein gene. b. Clinical features are very variable. They include arachnodactyly (long, spider-like fingers), tall stature, ligamentous laxity, subluxed lens, dissecting aortic aneurysm, usually of the ascending aorta (secondary to cystic medial necrosis of the vessel wall), mitral valve prolapse, and a short life-span, often due to a ruptured aorta. 4. Familial polyposis coli (FPC)
a. Thousands of adenomatous polyps appear, starting in the colorectum and spreading throughout the colon. Polyps first appear in the patient's twenties, become symptomatic in the thirties, and transform to adenocarcinoma by approximately age 40. b. Gardner syndrome has colonic polyps with soft tissue and bone tumors.
General Pathology
Table III -1-1. Autosomal-dominant disorders.
Disease
Incidence
Population Affected
17q
Neurofibromatosis Familial hypercholesterolemia
Chromosome with Defective Gene
19p
1:5,000 heterozygote 6
1:10 homozygote
Marfan syndrome
1:20,000
FPC
1:8,000
APCKD
1:1,250
Huntington disease
1:3,000
Wilms tumor Retinoblastoma
15 205-405
sq 16p
305-505
4p
Children
IIp
1:20,000
13q
5. Adult polycystic kidney disease (APKC) a. Renal cysts, increasing with age, cause progressively enlarged kidneys. The rate of enlargement of kidneys proceeds at the same rate in affected families. b. Hypertension, renal failure, and anemia are the presenting signs, typically starting when patients are in their forties. The age of onset of symptoms also proceeds at the same rate in a given family. c. Cysts are also found in the liver, pancreas, spleen, and gonads. There is an increased risk of berry aneurysms and abnormalities of the cardiac valves.
6. Huntington disease a. This is a progressive neurologic disorder; the age of onset tends to be the same in affected families. b. The onset of symptoms is usually between the ages of 30 and 50 years with involuntary choreic movements (Huntington chorea), cognitive impairment, and changes in behavior. Death follows after 15-20 years. c. It is associated with degeneration of the caudate nucleus. 7. Wilms tumor a. This is an embryonal tumor, one of the most common solid tumors in children under 4, involving one or both kidneys and characterized by primitive mesenchyme and immature tubules. Sporadic forms also occur. b. Wilm's tumor, aniridia, gonadoblastoma, and mental retardation (WAGR syndrome) are associated with a gene at chromosome llp13. c. This tumor often reaches enormous sizes and can be easily palpated on physical exam as a large abdominal mass.
KAPLA~. I meulca
75
Pathology
8. Retinoblastoma a. This disorder is an embryonal tumor affecting one or both eyes. Familial forms are characterized by the inheritance of one abnormal Rb gene (13q14) with the other normal Rb gene undergoing mutation early in the individual's life. Sporadic forms are not characterized by abnormal inherited genes but arise through spontaneous mutation of both Rb genes. b. Osteosarcoma is associated with familial forms of retinoblastoma. c.
The Rb gene is also spontaneously mutated in other malignancies (e.g., breast cancer).
B. Glycogen storage diseases are inherited via an autosomal recessive pattern. 1. Type I (von Gierke disease) is caused by an enzyme defect in glucose-6-phosphatase. The
affected organs are the liver and kidneys. The patient suffers hypoglycemic seizures within the first year, hyperlipidemia, hepatomegaly, growth retardation and failure to thrive, leading to a 50% mortality rate. 2. Type II (Pompe disease) is an enzyme defect in lysosomal a-l,4-glucosidase, which affects all organs, especially the heart and brain. Symptoms include muscle weakness and cardiac and neurologic impairment, resulting in death by age 2. 3. Type III is caused by an enzyme defect in glycogen debranching enzymes, which affects all organs. Symptoms include hepatomegaly, hypoglycemia, and growth retardation, but the disease is usually mild. 4. Type IV is caused by an enzyme defect in branching enzymes, which affects all organs. It causes liver cirrhosis and is lethal by age 3. 5. Type V (McArdle disease) is caused by a defect in striated muscle phosphorylase, which specifically affects striated muscle. Symptoms include muscle weakness, beginning in the second or third decade, and following a mild course. 6. Type VI is caused by a defect in liver phosphorylase, which affects only the liver. Symptoms include hepatomegaly, growth retardation, and fasting hypoglycemia, but the patient lives a normal life span. C. Lysosomal storage diseases
1. Mucopolysaccharidoses. Various lysosomal enzymatic defects lead to the accumulation of glycosaminoglycans throughout the body and brain. All except Hunter syndrome show autosomal recessive inheritance. a. Pathology. Storage of glycosaminoglycans occurs mainly in the endothelium, reticuloendothelium, and fibroblasts of the liver, spleen, lymph nodes, vessels, and bone marrow. Balloon cells are formed. These are distended cells with multiple small cytoplasmic PAS-positive vacuoles (lysosomes). In Hurler and Sanfilippo syndromes, lysosomes contain characteristic laminated structures on electron microscopy. Patients also have cardiac valve lesions, hepatosplenomegaly, arterial lesions in coronary and cerebral vessels, and skeletal deformities. b. Types of mucopolysaccharidoses (MPS) (1) MPS I H (Hurler syndrome) is caused by a defect in a-L-iduronidase, which causes an accumulation of heparan and dermatan sulfate. It is lethal by age 10 and is characterized by hepatosplenomegaly, dwarfism, skeletal abnormalities, mental retardation, and corneal clouding.
76
m8CIical
General Pathology
(2) MPS I S (Scheie syndrome) results from a defect in the same enzyme as Hurler syndrome but is a much milder disease. Patients have a normal life span and normal intelligence. (3) MPS I HIS (Hurler-Scheie syndrome) also results from a defect in the same enzyme as Hurler syndrome, with symptoms intermediate between Hurler and Scheie syndromes. (4) MPS II (Hunter syndrome) demonstrates an X-linked recessive inheritance pattern as a result of a defect of L-iduronate sulfatase, which causes accumulation of heparan and dermatan sulfate. Severity and life expectancy are variable. Symptoms are similar to those of Hurler syndrome except that there is no corneal clouding. Patients also have retinal abnormalities and deafness. (5) MPS III (Sanfilippo syndrome) is a group of variable enzyme defects (types A, B, C, and D) that lead to the accumulation of heparan sulfate. Patients present with mental retardation and skeletal abnormalities, but no corneal, cardiac, or liver abnormalities are seen. Death occurs in the second or third decade.
Mnemonic "A Hunter will aim for the X." Hunter disease is the only mucopoly-saccharidosis that is X-linked recessive.
(6) MPS IV (Morquio syndrome) causes an accumulation of keratin and chondroitin sulfate, which results in dwarfism, Hurler-like facies, and arterial lesions, but a normal intelligence. 2. Sphingolipidoses a. Tay-Sachs disease (GM 2 gangliosidosis type 1) is caused by a deficiency of hexosaminidase A, which leads to an accumulation of GM 2 ganglioside, affecting all organs but predominantly the brain, retina, and peripheral nervous system. (1) Clinical features. The onset of symptoms begins at 6 months of age with an exaggerated startle response and progressive mental, motor, and visual deterioration, leading to death by age 3. It can be detected prenatally by amniocentesis. The highest incidence is in Ashkenazic Jews (carrier rate is 1/30).
Note Sandhoff disease shows exactly the same symptoms as Tay-Sachs and is caused by deficiency of an enzyme that forms a complex with hexosaminidase A.
(2) Pathology. Characteristic pathologic findings include an enlarged brain, neuronal loss, and gliosis with enlarged neuronallysosomes forming balloon cells. Electron microscopy shows membrane whorls and other lysosomal inclusions. The retina has swelling of ganglion cells, particularly at the edge of the macula, which appears as a cherry-red spot against a pale, swollen retina. b. Gaucher disease is caused by defects in p-glucocerebrosidase, leading to the accumulation of glucocerebroside, which affects reticuloendothelial cells and the central nervous system. (1) Types. Three types are recognized, which vary in severity. (a) Type 1 (adult) affects primarily Ashkenazic Jews (1:625) and does not involve the CNS. It causes hepatomegaly and splenomegaly as a result of the accumulation of glucocerebrosides in phagocytic cells in these organs. It is compatible with a normal life-span. (b) Type 2 (infantile) produces an acute cerebral pattern with few systemic manifestations. There is prominent CNS deterioration, leading to an early death. (c) Type 3 (juvenile) produces early systemic symptoms with onset of CNS involvement in early adulthood.
KAPLA~. I meulca
77
Pathology
(2) Pathology. All three show Gaucher cells (i.e., distended reticuloendothelial cells in the liver, spleen, lymph nodes, and marrow). Cells are filled with a PASpositive fibrillary substance. c. Niemann-Pick disease is caused by a defect in sphingomyelinase, leading to an accumulation of sphingomyelin and cholesterol in a variety of organs. There are five phenotypes (types A-E) that are distinguished by the severity of CNS involvement and the age of onset. (1) Clinical features. Eighty percent of cases are type A, which is characterized by extensive CNS and systemic accumulations. Patients suffer from hepatosplenomegaly, xanthomas, fever, vomiting, failure to thrive, neurologic dysfunction, and death by age 2. (2) Pathology. Characteristic findings include enlarged "foamy" cells filled with distended lysosomes containing sphingomyelin. d. Krabbe disease is a galactocerebrosidase deficiency that causes an accumulation of galactocerebroside. e. Metachromatic leukodystrophy is an aryl sulfatase A deficiency that causes an accumulation of sulfatide.
Note
D. Other metabolic disorders
Aspartame, an artificial sweetener, contains phenylalanine and should be avoided by phenylketonurics.
1. Phenylketonuria is a disorder resulting from an absence of phenylalanine hydroxylase in
homozygotes, which halts the conversion of phenylalanine to tyrosine, resulting in elevated levels of phenylalanine in the blood. a. Clinical features. Infants are normal at birth, but within months, develop an abnormal pattern on EEG with seizures and mental retardation. There is minimal melanin production, causing light hair and skin, and blue eyes. The urine has a musty odor as a result of the urinary excretion of phenylacetic acid. Pathology can be prevented with a special diet free of phenylalanine and supplemented with tyrosine during childhood. b. Diagnosis is by the Guthrie bacterial inhibition assay (routine newborn screening) or by measurement of phenylalanine levels in the blood. e. Pathology. There are nonspecific CNS changes, such as decreased brain weight,
abnormal myelin, demyelination, and gliosis. 2. Galactosemia can result from two different enzyme deficiencies. a. Galactokinase deficiency is a benign disease. The main complication is cataract formation. b. Galactose-I-phosphate uridyltransferase deficiency is a severe form of galactosemia. (1) Clinical features. Only homozygotes have the classic syndrome. The defect causes elevated serum galactose and galactosuria. Impaired renal tubular resorption results in aminoaciduria. Early in the neonatal period, infants develop vomiting, diarrhea, failure to thrive, jaundice, hepatosplenomegaly, cataracts, bleeding diathesis, hypoglycemia, and mental retardation. Death occurs during infancy. (2) Pathology shows neuronal loss in the CNS with edema and gliosis of the brain. In the liver, there are fatty changes and, eventually, cirrhosis. 3. Albinism is caused by an enzymatic deficiency that prevents melanin synthesis from tyrosine. a. Types (1) Tyrosinase-negative type is caused by a lack of tyrosinase in melanocytes.
78
meClical
General Pathology
(2) Tyrosinase-positive type, in which tyrosinase is present, is caused by a defect in tyrosine uptake. b. Clinical features. The lack of melanin may be limited to the eye (ocular albinism) or may involve total body pigmentation (oculocutaneous albinism). In the latter, the skin is particularly sensitive to the sun, resulting in premature wrinkling and a tendency to develop solar keratosis, as well as basal cell, squamous cell, and melanocyte carcinomas. Eyes are very photosensitive; visual acuity is decreased. 4. Cystic fibrosis is caused by an abnormality in chloride channels.
a. Diagnosis may be made by demonstrating elevated chloride and sodium in sweat. b. Clinical features. Hyperviscous secretions lead to meconium ileus (small bowel obstruction) in 5-10% of newborns. Patients suffer steatorrhea (from pancreatic insufficiency), pulmonary obstruction, and pneumonia, leading to infection. Secondary cardiac complications follow. Men may be sterile as a result of obstruction of the vas deferens. Cirrhosis of the liver is common. 5. Alpha1-antitrypsin deficiency a. Clinical features. The patient experiences progressive emphysema of the lower lobes of the lungs. This is in contrast to smoking-related emphysema, in which the upper lobes are affected first. Cirrhosis of the liver is seen in some patients. b. Incidence. The incidence of emphysema due to al-anti-trypsin deficiency is less than 5% of that caused by smoking. 6. Sickle cell anemia and the thaIassemias are discussed in Hematologic/Lymphoreticular Pathology in Organ Systems Book 1 (Volume III). E. Sex-linked diseases 1. Fabry disease is a lysosomal storage disease.
a. Pathogenesis. A deficiency of a-galactosidase leads to the accumulation of ceramide trihexoside. Affected cells include endothelial, reticuloendothelial, myocardial, ganglion, renal glomeruli and tubules, and connective tissue cells. Blood vessels throughout the body are thickened, leading to myocardial infarction and stroke as the most life-threatening results. b. Clinical features (1) Angiokeratoma corporis diffusum (dermal cavernous hemangioma with overlying epidermal keratosis) appear as purplish dermal nodules over the entire body.
(2) Proteinuria usually occurs by the second decade, leading to renal failure and hypertension by the fourth or fifth decade. c. Pathology. Intralysosomallaminated whorls give affected cells a foamy appearance.
2. Lesch-Nyhan disease a. Pathogenesis. Abnormal purine metabolism due to deficient hypoxanthine-guanine phosphoribosyltransferase (HGPRT) results in hyperuricemia. b. Clinical features include gout and CNS deterioration with mental retardation, selfmutilation, and spastic cerebral palsy. c. Pathology. Joints and kidneys exhibit gouty changes. eNS pathology is inconsistent.
IlPUlr I me illea
79
Pathology
F. Disorders of chromosome number or structure
1. Trisomic disorders are usually secondary to a meiotic defect. a. Down syndrome (trisomy 21) (1) Incidence. This defect increases with maternal age. It affects 1 in 2,000 live births if maternal age is less than 30 and 1 in 50 live births if maternal age is greater than 45. The incidence of having a second affected child is 1 in 60. (2) Clinical features include severe mental retardation, characteristic facies (flat nasal bridge, epicanthal folds, oblique palpebral fissures), dysplastic ears, hypotonia, a horizontal palmar crease, redundant neck skin, and a short trunk. There is also an increased incidence of ventricular septal defect (VSD), acute lymphoblastic leukemia (ALL), and neurologic changes similar to those of Alzheimer disease. b. Edward syndrome (trisomy 18) (1) Incidence is 1 in 5,000 births.
(2) Clinical features include severe mental retardation, VSD, micrognathia (a small lower jaw), rocker-bottom feet, low-set ears, prominent occiput, and hypertonia. The average lifespan is 2-3 months. c.
Patau syndrome (trisomy 13) (1) Incidence is 1 in 6,000 births. (2) Clinical features include microcephaly, severe mental retardation, arrhinencephalia, microphthalmia, cleft lip and palate, VSD, dextrocardia, and polydactyly. Death is usually in the neonatal period.
2. Chromosomal deletions a. Cri du chat syndrome (5p-) (1) Pathogenesis. There is a deletion of the short arm of chromosome 5. (2) Clinical features. The patient exhibits a cat-like cry up to 1 year of age, severe mental retardation, microcephaly, and epicanthal folds; one in four patients has a VSD. Patients may live to adulthood. b. DiGeorge syndrome is caused by absence of the thymus and parathyroids, cardiovascular abnormalities, and low-set ears. It results from a deletion of chromosome 22qll during development. 3. Disorders of sex chromosomes a. Klinefelter syndrome (1) Karyotypes. The most common karyotype is 47,XXY, but other patterns may
also be seen. (2) Etiology. Nondisjunction during meiosis in either the maternal or paternal gamete may result in an extra X chromosome. (3) Incidence increases with maternal age or irradiation and affects 1 in 800 male births. (4) Clinical features include testicular atrophy, sterility, a small penis, failure of development of male secondary sexual characteristics, gynecomastia, and mild mental retardation. Mental deficiency is more marked with a greater number of X chromosomes.
80
m.Ctical
General Pathology
(5) Laboratory values show positive X chromatin, azospermia, low serum testosterone, and elevated urinary excretion of FSH. b. Turner syndrome (1) Karyotype is typically 45,XO.
(2) Incidence is 1 in 3,000 female births. (3) Clinical features may be subtle in mosaics. There is edema during infancy, a web neck, short stature, broad chest with wide-spaced nipples, low hairline, primary amenorrhea, infertility, coarctation of the aorta, and streak ovaries. c. Supernumerary Y chromosomes (1) Karyotypes are typically 47,XYY and 48,XYYY.
(2) Incidence is 1 in 1,000 male births. Affected individuals are usually tall with severe acne. The syndrome has been associated with antisocial aggressive behaviors in incarcerated individuals. d. Supernumerary X chromosomes (1) Karyotypes are typically 47,XXX and 48,XXXX. (2) Incidence is 1 in 1,200 female births. (3) Clinical features. Most patients are phenotypically normal, although there is an increased incidence of mental retardation and menstrual irregularities. e. Fragile-X syndrome (1) Karyotypes are typically 46,XY and 46,XX. (2) Etiology. Cytogenetic abnormality of the long arm of the X chromosome leads to chromosome breakage in vitro. (3) Clinical features are manifest in both males and females. In males, macroorchidism (enlarged testes) is observed bilaterally. Fragile-X syndrome is the second most important cause of hereditary mental retardation (Down syndrome is the most important).
IAPLA~.
meulca
I
81
SECTION IV
Pharmacology
Pharmacodynamics and Pharmacokinetics Pharmacology is the study of the action and disposition of chemicals that have a beneficial action in the body. These chemicals or drugs are used by physicians to diagnose, prevent, or treat disease. This chapter covers pharmacodynamic and pharmacokinetic principles.
GENERAL PRINCIPLES
In a Nutshell
A. Pharmacodynamics characterizes the action of drugs on the biochemical and physiologic
• Pharmacodynamics: drug's effect on the body
systems of the body and identifies the sites and modes of action. B. Pharmacokinetics characterizes quantitative aspects of drug absorption, distribution,
metabolism, and excretion and describes the time course of drug and metabolite concentrations at their site of action.
• Pharmacokinetics: body's effect on a drug
C. Therapeutics characterizes the clinical applications, contraindications, drug interactions,
and adverse effects of drugs. All drugs have beneficial and unwanted, adverse, and toxic actions, which can be further categorized. 1. Side effects are predictable effects seen in all individuals to a varying degree. 2. Idiosyncratic reactions are due to the individual, do not involve the immune system, are seen in a few patients, and are unpredictable. 3. Allergic reactions are due to the immune response of the individual, are seen in a few patients, and are unpredictable.
PHARMACODYNAMICS A. Drugs that act independently of receptors include: 1. Antacids. The base moiety of the compound neutralizes stomach acids. 2. Chelating drugs. These drugs bind metallic ions. 3. Osmotically active drugs include certain diuretics (e.g., mannitol) and cathartics (e.g., methylcell ulose). 4. Volatile general anesthetics. These drugs cause reversible changes in synaptic function from within the cell membranes. Drug potency correlates with lipid solubility. B. Drug-receptor interactions 1. Receptors. Many drugs work by combining with specific target molecules on cells to initiate a biochemical "cascade" to produce their effect. UPLAlr me il1C8I
85
Pharmacology
a. Receptors may be proteins, carbohydrates, nucleic acids, or lipids. b. Binding of drug to a receptor may involve ionic, covalent, hydrogen, or van der Waals bonds. c. Four receptor families have been categorized as: (I) Cell membrane-embedded enzymes. Surface receptor binding activates an enzyme inside the cell to initiate a response. (2) Ligand-gated ion channels. Receptor binding opens a channel to facilitate transmembrane flow. (3) G protein-coupled receptor systems. Receptor binding activates a G protein that then activates an effector (an enzyme or ion channel). (4) Transcription factors. These are located in the nucleus on DNA rather than on the cell membrane. Receptor binding produces prolonged influence on transcription. 2. Agonists are drugs that bind to receptors and stimulate them. 3. Antagonists are drugs that bind to receptors and decrease or block the effect of an agonist. They do not stimulate the receptors; they have zero efficacy.
In a Nutshell Competitive antagonists bind reversibly and can be overcome by a large amount of agonist. Noncompetitive antagonists cannot be overcome, usually because they bind irreversibly.
a. Competitive antagonist. These drugs reversibly bind to the receptor and prevent binding of the agonist (i.e., the antagonist and agonist are vying for the same receptor). High concentrations of the agonist can overcome the effect of a competitive antagonist. A competitive agonist produces a parallel right shift in the dose-response curve (Figure IV-I-I). b. Noncompetitive antagonist. These drugs usually bind to the receptor in an irreversible way and prevent any agonist action. After administration of a noncompetitive antagonist, high concentrations of agonist cannot reverse the antagonist's effects. Duration of action depends largely on the turnover rate of the receptors. A noncompetitive antagonist decreases the height of the dose-response curve (Figure IV-I-I). 4. Partial agonists are drugs that activate receptors at an intermediate level. These drugs bind to receptors to produce a submaximal response, but they also effectively act as antagonists because they compete with full agonists for access to the receptor binding site. C. Graded dose-response curves 1. These graphically depict the response of a particular system to increasing concentrations of a drug (agonist). An agonist is a drug that binds to receptors and stimulates them. The effect
of a drug is best analyzed by plotting the response versus the log of the drug concentration.
In a Nutshell A drug with high efficacy but low potency reaches a high level of response with a greater dose; a potent drug reaches its maximum response at a lower dose.
86
iiieilical
a. Efficacy. This is the maximum response that an agonist can produce. Efficacy increases as you proceed up the y-axis. b. Potency. This is a measure of how much drug is required to produce a given effect. Potency is typically expressed as the concentration that can elicit a 50% response, the EC50. The less drug required to produce an effect, the more potent a drug is. Potency increases as the curve shifts to the left on the x-axis.
Pharmacodynamics and Pharmacokinetics
Agonist with competitive antagonist
Log (dose)
Figure IV-1-1. Graded dose-response curves for the same agonist alone, in the presence of a noncompetitive antagonist and a competitive agonist.
In a Nutshell
D. Quantal dose-response curves 1. These curves show the minimum drug dose needed to produce a predetermined response in a population. The percent of the population responding is plotted against the log [dose] (Figure IV-1-2). a. ED50 (median effective dose) is the dose of drug that will produce the effect in 50% of the population. b. TD50 is the minimum dose that produces a specific toxic effect in 50% of the population. c. LD50 is the minimum dose that kills 50% of individuals in the population.
d. Therapeutic index (TI) is the ratio of the dose of drug required to produce a toxic or lethal effect to the dose needed for a therapeutic effect. The TI is used as an indication of drug safety and is expressed as: TI = TD50 or LD50 ED50 ED50
100
Therapeutic effect
Low therapeutic index indicates a relatively high incidence of side effects at usual doses (narrow range for therapeutic and toxic doses). High therapeutic index indicates a relatively low incidence of side effects at usual doses. So, the higher the TI, the safer the drug. Drug companies shoot for a ratio of at least 4. Anything less than 2 requires close patient monitoring (e.g., lithium).
Death
C
00>
~c
~'5
~§
50
00. 0.(1) -0)
0 ....
~
Log [drug] ED50
LD50
Figure IV-1-2. Quantal dose-response curves.
meclical
87
Pharmacology
PHARMACOKINETICS The following concept map (Figure IV-1-3) presents the factors that determine the concentration of drug at its site of action or biophase.
Dose and route of administration
Other compartments
Figure IV-1-3. Concept map of factors that affect drug concentration at the site of action.
A. Drug absorption 1. Factors affecting absorption. These are factors that affect absorption from the site of administration and transport. a. Permeability (1) Lipid solubility. This correlates with the ability of a drug to cross cell mem-
branes. Weak acids and bases are more lipid soluble in the nonionized state. (2) Aqueous solubility. Charged, water-soluble molecules are excluded from crossing many barriers (e.g., epithelial lining of the gastrointestinal tract and skin) unless they are very small. (3) Facilitated transport. Membrane carriers transport the molecule into the cell.
Note First-pass metabolism = some drugs are metabolically inactivated by the liver or gut before reaching the systemic circulation.
b. Bioavailability. This is the fraction of administered drug that reaches the systemic circulation. Bioavailability is 1 (or 100%) when a drug is given intravenously. It is generally less than 1 when a drug is administered by other routes (e.g., oral) because of factors such as incomplete absorption and first-pass metabolism. c. First-pass metabolism. This describes drugs that are absorbed from the gastrointestinal tract, enter the portal circulation, and are subject to inactivation by the liver before reaching the systemic circulation, thus decreasing bioavailability. 2. Routes of administration a. Oral (PO). Administration by mouth is the most common route. It is safe, economical, and convenient, but the drug must be lipid soluble and resistant to destruction by gastric acid, digestive enzymes, and gastrointestinal flora. The rate and degree of absorption can be variable.
88
metlical
Pharmacodynamics and Pharmacokinetics
b. Sublingual (buccal). Venous drainage from the mucosa under the tongue enters the systemic circulation (superior vena cava) and bypasses the portal circulation to the liver, where many drugs are metabolized. This route is useful for drugs that must be self-administered, require rapid onset of action (e.g., nitroglycerin in the treatment of angina pectoris), or are highly metabolized by the liver. c. Rectal. Absorption from the rectal mucosa has less of a first-pass effect than from oral
administration. This route is useful in vomiting or unconscious patients, although the absorption is irregular. d. Intravenous (IV) administration. The rapid and complete delivery of drugs to most target tissues is possible with intravenous administration. This route is useful in emergencies and for drugs that are highly metabolized by the liver or poorly absorbed from the gastrointestinal tract. e. Intramuscular (1M) administration. Aqueous solutions are absorbed rapidly, whereas oil solutions (depot forms) are absorbed slowly. This route is contraindicated for patients on anticoagulants. f. Subcutaneous (SC) administration. Only small volumes can be given by this route; drugs are relatively slowly absorbed. g. Topical administration. Drugs are applied locally to the skin, vagina, eyes, ear, nose, and throat. The transdermal route is for systemic administration of drugs applied to the skin; absorption is slow (e.g., nicotine or nitroglycerin patch). h. Intrathecal (IT) administration. Injection of drug into the subarachnoid space or ventricular system is by lumbar puncture or Ommaya reservoir, respectively. This route bypasses the blood-brain barrier and the blood-CSF barrier and therefore is useful for drugs with poor or slow CNS penetration or when high CNS concentrations are rapidly needed (e.g., severe meningitis, spinal anesthesia). 1.
Intra-arterial (IA) administration. This route allows delivery of high drug concentrations to selective organs. It is also used for x-ray contrast studies.
j. Inhalation. The inhalation route is for gaseous and volatile drugs (e.g., anesthetics, bronchodilators) .
B. Drug distribution. Once the drug reaches the circulatory system, several factors determine its disposition. 1. Plasma protein binding. The fraction of drug bound to plasma proteins is determined
by the amount of protein, mostly albumin, and the binding constant for the drug. Binding is nonspecific, so several drugs may compete for the same binding sites. 2. Volume of distribution (Vd ). Vd is the apparent or "virtual" volume into which a drug
distributes and is given by: Vd
total drug in body (g) plasma drug concentration (giL)
= - - - - - -........---'--'"'"'-'------
a. Drugs that are stored may have a Vdgreater than total body water (e.g., lipid-soluble drugs). b. Drugs that strongly bind to plasma proteins have a Vd that approaches plasma volume. c. The greater the Vd, the slower the elimination rate.
Note Competition for plasma protein binding explains some drug-drug interactions. For example, both sulfonamides and coumarins are highly bound to plasma proteins. Therefore, the administration of sulfonamides to a patient chronically treated with warfarin can displace the drug from plasma proteins and cause dangerously high free warfarin concentrations in the blood.
meClical
89
Pharmacology
3. Unequal distribution. Factors that account for unequal drug distribution include the following: a. Tissue affinity. Binding to mucopolysaccharides, nucleoproteins, and phospholipids reduces the availability of drugs. b. Body fat acts as a reservoir for lipid-soluble drugs. c. Blood-brain barrier is highly selective for lipid-soluble, non ionized compounds. d. Blood flow, if high, allows drugs to reach equilibrium faster (e.g., in brain). C. Drug elimination. Pharmacologic effects of drugs are terminated by the biotransformation
of the drug to an inactive metabolite before excretion or by the excretion of unchanged drug or active metabolite. 1. Metabolism and biotransformation. The liver is the most important site of drug metabolism and biotransformation. Metabolic enzymes, the hepatic microsomal enzymes, are predominantly found in the smooth endoplasmic reticulum, e.g., the cytochrome P-450 systems. Other enzymes are located in mitochondria (e.g., monoamine oxidase), the cytosol (e.g., alcohol dehydrogenase), and lysosomes. a. Phase I. Most metabolic reactions are oxidations, reductions, or hydrolyses (phase I reactions). Phase I reactions may be followed by phase II conjugations. b. Phase II. Conjugation of drugs or metabolites involves the addition of an endogenous substance (e.g., carbohydrate or sulfate). This usually inactivates the drug or metabolite and facilitates excretion by making the drugs more hydrophilic. (1) Conjugation may occur with glucuronic acid (most common), sulfate, and
amino acids, or by acetylation. (2) Enterohepatic circulation. Conjugated drugs are actively secreted in the bile. In the small intestine, the drugs are hydrolyzed, and most bile salts are reabsorbed in the terminal ileum. The drug may be excreted in the feces or reabsorbed and excreted in the urine. c. Factors that affect hepatic metabolism (1) Age. Very young and elderly individuals may have impaired metabolism or con-
In a Nutshell
jugation.
An important source of drug interaction is induction or inhibition of metabolism by the liver.
Inducers
Inhibitors
Barbiturates Cimetidine Phenytoin Ketoconazole Isoniazid Rifampin Carbamazepine
(2) Genetics. The activity of N-acetyltransferase is regulated by genetic factors and influences the metabolism of procainamide, dapsone, and isoniazid. (3) Hepatic insufficiency may impair metabolism (e.g., cimetidine). (4) Drug interactions. Some drugs may competitively inhibit the metabolism of other drugs by the microsomal enzymes. Others may induce increased microsomal enzyme activity, thereby increasing the metabolism of other drugs. (5) Hepatic blood flow. Congestive heart failure (CHF) and drugs that reduce cardiac output (e.g., propranolol) can impair hepatic metabolism by reducing hepatic blood flow. 2. Drug excretion a. Kidney. The kidney is the primary site of drug excretion. (1) Glomerular filtration is a passive, nonsaturable process. Drugs that are bound
to plasma proteins are not readily filtered.
90
meclical
(2) Tubular secretion is usually an active, saturable process; this takes place mostly in the proximal convoluted tubule.
Pharmacodynamics and Pharmacokinetics
(3) Passive excretion. Charged particles cannot passively cross tubular membranes; neutral molecules can. This principle can be used to enhance the secretion of toxic charged particles. b. Lungs are important for the excretion of gaseous anesthetics and contribute to paraldehyde, alcohol, and garlic excretion. c. Gastrointestinal tract. Some drugs are secreted into the liver biliary tract and eliminated in the feces. d. Sweat, saliva, tears, and breast milk contribute minimally to the excretion of drugs. Lactating mothers should be under close medical supervision when breast feeding because many drugs are excreted in breast milk and can cause neonatal toxicity. D. Drug decay curves. Fundamental pharmacokinetic principles are based upon the most elementary kinetic model, i.e., that the body is considered a single compartment (Figure N-1-4). Drug decay curves describe the time course of drug in the compartment or body. 1. Zero-order kinetics. This occurs when the elimination process is saturated. A constant
amount (not a fraction) of the drug is eliminated over a given time period (e.g., ethanol).
Plasma [drug]
~ Time Zero-order kinetics
Plasma [drug]
~ Time First-order kinetics
Clinical Correlate Alkalinization "traps" salicyclic acid in the renal tubule by increasing the ratio of charged to uncharged molecules. Because only the uncharged molecules are in equilibrium across the tubular membrane, excretion is enhanced.
In a Nutshell • Zero-order kinetics-drug decreases at a constant rate regardless of plasma drug concentration • First-order kineticselimination rate is proportional to plasma drug concentration First-order kinetics are characterized by the concept of half-life (tl/2) elimination.
Figure IV-1-4. Drug decay curves.
2. First-order kinetics. Most drugs at therapeutic doses follow first-order kinetics, i.e., elimi-
nation is concentration dependent and follows exponential kinetics. In first-order kinetics: a. Processes necessary for absorption and excretion are not saturated. b. A constant fraction of the drug is eliminated per unit time. c. The rate of drug removal is proportional to the plasma concentration, and the concentration of drug diminishes logarithmically with time. d. The rate of elimination may be described in two ways: (1) Physiologic half-life (t 1/2), which is the time required for 50% of the drug to be
eliminated, where t1/2 = 0.69/ke (2) Rate constant of elimination (ke), which is the percentage change per unit of time ke
3. Clearance (CI) of drug from the body is equal to the product of the rate constant (ke ) and volume of distribution:
In a Nutshell Clearance is mathematically equivalent to the volume of blood that can be completely cleared of a drug per unit time.
KaP LA I'dme leaI
91
I.
Pharmacology
4. Drug accumulation. Repeated doses may cause accumulation of the drug (Figure IV-1-5). Assuming first -order kinetics: a. If the rate of administration exceeds the rate of elimination, accumulation occurs.
Dose of drug
Absorption
Single compartment V
Metabolism
--H~and
excretion
Figure IV-1-5. The single-component pharmacokinetic model.
Note With first-order kinetics, the average drug concentration is determined by the ratio of the dose to the dosing interval. Therefore, 4 gj4 h would produce the same average concentration that 8 gj8 h would, except that the peaks and troughs would be more severe in the latter case.
b. Accumulation ceases when the rate of elimination is equal to the rate of administration; at that time, a steady state is established. c. The time required for a drug to be eliminated is related to
t\/2. Just as it takes 4-5 halflives for drug accumulation to reach steady state, it takes 4-5 half-lives for drugs to be almost completely eliminated.
E. Clinical implications 1. Half-life. The half-life of a drug determines the dose interval necessary to obtain the
desired level of drug. a. Drug with short half-life. Giving twice the dose does not double the duration of action of a drug with a short half-life. b. Drug with long half-life. A large loading dose followed by smaller maintenance doses (e.g., digitalis) are typical for drugs with a long half-life. c. Drug accumulation. Because approximately four half-lives are required for almost complete elimination of a drug, any dosage interval shorter than this leads to drug accumulation. 2. Prolongation of drug action a. Frequent doses (e.g., sulfonamide every 4 hours) are necessary. b. Coating tablet (time-release) or a "depot" form of the drug (e.g., crystalline insulin) allows slow absorption.
100 90 c:: 80 ,g 70 ~ 60 c:: ~ 50 § 40 () 30 20 10 0
Elimination rate constant ke =0.693/t1/2 Half-life, t1/2 = 0.693/ke' where 0.693 = In(2)
25
/
93.75% complete after four half-lives
12.5 6.25+--+--+--'"""'''';''''
1 2 3 4 Time (half-life multiples)
Figure IV-1-6. A "drug decay curve" showing the time course of exponential elimination of a drug from the circulation over time.
92
meCtical
Pharmacodynamics and Pharmacokinetics
c. Slow excretion of drug (e.g., blocking secretion of penicillin G with probenecid) pro-
longs drug action. d. Inhibiting the metabolism of drug (e.g., blocking the metabolism of 6-mercaptopurine [6-MPj with allopurinol) also prolongs the drug action. 3. Loading dose. Certain drugs in clinical situations may require a loading dose to produce therapeutic levels without the delay of 4-5 half-lives (e.g., lidocaine in the setting of an acute myocardial infarction). 4. Disease states requiring adjustment of drug dose and dosing interval
Clinical Correlate
a. Renal insufficiency ( 1) Creatinine clearance correlates well with elimination of a drug by the kidney. Serum creatinine and blood urea nitrogen (BUN) correlate less well. (2) The initial or loading dose is usually the same, but the maintenance dose must be decreased or the interval between doses increased in proportion to the decreased creatinine clearance and the fraction of drug excreted unchanged in the urine.
A low creatinine clearance indicates renal insufficiency and often necessitates a decrease in dose or a decrease in dosing frequency of renally excreted drugs.
b. Hepatic insufficiency. Although these patients may require adjustments in the dose and intervals of drugs that are metabolized by the liver, accurate prediction of the adjustment is not possible based on liver function tests or other parameters. Serum drug concentration and clinical manifestations of toxicity must be followed closely.
meCtical
93
Autacoids Autacoids are endogenously produced substances of intense pharmacologic activity that do not fit into more specific classifications, such as hormones or neurotransmitters. They are also called paracrine secretions or "local hormones" and "autopharmacologic agents." The autacoids include histamine, serotonin, angiotensins, kin ins, and the eicosanoids (prostaglandins).
HISTAMINE A. Biosynthesis and physiologic properties 1. Histamine is synthesized by decarboxylation of the amino acid histidine (L-histidine decarboxylase) .
2. Histamine is found in varying concentrations in nearly all mammalian tissues. The highest concentrations are found in skin, lung, and especially the gastrointestinal mucosa. Large amounts are normally stored in the body, particularly in the circulating basophils and tissue mast cells. 3. Histamine release from mast cells is a secretory process triggered by the binding of ~pe cific antigen to two adjacent surface 19E molecules ("bridging"). Degranulation liberates histamine, which is responsible for many of the signs of immediate hypersensitivity, allergy, and anaphylaxis. An increase in intracellular Ca2+ results from the cross-linking of receptors, leading to increased Ca2+ permeability and release to initiate degranulation. 4. Reduced cAMP or cGMP favors histamine release. Beta-adrenergic stimulation and glucocorticoids decrease release by increasing intracellular cAMP. 5. Other substances present in mast cell granules that contribute to allergy and anaphylaxis are: a. Kallikrein b. Kinins c. Prostaglandins
d. Slow-reacting substance of anaphylaxis (SRS-A) B. Histamine receptors
1. HI receptors
a. These receptors mediate constriction of smooth muscle in bronchi and the gastrointestinal tract. b. They mediate vasodilatation of small vessels and increase capillary permeability.
KAPLAlf I medlea
95
Pharmacology
In a Nutshell Receptor Action
c. They are blocked by pyrilamine and diphenhydramine; the classic agonist is 2-methylhistamine. Blocker
HI
Vasodila- Diphentation hydramine Broncho- and others constrdion
Hz
Gastric acid Cimetidine secretion and others
HJ
CNS
N/A clinically
d. They are coupled to phospholipase C. Activation leads to inositol l,4,S-triphosphate (IP 3 ) and diacylglycerol (DAG), which activate protein kinase C, calmodulindependent kinases, and phospholipase A2, leading to response. e. HI blockade has no effect on gastric acid secretion. 2. H2 receptors a. These receptors mediate gastric acid secretion and vasodilatation. b. They are blocked by cimetidine, ranitidine, famotidine, and nizatidine. A selective agonist is dimaprit; the classic agonist is 4-methylhistamine. c. They are linked to the stimulation of adenylate cyclase and, thus, to activation of cAMP-dependent protein kinases. 3. H3 receptors a. These receptors were discovered in the late 1980s. b. They are found mainly in the CNS, where they inhibit the release of neurotransmitters. c. They may be involved in synthesis and release of histamine.
d. They are selectively blocked by thioperamide; the selective agonist is a-methylhistamine. C. Organ system effects 1. Cardiovascular system a. Histamine produces a dilatory effect on vasculature, which causes flushing, lower peripheral resistance, hypotension, and increased capillary permeability (predomi. nantly HI-mediated). b. There is positive inotropic and chronotropic effects on the heart (H 2 -mediated). c. The classic "triple response" following intradermal injection (mainly HI) includes:
(1) Localized erythema due to vasodilatation (2) Bright red flare surrounding the local spot as a result of axon reflexes that produce additional vasodilatation (3) A wheal of edema secondary to increased permeability of postcapillary venules 2. Extravascular smooth muscle a. HI agonists cause contraction; bronchial smooth muscle is very histamine sensitive, and fatal bronchoconstriction can occur with excessive HI-receptor stimulation. b. H2 agonists cause relaxation. 3. Exocrine glands (gastric glands are the prototype) a. Histamine is the primary terminal common mediator of gastric acid secretion. Copious, highly acidic gastric juice is produced in response to histamine (H 2 receptor-mediated). b. Histamine can also stimulate secretion from the pancreas, salivary glands, and bronchiolar glands. 4. Nerve endings cause sensations of pain (dermis) and itch (epidermis); classically, these effects are part of the triple response. 5. Histamine stimulates the adrenal medulla to release catechols.
96
meClical
Autacoids
D. Metabolism 1. Histamine acts rapidly when given parenterally; oral histamine is, for the most part, inactivated by bowel flora. 2. Most histamine is metabolized by methylation (N-methyltransferase), yielding N-methylhistamine. 3. Most of the N-methylhistamine is then converted by monoamine oxidase (MAO) to N-methyl imidazole acetic acid and excreted by the kidney. 4. Alternatively, some histamine is oxidatively deaminated by diamine oxidase (DAO) and then excreted as ribose conjugates.
E. Histamine-receptor agonism 1. Certain compounds release histamine directly without antigen-IgE interaction, e.g.,
cationic organic compounds (including a variety of drugs), amides, alkaloids, and certain antibiotics. 2. The action of some venoms and toxins may be mediated by histamine release. 3. Pathologic aggregations of mast cells and basophils may cause a variety of histaminic symptoms. Conditions such as urticaria pigmentosa (mastocytosis), systemic mastocytosis, carcinoid syndrome, and myelogenous leukemia are associated with urticaria, pruritus, headache, weakness, flushing, and gastric distress (including peptic ulcers).
F. Clinical uses. Histamine has no current therapeutic uses but is used clinically in some system function tests. 1. Gastric function tests. Hyposecretion or hypoacidity of gastric juice in response to his-
tamine is associated with pernicious anemia and atrophic gastritis; a hypersecretory response is found with Zollinger-Ellison syndrome. 2. Sensory nerve tests. Local flare after intradermal injection implies intact sensory nerves. 3. Bronchial reactivity. Inhalation of histamine is used to test the reactivity of bronchi. G. HI antagonists ("antihistamines") are used to control the symptoms of immediate hypersensitivity. 1. Classes of drugs used for their HI-blocking activity
a. First-generation (nonselective) (1) The ethanolamines include diphenhydramine, dimenhydrinate, and clemastine. Ethanolamines have strong sedative and anticholinergic effects; gastrointestinal disturbance is rare.
Note StratEgies for treating hypersensitivity may also include physiologic antagonists, such as epinephrine or ephedrine.
(2) The ethylenediamines include pyrilamine and tripelennamine. Ethylenediamines are sedating and have local anesthetic actions; gastrointestinal disturbance is common. (3) The alkylamines include chlorpheniramine, brompheniramine, and dexclorpheniramine. Alkylamines are less sedating than ethanolamines and ethylenediamines; they produce more CNS stimulation than other groups. (4) The phenothiazines include promethazine. Phenothiazines possess considerable anticholinergic activity and moderate sedative effects. They are used primarily for their antiemetic effects.
metlical
97
Pharmacology
(5) The piperazines include meclizine, hydroxyzine, and cyclizine. Piperazines have comparatively little sedative effects. CNS and anticholinergic effects are moderate and long acting. They are used for treating vertigo and motion sickness. Hydroxyzine has significant antipruritic action. b. Second-generation (peripherally selective) (1) Cetirizine is in the piperazine class. It is a metabolite of hydroxyzine, but it does not cross the blood-brain barrier. Thus, cetirizine is nonsedating. (2) The piperidines include astemizole, fexofenadine, and loratadine. These are H} antagonists that do not cross the blood-brain barrier effectively and, thus, produce minimal CNS actions. Most piperidines are nonsedating. 2. Pharmacokinetics. All of the antihistamines are well-absorbed orally, metabolized by the liver, and excreted by the kidney. 3. Pharmacologic effects a. H] antagonists act by occupying the histamine H} receptor without initiating a response (i.e., they provide competitive inhibition).
Clinical Correlate Physiologic antagonists, such as epinephrine (which also exhibits antihistamine actions to some extent), are more effective for the management of acute asthma and anaphylaxis than are the specific histaminereceptor antagonists.
b. They have no effect on gastric secretion. c. They antagonize the bronchoconstrictor activity of histamine as well as the cutaneous "triple response" to intradermal histamine. d. They exert cough suppressive (antitussive) action via a presumed CNS effect. Other CNS mechanisms include action in the medullary chemoreceptive trigger zone ("vomiting center"), possibly by antagonism of acetylcholine. e. They provide relief of the effects of motion sickness via a presumed CNS action. f. They are useful as nighttime sleep aids because of their sedative effects. 4. Indications for use a. Antihistamines are used for the palliation of symptoms of allergy, hay fever, and allergic rhinitis and for the palliation of cutaneous allergic symptoms associated with chronic urticaria, atopic and contact dermatitis, and the urticaria of serum sickness and drug eruptions. b. They are not beneficial for treating bronchial asthma. c. They are mildly useful as secondary agents in the treatment of anaphylaxis and angioedema.
d. They are useful in the treatment of rhinitis associated with the common cold. e. They are used to treat motion sickness and vestibular disturbances (e.g., Meniere disease). 5. Side effects and toxicity. The spectrum of side effects is frequently the basis for preference of specific agents. a. Sedation is the most common side effect; it is common to all the antihistamines, except the piperidines. b. CNS effects include dizziness, lack of coordination, tremors, and diplopia. c. Gastrointestinal effects include anorexia, nausea, vomiting, constipation, and diarrhea. d. Antimuscarinic effects include dryness of mucous membranes and urinary retention.
98
meClical
Autacoids
e. Cardiovascular effects include palpitations and hypotension. Serious cardiovascular side effects, including prolongation of the QT interval, have been associated with astemizole and terfenadine, especially with concomitant use of an azole derivative or macrolide antiobiotic. f. Peripheral nervous system effects include paresthesias and weakness of the extremities. g. Teratogenicity may occur (especially with the piperazines). h. Acute poisoning may occur, producing hallucinations, excitement, lack of coordination, seizures, fixed and dilated pupils, and fever.
H. H2 antagonists ("H2 blockers") act selectively on H2 receptors with virtually no effect on HI receptors. They block gastric acid secretion.
Bridge to Pharmacology A USMLE favorite involves the interaction between the antifungal ketoconazole and astemizole. Ketoconazole inhibits liver metabolism of the antihistamines, leading to increased blood concentrations that can result in lethal cardiac arrhythmias.
1. Cimetidine
a. Pharmacologic properties. Cimetidine is a histamine analog that contains the imidazole ring that is thought to convey receptor affinity. It acts as a competitive antagonist at H2 receptors and greatly reduces both basal gastric acid secretion and mealstimulated acid secretion. It also reduces gastric juice secretion induced by histamine, gastrin, caffeine, and insulin. It is well absorbed orally and is mostly excreted unchanged in the urine. It inhibits hepatic microsomal enzymes. b. Indications for use. Cimetidine is used to treat duodenal and gastric ulcers, Zollinger-Ellison syndrome, and hypersecretion due to systemic mastocytosis and basophilic leukemia. It is also used to decrease gastric acidity in reflux esophagitis, stress gastritis, and the short bowel syndrome. It is of unproven benefit in active upper gastrointestinal bleeding and in the prophylaxis of upper gastrointestinal bleeding in critically ill patients. c. Side effects and toxicity ( 1) Side effects are minor, and their incidence is infrequent. Rash, fever, headache, dizziness, fatigue, and myalgias may occur; rarely, there may be confusion or coma (in elderly patients). Elevated creatinine may occur, probably as the result of competition between cimetidine and creatinine for excretion (i.e., it is not an indication of change in renal function). (2) Antiandrogenic effects, including gynecomastia, loss of libido, galactorrhea, and reduction in sperm count, have been reported; there are no documented effects on fertility. (3) Cimetidine reduces hepatic blood flow and can slow clearance of other drugs (e.g., lidocaine); it reduces the activity of cytochrome P-450, thereby decreasing the metabolism of many other drugs (e.g., warfarin, theophylline, diazepam). (4) Rarely, leukopenia, thrombocytopenia, and hepatotoxicity may occur. 2. Ranitidine and famotidine
Note In addition to cimetidine, another important drug that inhibits the cytochrome P-4S0 is the antifungal ketoconazole.
a. Pharmacologic properties (1) They are much more potent than cimetidine (approximately six times more
potent). (2) These drugs effectively inhibit gastric acid secretion. They do not bind strongly to hepatic cytochrome P-450 enzymes. (3) They produce less CNS penetration than cimetidine and, therefore, may have less CNS toxicity. These drugs have no antiandrogenic effects. KAPLA~. I meulca
99
Pharmacology
b. Indications for use are similar to cimetidine; they are preferred in patients prone to CNS toxicity with cimetidine (e.g., elderly patients). They are used with patients taking drugs known to interact with cimetidine (e.g., warfarin and theophylline). c. Side effects and toxicity have not been completely defined; rash, dizziness, headache,
diarrhea, impotence, and confusion have all been reported.
SEROTONIN (5-HYDROXYTRYPTAMINE) A. Biosynthesis and physiologic properties 1. Serotonin is endogenously synthesized by the hydroxylation and subsequent decarboxylation of the amino acid tryptophan. 2. Serotonin functions as a neurotransmitter in the CNS. It is present in enterochromaffin cells of the gastrointestinal tract, where it regulates smooth muscle function, and in platelets, where it serves to regulate platelet function. Approximately 90% is in the enterochromaffin cells. 3. Serotonin agonists are well known for producing hallucinogenic activity (e.g., lysergic acid diethylamide [LSD) and psilocybin). B. Organ system effects
1. Respiratory system a. Serotonin produces a transient increase in respiratory rate. b. It also produces bronchoconstriction. 2. Cardiovascular system a. Serotonin usually produces vasoconstriction (especially of splanchnic and renal beds), but it produces vasodilatation of skeletal muscle vascular beds. b. It produces both positive inotropic and chronotropic effects. c. It is responsible for the coronary chemoreflex, leading to hypotension and bradycar-
dia (due to vagal potentiation and sympatholytic effects). d. It has a triphasic pressor effect. The early depressor effect, followed by the pressor phase and then the late depressor effect, is a result of competing influences from the varied responses (constriction in splanchnic arterial beds and dilatation in muscle arterial beds). e. It produces venous constriction. f. It enhances platelet aggregation.
3. Smooth muscle. Through the action of multiple receptors, serotonin usually inhibits, but may also enhance, gastric and large intestine motility while stimulating small intestine motility. 4. Exocrine glands. Serotonin reduces the volume and acidity of gastric juice. S. Nerve endings a. Serotonin is generally stimulatory, producing pain at the site of injection and stimulating autonomic efferents. b. It alters ganglionic transmission variably at different doses. c. It depolarizes adrenal medullary chromaffin cells to induce catechol secretion.
100
meClical
Autacoids
6. CNS. Serotonin functions primarily as an inhibitory neurotransmitter. It is primarily localized in the raphe nuclei of the brain stem with axons projecting to the spinal cord, brain stem, and forebrain. 7. In the pineal gland, serotonin functions as precursor of melatonin.
8. In the platelets, serotonin potentiates aggregation. 9. There are pathologic accumulations of serotonin in carcinoid tumors; malignant tumor of enterochromaffin cells is associated with excess serotonin production, yielding symptoms of diarrhea, abdominal cramps, malabsorption, and flushing. C. Metabolism. The metabolism of serotonin begins with oxidative deamination by MAO to
5-hydroxyindoleacetaldehyde, which is further oxidized to 5-hydroxyindoleacetic acid (5-HIAA) by aldehyde dehydrogenase, and then renally excreted. D. Clinical uses. There are no current therapeutic uses for serotonin. E. Serotonin receptors. Multiple serotonin receptor subtypes have been identified. At least seven 5-HT receptor families have been cloned, of which four, designated 5-HT j through 5-HT4 have been characterized. 5-HT 2 and 5-HT4-7 are G-protein-coupled receptors, whereas 5-HT3 is a Na+/K+ ligand-gated ion channel receptor. The 5-HT j family has been characterized as five groups designated 5-HT jA through 5-HT\E. 5-HT lD has been the one most associated with migraine headaches. F. Serotonin agonists
1. Sumatriptan, naratriptan, rizatriptan, and zolmitriptan a. Pharmacologic properties (1) These are indole derivatives structurally related to serotonin. (2) They are selective agonists of 5-HT\ receptors (more specifically, at 5-HT lD receptors). (3) These are administered orally. In addition, sumatriptan is administered
intranasally and subcutaneously (but not intravenously because the latter route may cause coronary vasospasms.) (4) Sumatriptan is metabolized to an indole acid metabolite, which, along with the parent drug, is excreted in the urine. b. Indications for use. These are used in the acute treatment of migraine headaches. Agonist action at 5-HT lD receptors causes vasoconstriction, which blocks release of pro-inflammation neuropeptides to reduce the pain of a migraine attack. c. Side effects and toxicity
In a Nutshell Sumatriptan is a S-HT, receptor agonist used as treatment for migraine headaches.
(1) With sumatriptan, there may be pain at the injection site, dizziness, chest discomfort, and transient elevation of blood pressure. (2) They should be used with caution in patients with liver and renal dysfunction. (3) Use is contraindicated in patients with ischemic heart disease, angina, or uncon-
trolled hypertension. 2. Ergot alkaloids (selective, partial agonists with some antagonist action) a. Ergotamine (and dihydroergotamine) ( 1) Pharmacologic properties. Ergotamine is administered orally, by inhalation, by the sublingual route, and in suppository form. It is often given along with caffeine,
meclical
101
Pharmacology
which enhances absorption and provides additional vasoconstriction. The ergot alkaloids are partial agonists and antagonists at 5-HT receptors. The mechanism of action for treating migraine is thought to be from agonist action like that of sumatriptan. (2) Indications for use. Acute migraine headaches and reduction in postpartum hemorrhage (3) Side effects and toxicity. Adverse reactions include na'lsea and vomiting, diarrhea, paresthesia of limbs, and cramps. It is not indicated for long-term treatment because of its potential to cause gangrene.
Clinical Correlate Ergonovine, methyl ergonovine, and ergotamine cause uterine constriction and are therefore used in the control of postpartum bleeding.
b. Ergonovine and methylergonovine
(1) Pharmacologic properties. The uterine-stimulating action of these drugs is evidently related to their direct effect on uterus agonistic action at 5-HT2 receptors. Administration is oral, intramuscular, and intravenous (reserved for emergencies). (2) Indications for use. These drugs are used to treat postpartum bleeding. (3) Side effects and toxicity. Adverse reactions include nausea, vomiting, blurred vision, headache, hypertension, convulsions, and abortion. G. Serotonin antagonists
1. Methysergide is a semisynthetic ergot derivative. a. Pharmacologic properties (1) Methysergide inhibits the vasoconstrictor effect of serotonin as well as its effect on extravascular smooth muscle. (2) Its mechanism of action is evidently related to blockade of peripheral 5-HT receptors, but it may also act as an agonist at some central receptors.
b. Indications for use (1) Methysergide is used in the prophylaxis of vascular headache syndromes. (2) It is used in the treatment of postgastrectomy dumping syndrome. (3) It is used to treat intestinal hypermotility of the carcinoid syndrome. c. Side effects and toxicity (1) Ergotism produces vasoconstrictive complications, including chest pain, pulse-
lessness, weakness, myalgias, and paresthesias. (2) Retroperitoneal fibrosis may develop with prolonged use. 2. Cyproheptadine
a. Pharmacologic properties
(1) Cyproheptadine is a phenothiazine derivative. (2) It blocks both histamine (HI) and serotonin receptors. (3) It has weak anticholinergic effects, mild sedative effects, and calcium-channel activity. b. Indications for use
(1) Cyproheptadine is used in the treatment of pruritic dermatoses.
102
meClical
Autacoids
(2) It is used as a prophylaxis of vascular headache.
(3) It is used to stimulate appetite and weight gain. (4) It is used in the treatment of intestinal hypermotility of the carcinoid tumor. (5) It is used in the treatment of Cushing syndrome. c. Side effects and toxicity
(1) Drowsiness, ataxia, and confusion may occur. (2) Hypotension and tachycardia may develop.
(3) Blood dyscrasias may develop. (4) Weight gain and increased growth in children (via distortion of insulin and growth hormone secretion) may occur.
ANGIOTENSINS The vasoconstrictive polypeptides angiotensin II and angiotensin III are products of the reninangiotensin system. A. Biosynthesis and physiologic properties 1. Renin
a. Renin is an acid protease enzyme synthesized and secreted by cells of the kidney juxtaglomerular apparatus; stimuli include: (1) Lowering of renal perfusion pressure (e.g., decreased cardiac output or blood
volume, hemorrhage, lowered total peripheral resistance, renal artery stenosis) (2) Reduction in sodium load to the kidney
(3) Sympathetic ~I-receptor stimulation (juxtaglomerular cells have ~1 receptors) b. Renin is metabolized by the liver and kidney. 2. Angiotensinogen
a. Angiotensinogen is an (X2-macroglobulin, produced primarily by the liver. b. It serves as a substrate for renin to produce angiotensin I. c. There is increased synthesis with glucocorticoids and thyroid hormone.
d. Angiotensin-specific cell surface receptors are believed to mediate effects on cells. They are involved in the constriction of arterioles and the stimulation of synthesis and secretion of aldosterone. 3. Angiotensin I and angiotensin-converting enzyme (ACE) a. Angiotensin I is converted to angiotensin II by ACE; 20-40% of ACE is in the vascular endothelium, especially in the lung. b. ACE is a zinc-binding exopeptidase. c. ACE also participates in degradation of bradykinin and enkephalins.
4. Angiotensin II a. Angiotensin II is a vasoconstrictive octapeptide. b. It stimulates the production and release of aldosterone. KAPLI~. I meulca
103
Pharmacology
Bridge to Physiology JGA - - Decreased t perfusion Renin pressure
I
t
Angiotensinogen
l
Angiotensin I
1
ACE
Angiotensin II
t ..
Vasoconstnctlon and aldosterone release
c. It is the most important hormone of the renin-angiotensin system because it is responsible for the conservation of sodium and the maintenance of blood volume through its control of aldosterone release. d. Angiotensin II is hydrolyzed by aminopeptidase to a heptapeptide, angiotensin III, which is also active (but less so than angiotensin II). 5. Renin-angiotensin system in hypertension
a. Elevated plasma renin activity (PRA) is associated with hypertension, resulting from renal artery stenosis and malignant hypertension. b. Normal or low PRA is found in most patients with essential hypertension. c. Antagonists of the renin -angiotensin system are potent antihypertensives even in cases
where PRA is not elevated. d. Prostaglandins and cyclic nucleotides have been implicated as intracellular mediators. B. Organ system effects of vasoconstrictive angiotensins (angiotensin II and angiotensin III) 1. Cardiovascular system
a. The active angiotensins produce vasoconstriction of precapillary arterioles and postcapillary venules. Angiotensin II is one of the most potent pressor agents known (it is 40 times stronger than norepinephrine). b. The vasoconstriction is most striking in skin and in renal and splanchnic beds. c. They produce increased inward calcium current in cardiac muscle; there is a positive
inotropic effect. d. They increase extravascular fluid as a result of the separation of endothelial cells. e. They increase lymph flow. 2. Central nervous system
a. They increase sympathetic outflow, contributing to a rise in blood pressure. b. They stimulate drinking behavior (dipsogenic). c. They stimulate ADH release. 3. In the peripheral nervous system, they increase release of and response to catechols. 4. In the adrenal cortex, they stimulate aldosterone synthesis and secretion. 5. Kidney
a. There are complex effects of the angiotensins because of vasoconstriction, aldosterone, and ADH action; the net result is usually antidiuresis and antinatriuresis. b. The angiotensins may cause opposite effects in the presence of hepatic cirrhosis. C. Angiotensin antagonists 1. Antagonists of angiotensin II (the prototype is saralasin)
a. Pharmacologic properties (1) These antagonists competitively block angiotensin II receptors. (2) There is lower blood pressure in high-renin and normal-renin states, reflecting the contribution of the renin-angiotensin system to the maintenance of blood pressure.
104
meClical
Autacoids
b. Indications for use. In the past, angiotensin antagonists were used mainly diagnostically. They are currently not in clinical use. e. Side effects and toxicity. They may cause dangerous hypotension in renal artery stenosis or malignant hypertension. 2. ACE inhibitors (e.g., captopril, enalapril) a. Pharmacologic properties (1) These drugs block the conversion of angiotensin I to angiotensin II. (2) They cause decreased vascular resistance and a drop in blood pressure in hypertensive patients. Little reflex tachycardia has been noted. (3) They exert their most profound effects in high-renin hypertension; they are also efficacious in normal-renin hypertension. The latter effects may be due in part to decreased inactivation of endogenous hypotensive peptides, such as bradykinin. b. Indications for use (1) ACE inhibitors are diagnostically important in identifying patients with surgi-
cally reversible renovascular hypertension. (2) These drugs are used in the treatment of mild-to-severe essential hypertension, elevated-renin hypertension, CHF (they reduce afterload and preload), and hypertension in chronic renal failure patients. e. Side effects and toxicity (1) Severe hypotension may occur after the initial dose in patients taking diuretics; patients may be sodium depleted. (2) Rash, loss of sense of taste, and cough may occur. (3) Leukopenia and proteinuria rarely occur.
In a Nutshell ACE Inhibitors • Block angiotensin I ~ angiotensin II (decrease blood pressure) • Inhibit bradykinin degradation (can cause side effects, e.g., cough) • Are used in the treatment of hypertension and congestive heart failure
PLASMA KININS (BRADYKININ, KALLIKREIN, KALLIDIN, AND RELATED PEPTIDES) A. Biosynthesis and physiologic properties Kinins are produced and cleaved by a group of enzymes called kininogenases; the most interest has been in a group of enzymes called the kallikreins. 2. Prekallikrein is converted to kallikrein by the Hageman factor (factor XII). Kallikrein catalyzes the conversion of high-molecular weight kininogen (HMWK) into bradykinin and the conversion of both HMWK and low-molecular-weight kininogen (LMWK) into kallidin. 3. The formation of bradykinin and kallidin is extensively interwoven with the activation of the clotting and fibrinolytic cascades as well as with the complement system. 4. Kinins have half-lives of 10-20 seconds; most are inactivated in the pulmonary bed by kinase II. 5. Kininase I converts some bradykinin and kallidin to their respective des-Arg metabolites, which are agonists of Bl receptors.
I KAPLAlf me dlea
105
Pharmacology
B. Organ system effects 1. Cardiovascular system. Kinins have a potent vasodilatory and flushing effect. They also
increase microcirculatory permeability and edema formation. 2. Kidney. Kinins regulate urine volume and composition.
3. Extravascular smooth muscle. The most important effect plasma kinins have on smooth muscle is constriction of the tracheobronchial muscle. 4. Nerve endings. Plasma kinins are powerful pain stimulators. 5. Inflammation. Injected kinins mimic inflammation. 6. Adrenal gland. Plasma kinins are powerful stimuli for catechol discharge. C. Mechanism of action. The mechanism of action of kinins is not completely understood. 1. Two kinin receptors, B] and B2 , have been characterized.
a. The B2 receptor, previously studied as the bradykinin receptor, mediates most of the actions of bradykinin and kallidin in the absence of inflammation. B2 receptors are coupled via G-proteins, producing increases ofIP 3 and DAG. b. The B] receptor is selective for the des-Arg metabolites of bradykinin and kallidin. B] receptors are increased during inflammation and may predominate during episodes of tissue damage or inflammation. 2. Prostaglandins and phospholipase A2 are involved; cyclic nucleotides may be involved in
some tissues. 3. Hereditary angioedema is a result of a deficiency of C] esterase inhibitor; episodes of edema are caused in part by excess bradykinin. 4. Septic and anaphylactic shock are partly becaused by bradykinin release. D. Clinical uses. There are no current clinical uses for the kinins; however, a kallikrein inhibitor, aprotinin, has had some success in the treatment of acute pancreatitis and carcinoid syndrome. E. Other kinins 1. Substance P is a probable neurotransmitter. a. Its effects include vasodilatation, stimulation of smooth muscle, salivation, diuresis, and natriuresis. b. It is present in enterochromaffin cells. e. It contributes to symptoms of the carcinoid syndrome.
d. It is involved as a mediator of pain in sensory pain neurons. 2. Vasoactive intestinal peptide (VIP) is a potent vasodilator and pancreatic secretagogue.
a. It is found in the nervous system and pancreas. b. It may be responsible for the watery diarrhea syndrome (Verner-Morrison or pancreatic cholera).
106
meclical
Autacoids
EICOSANOIDS: PROSTAGLANDINS, PROSTACYCLlN, THROMBOXANES, AND LEUKOTRIENES A. Biosynthesis and physiologic properties (Figure IV-2-1)
15-HETE rl5-HPETE
t
I
Leukotriene ~
I PG D2
I
PGI2 (Prostacyclin)
(LT~)
Thromboxane synthetase
Figure IV-2-1. Biosynthesis of prostaglandins (PGD 2 , PGE 2 , PGF2 , PGG 2 , PGH 2), prostacyclin (PGI 2), thromboxane (TXA2), and leukotrienes (LTA4 , LTB 4 , LTC4 , LTD 4 , LTE 4 , LTF4). (5-HPETE = 5-hydroperoxyeicosatetraenoic acid; and 5-HETE = 5-hydroxyeicosatetraenoic acid)
1. Generally, prostaglandins are derived from 20-carbon fatty acids; they contain three to five double bonds and a central cyclopentane ring.
2. Arachidonic acid is the chief precursor in humans; it is derived from dietary linoleic acid (an essential fatty acid) or as a component of meat. 3. Body arachidonate is stored by esterification to the phospholipids of cell membranes. Phospholipase A2 acts on these esterified lipids to release arachidonate; it is believed to be rate limiting in the formation of free arachidonate. Arachidonate, once released, is acted upon by either of two enzymes: cyclooxygenase or lipoxygenase. a. Cyclooxygenase produces prostaglandins. (1) There are two isozymes of cyclooxygenase (COX-1 and COX-2) i.
COX-1 is normally present in most cells. It has been associated with protection of stomach lining, reduction of fever, and promotion of platelet aggregation.
meclical
107
Pharmacology
ii. COX-2 is induced by the presence of certain cytokines and growth factors. It has been associated with the production of pain and inflammation. (2) Oxidation and cyclization of arachidonate forms endoperoxides. (3) Prostaglandin G and H (PGG 2 , PGH 2 ) are the first two products. (4) PGG 2 and PGH 2 are unstable; they isomerize to form PGD 2 , PGE 2, or PGF r
(5) PGH2 is broken into thromboxane breaks down to TXBr
Az
(TXAz), which is likewise unstable and
(6) PGH 2 may alternatively be converted to prostacyclin (PGI 2 ) by prostacyclin
synthetase. (7) Certain tissues synthesize relatively more or less of certain prostaglandins; lung and spleen synthesize all types, whereas endothelia synthesize PGI 2 and platelets synthesize TXAz.
b. Lipoxygenase produces leukotrienes. (1) It is present in lung, platelets, and leukocytes.
(2) It converts arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE), which is then converted to 5-hydroxyeicosatetraenoic acid (5-HETE) or leukotriene A4 (LTA4). (3) LTA4 can be converted to LTB4 or LTC 4. (4) LTD 4, LTE4, and LTF4 are produced in successive steps from LTC 4.
(5) Slow-reacting substance of anaphylaxis (SRS-A) is a mixture ofLTC 4 and LTD 4 •
B. Organ system effects 1. Cardiovascular system
a. Most prostaglandins are potent vasodilators, but in some sites and species, they can induce vasoconstriction. b. In response to peripheral vasodilatation induced by prostaglandins, cardiac output and rate increase. c. TXAz contracts vascular smooth muscle.
d. PGI 2 causes vasodilatation and hypotension. e. Leukotrienes cause an initial increase in blood pressure, then prolonged hypotension. The latter effect is probably due to leukotriene-induced reduction in coronary blood flow, which leads to reduced cardiac output. 2. Blood
a. Platelets
In a Nutshell
(1) Prostaglandins inhibit platelet aggregation; PGI 2 is the most potent.
• Vascular endothelium produces PGI 2 ~ platelet inhibition • Platelets produce TXA2 platelet aggregation
108
iii8&ical
~
(2) TXAz promotes platelet aggregation. b. Prostaglandins promote erythropoietin release from the kidney. c. LTB4 is a polymorphonuclear leukocyte chemoattractant.
Autacoids
3. Kidney a. PGI 2 and PGE z can increase renal blood flow to produce diuresis with sodium and potassium excretion. b. TXA z decreases renal blood flow. c. Prostaglandins can stimulate renin release.
d. In animals, PGE 2 inhibits ADH release. 4. Smooth muscle
a. Bronchial (1) PGF 2 induces bronchoconstriction.
(2) PGE 2 dilates bronchial muscle. (3) LTC4 and LTD4 are potent bronchoconstrictors. b. Uterus (1) PGE, PGA, and PGD cause uterine relaxation. (2) PGF causes uterine contractions. c. Gastrointestinal muscle. The effects of different prostaglandins on different gastroin-
testinal muscles are variable. Oral PGE produces decreased gastrointestinal transit time, diarrhea, and cramps. 5. Gastrointestinal system. Gastric acid secretion is inhibited by PGE z and PGI2' Small bowel secretion is increased by PGE 2 and PGF 2 • 6. eNS. Intraventricular injections of PGEs cause sedation, stupor or catatonia, and fever. 7. Afferent nerves a. PGEs cause pain when injected intradermally. b. PGEs and PGl z sensitize afferents to incoming chemical or mechanical stimuli. 8. Endocrine system a. PGE) stimulates release of ACTH, growth hormone, prolactin, and gonadotropins. b. PGE 2 facilitates release of leutinizing hormone and thyroid-stimulating hormone, insulin, and steroids. c. PGF z reduces progesterone secretion from the corpus luteum (luteolysis) in certain mammals; however, this effect is not observed in humans. 9. Metabolic effects. PGEs inhibit lipolysis. 10. Autonomic nervous system a. PGEs depress catechol release and end-organ responsiveness. b. PGFs stimulate catechol release and end-organ sensitivity. C. Mechanism of action
1. Receptors for prostaglandins have been identified. They are classified into five groups
(DP, EP, FP, IP, and TP) according to the prostaglandin for which they are most selective (PGD, PGE, PGF, PGI 2 , and TXA2 , respectively). Prostaglandin receptor activities are associated with adenylate cyclase activation, adenylate cyclase inhibition, and phospholipase C stimulation. IIPLA~. I meulca
109
Pharmacology
------------
2. Receptors for leukotrienes that activate phospholipase C have been described.
3. cAMP also stimulates prostaglandin synthesis; this may represent a positive feedback loop. 4. PGI 2, PGEI' and PGD z increase platelet cAMP and inhibit platelet aggregability. S. TXA2 reduces cAMP levels, which causes platelet clumping and may also act as a calcium ionophore. D. Metabolism 1. Prostaglandins are rapidly and efficiently catabolized by enzymes widely distributed
throughout the body. 2. The initial step in their breakdown is accomplished by prostaglandin-specific enzymes.
3. The second, slower degradation is accomplished by the general beta and omega oxidation systems for fatty acids.
E. Prostaglandins in physiologic and pathologic processes 1. PGI z and TXA, have opposite actions in modulating platelet-endothelial interactions and
the formation of hemostatic platelet plugs and thrombi.
Clinical Correlate Prostaglandins may playa causal role in dysmenorrhea.
2. There is high concentration of prostaglandins in human semen (role unknown).
3. Increased prostaglandin synthesis may playa role in the genesis of dysmenorrhea; this is a proposed mechanism for how cyclooxygenase inhibitors relieve dysmenorrhoeic pain. 4. Prostaglandins are elevated during labor; cyclooxygenase inhibitors delay parturition and arrest premature labor. S. Increased prostaglandins are associated with Bartter syndrome of high PRA, hyperaldosteronism, potassium loss, normal blood pressure, and insensitivity to angiotensin; chronic administration of cyclooxygenase inhibitors normalizes angiotensin response, PRA, and aldosterone level, although potassium wasting persists. 6. Local generation of PGE 2 and PGl z may maintain patency of the ductus arteriosus; aspirin-like agents induce closure of a patent ductus.
In a Nutshell • In the congenital heart defect, transposition of the great arteries, which is incompatible with life, prostaglandins are given to maintain a patent ductus arteriosus. This can allow an infant to survive until it is mature enough to undergo corrective surgery. • Indomethacin is the drug of .~hoice for closing a patent ductus arteriosus.
7. PGE 2 can dilate bronchial smooth muscle. PGF z and TXA2 cause bronchoconstriction. Leukotrienes (e.g., LTC 4 ) are probably the major autacoids responsible for allergic bronchoconstriction of asthma. 8. Certain tumors are associated with elevated circulating prostaglandin levels; these include medullary carcinoma of the thyroid and breast carcinoma . 9. PGEs are potent osteolytic agents and may contribute to hypercalcemia of malignancy. 10. PGE 2 and PGI 2 increase blood flow to areas of inflammation. Leukotrienes increase vascular permeability and are leukocyte chemoattractants. 11. PGEs can inhibit neutrophil and macrophage hydrolase release, killer T-cell function, and release of lymphokines by activated T cells. PGEs suppress mast cell degranulation and inhibit lymphocyte participation in delayed hypersensitivity. F. Clinical uses 1. PGl z can be used in place of heparin in renal hemodialysis . 2. PGE) and PGI 2 can dilate a patent ductus arteriosus and thereby improve blood oxygen-
ation in infants with certain congenital heart defects. 3. PGE) and PGl z are used in clinical trials in severe peripheral vascular disease.
~o
meClical
Autacoids
4. PGI z has been used experimentally to protect against platelet loss during dialysis or extracorporeal circulation. 5. PGE 1 improves harvest and storage of platelets for transfusion. 6. Dinoprostone is a PGE 2 preparation available in vaginal suppository form to induce abortion, to evacuate a missed abortion, or to treat benign hydatidiform mole; side effects include nausea, vomiting, and diarrhea.
II'! a Nutshell
G. Inhibitors of prostaglandin synthesis 1. Cylcooxygenase inhibitors
a. Aspirin and related anti-inflammatory agents block production of prostaglandins by permanently inhibiting both COX-I and COX-2. This appears to be a major mechanism of their action because their efficacy as anti-inflammatory agents is proportional to their potency as cyclooxygenase inhibitors. The inhibition of COX-2 accounts for their analgesic and anti-inflammatory effects. The inhibition of COX-I accounts for their GI bleeding and irritation side effects.
NSAIDs act to inhibit cyclooxygenase, thereby decreasing prostaglandin production.
b. COX-2 inhibitors celecoxib and rofecoxib do not have the above GI side effects because they do not interface with COX-I activity. 2. Imidazole inhibits thromboxane synthetase but does not yet have clear clinical relevance.
KAPLA~. I meulca
Lead Toxicity and Chelating Agents Lead toxicity is the most frequent cause of heavy metal poisoning and is usually the result of industrial or environmental exposure. Chelating agents are used in the treatment of heavy metal toxicity to bind to the metal and prevent it from binding competitively with other essential elements.
LEAD POISONING Lead poisoning in the home environment produces devastating neurologic damage to the CNS in children (encephalopathy) that is characterized by edema, convulsion, and coma. Lead poisoning in adults results largely from occupational exposure, producing clinical or subclinical signs of peripheral neuropathy, usually without CNS involvement. A. Pharmacologic properties l. Absorption. Lead is absorbed by ingestion or by inhalation. Although inorganic lead is
poorly absorbed through the skin, organic compounds like tetraethyl lead are wellabsorbed. a. Gastrointestinal absorption varies with age. Although the average lead absorption is 10%, children absorb lead to a much greater degree than adults. b. Dietary calcium, iron, and phosphorus alter lead absorption. Enhanced gastrointestinal absorption occurs with iron, calcium, and zinc deficiency. 2. Distribution. Lead is bound to red blood cells and is widely distributed throughout the body. It concentrates first in the kidneys and liver, but most retained lead is eventually deposited in bone and hair. It can also cross the placenta and is a hazard to the fetus. 3. Excretion. Approximately 90% of lead is eliminated by the fecal excretion of unabsorbed lead or by the kidneys' excretion of intestinally absorbed lead. B. Mechanism of toxicity. Lead has an affinity for sulfhydryl, carboxyl, and phosphoryl groups,
forming complexes that impair enzyme activity. Enzymes leading to the synthesis of porphobilinogen are most sensitive to lead; inhibition leads to the accumulation of its precursor (i.e., b-aminolevulinic acid [ALA)) in urine. The amount found serves as a diagnostic indicator of lead poisoning. C. Major forms of lead intoxication
1. Acute lead poisoning is less common today. Industrially, it may result from ingestion of lead oxide. In small children, it may result from ingestion of lead oxide paints. Removal oflead from paints and organic lead from gasoline has significantly reduced the incidence of poisoning, but it still exists.
KAPlllf . ._ I me lea
113
Pharmacology
Clinical Correlate
a. Household ingestion by children of lead-based paint flakes (pica) from old painted structures remains a significant problem.
Lead ingestion from paint is a frequent cause of anemia in children.
b. Urine samples collected for 24 hours and analyzed for lead is the usual method of screening. c. X-rays show deposition of lead along bone metaphyses, called "lead lines:' d. Symptoms of acute lead poisoning include a local astringent effect in the mouth, thirst, metallic taste, nausea, vomiting, abdominal pain, paresthesias, pain, weakness, and hemolytic anemia. 2. Chronic lead poisoning is more common than acute poisoning. Symptoms include the following: a. Abdominal syndrome involves anorexia, constipation, metallic taste, nausea, vomiting, and abdominal pain. b. Neuromuscular syndrome includes weakness, fatigue, myalgia, and wrist- and footdrop (so-called "lead palsy"). c. CNS syndrome includes vertigo, ataxia, headache, irritability, confusion, seizures,
coma, vomiting (projectile), meningismus, and visual disturbances. The most serious effect is lead encephalopathy. d. Renal tubular necrosis occurs after years of exposure to lead. Renal hypertension may also occur. e. Effects on blood include basophilic stippling of RBCs (not pathognomonic but highly indicative) and microcytic anemia (with iron deficiency). f. Coproporphyrinuria due to inhibition of the enzyme ferrochelatase can also occur. D. Treatment of lead poisoning
1. Removal of the patient from exposure and decontamination of the skin are the first steps. Supportive measures are then applied, and anticonvulsant drugs to treat seizures are used judicially. 2. Chelation
a. For severe poisoning, dimercaprol plus calcium-sodium ethylenediaminetetraacetic acid (EDTA) is the first line of treatment. To avoid decreased available calcium, the calcium salt is used. b. Succimer (2,3-dimercaptosuccinic acid) is approved for treating lead poisoning in children. c. Penicillamine can be used for less severe cases and for long-term therapy, although
succimer is preferred. 3. Fluids are used to prevent shock and to increase lead elimination.
CHELATING AGENTS Chelating agents are compounds that form complexes with metals in competition with reactive groups essential for enzyme or other activity. The stability of the complex varies with the metal. Lead and mercury have greater affinity for sulfur and nitrogen than for oxygen, whereas calcium has a greater affinity for oxygen.
114
meclical
Lead Toxicity and Chelating Agents
A. Dimercaprol was developed for its affinity and treatment of the arsenical compound, lewisite, which is a vesicant. It is sometimes referred to as British antilewisite (BAL). 1. Pharmacologic properties
a. Dimercaprol chelates lead, arsenic, mercury, and antimony. b. It is a rapid source of sulfhydryl groups that bind metal ions and reactivate enzymes inactivated by heavy metals. 2. Indications for use include arsenic poisoning, mercury poisoning, and lead poisoning (with calcium-sodium EDTA). 3. Side effects and toxicity of this drug include increased blood pressure, tachycardia, nausea, vomiting, and headache. B. EDTA-edetate calcium disodium (CaNa2 EDTA) 1. Pharmacologic properties
a. EDTA is a chelator of divalent and trivalent ions. It is available as calcium-sodium EDTA (usual preparation to avoid calcium loss) and sodium EDTA (used in hypercalcemia). b. EDTA enhances the excretion of zinc, copper, iron, cadmium, lead, and manganese. c. EDTA is poorly absorbed from the gastrointestinal tract, so it is usually given intra-
venously. d. EDTA is cleared by glomerular ftltration; therefore, normal renal function is required for effective therapy. 2. Indications for use. CaNa EDTA is indicated principally in lead poisoning. 3. Side effects and toxicity include fatigue, malaise, chills, fever, and anorexia; renal damage; and hypocalcemic tetany (if sodium EDTA is used intravenously). C. Succimer
1. Pharmacologic properties
a. Succimer (2,3-dimercaptosuccinic acid) is an analog of dimercaprol. b. It is an orally active heavy metal chelator. c. It only minimally mobilizes essential metals, e.g., zinc, copper, or iron.
2. Indications for use
a. Succimer is approved for treating all children with blood lead levels about 45 IlgidL. b. It is used for treating symptomatic lead intoxication without encephalopathy. c. It may also effectively chelate arsenic and mercury.
3. Side effects and toxicity
a. Toxicity is less than with dimercaprol and includes transient elevations of hepatic enzymes. b. Common adverse effects include nausea, vomiting, diarrhea, a metallic taste in the mouth, and loss of appetite. ' c. Rashes have been reported and may be limiting.
KAPLA~. I meulca
115
Pharmacology
d. There may be CNS effects including drowsiness, dizziness, and sensorimotor neuropathy. e. It may cause cloudy ftlm in the eyes, plugged ears, difficulty of urination, and increased proteinuria.
D. Penicillamine 1. Pharmacologic properties
a. Penicillamine is a product of penicillin degradation. b. Unlike other chelators, penicillamine has good gastrointestinal absorption and can be given orally. c. This compound chelates copper, mercury, zinc, and lead.
d. It inhibits pyridoxal-dependent enzymes. e. Penicillamine is metabolized by the liver and is excreted in urine. 2. Indications for use
a. Wilson disease and primary biliary cirrhosis b. Copper and mercury poisoning as well as secondary treatment oflead and arsenic poisoning c. Cystinuria
d. Rheumatoid arthritis 3. Side effects and toxicity include hypersensitivity rashes, fever; hematologic abnormalities, including leukopenia, agranulocytosis, and aplastic anemia; and renal toxicity.
E. Deferoxamine 1. Pharmacologic properties
a. Deferoxamine chelates free iron and removes iron from hemosiderin and ferritin. It does not effect hemoglobin or cytochrome iron. b. Oral absorption is poor, so it is administered parenterally.
In a Nutshell Deferoxamine is used to reduce iron toxicity in patients with transfusion-dependent thalassemia.
c. Deferoxamine is excreted rapidly in the urine. 2. Indications for use
a. Acute iron poisoning and iron storage disease b. Transfusion-dependent thalassemia (iron overload occurs due to repeated transfusions) 3. Side effects and toxicity include hypersensitivity, abdominal pain, cataracts, and neurotoxicity with chronic administration.
116
meClical
Antineoplastic Agents
Neoplasm can be defined as uncontrolled new growth, and when neoplasms are invasive or able to metastasize, they are classified as malignant. In view of these properties, treatment of malignant neoplasms is difficult because it requires elimination of all malignant cells. The three main approaches for removing malignancies are surgery, irradiation, and chemotherapy. Antineoplastic chemotherapy usually targets key stages of the general or differentiated cell cycle and, therefore, also produces damage to other actively growing or similarly differentiated cells. Categories of antineoplastic agents include alkylating agents that primarily disrupt replication of DNA, antimetabolites that block processes essential for DNA synthesis and cell division, plant derivatives that affect the mammalian cell cycle, antibiotics that affect the mammalian cell cycle, hormones that normally regulate growth of specific differentiated cells, and a few miscellaneous agents (Figure IV-4-1).
GENERAL PRINCIPLES A. Cell cycle
1. G 1 phase is the presynthetic phase. This is the most variable phase and involves protein
synthesis. 2. S phase is the synthetic phase. a. Biosynthesis and replication of DNA occur. b. Many of the chemotherapeutic agents act on cells during this phase. 3. G2 phase is the postsynthetic phase. a. RNA and protein synthesis occur. b. Cells contain double the amount of DNA. 4. M phase involves mitosis. B. Fate of cells after mitosis 1. Cells can re-enter the cell cycle (cycling cells).
2. Cells continue to differentiate without further cellular division. 3. Cells next enter a dormant state and are referred to as Go cells. a. These cells can re-enter the cell cycle at a later time. b. They are often not affected by chemotherapeutic agents.
IIP~~. I mvulca
117
-
I
co
Antineoplastic Agents
I
I
I
~
Nitrogen Mustards Mechlorethamine Cyclophosphamide Ifosfamide Melphalan (L-phenylalanine mustard; L-PAM) Chlorambucil
Plant Derivatives Vinca Alkaloids Vincristine Vinblastine Vinorelbine Podophyllotoxins Etoposide (VP-16) Teniposide (VP-26) Taxanes Paclitaxel (Taxol) Docetaxel
:1
Alkyl Sulfonate Busulfan
I Nitrosoureas Carmustine Lomustine Semustine Streptozocin
Antibiotics Dactinomycin (actinomycin-D) Anthracycline Antibiotics Daunorubicin Doxorubicin (adriamycin) Idarubicin Mitoxantrone Plicamycin (mithramycin) Mitomycin
Cell-Cycle Nonspecific Alkylating agents Antibiotics (except bleomycin) Specific Antimetabolites Vinca alkaloids Bleomycin Hydroxyurea
I Antimetabolites
Hormonal Agents Bicalutamide GnRH Inhibitors Glucocorticoid Leuprolide Prednisone Goserelin Progestins Hydroxyprogesterone Estrogens Medroxyprogesterone Ethinyl estradiol Diethylstilbestrol (DES) Megestrol Estramustine Androgens Antiestrogens Fluoxymesterone Tamoxifen Testosterone Antiandrogens Anastrozole Flutamide Aminoglutethimide
0-
I
,~
I
~ Other Triazene Derivative Dacarbazine Ethyleneimine Derivative Thiotepa (triethylene thiophosphoramide) Methylmelamine Derivative Altretamine (hexamethylmelamine) Platinum Coordination Compounds Cisplatin Carboplatin Procarbazine
...o DI
AlkYlating Agents I
~
"'a
I~ ...
Purine Analogs 6-Mercaptopurine (6-MP) 6-Thioguanine (6-TG) Pentostatin (deoxycoformycin) Fludarabine Cladribine Agents Related to Purine Analogs Azathioprine Allopurinol
Pyrimidine Analogs 5-Fluorouracil (5-FU) Floxuridine (fluorodeoxyuridine, FudR) Cytarabine (cytosine arabinoside, Ara-C) Gemcitabine
Biologic Response Modifiers Interferons (recombinant interferons alfa-2a, alfa-2b, alfa-n1, alfa-n3) Aldesleukin (recombinant Interleukin-2 [IL-2])
Unique Side Effects Cyclophosphamide-hemorrhagic Common cystitis • Bone marrow suppression Vincristine-neurotoxicity Oral and gastrointestinal Cisplatin-nephrotoxicity ulcers/stomatitis Daunorubicin-cardiotoxicity Nausea and vomiting Doxorubicin-cardiotoxicity • Exceptions: Bleomycin-pulmonary toxicity L-Asparaginase Plicamycin-hemorrhagic diathesis Bleomycin Vincristine Hormonal agents
Figure IV-4-1. Summary of the antineoplastic agents.
I Folic Acid Analogs Methotrexate
Miscellaneous Agents L-Asparaginase Hydroxyurea Mitotane Topoisomerase I Inhibitors Topotecan Irinotecan
Antineoplastic Agents
C. Tumor doubling time. The doubling time of a tumor is related to several factors.
1. Length of cell cycle
2. Growth fraction (proportion of cells undergoing cell division) 3. Cell loss
ALKYLATING AGENTS A. Overview
1. Mechanism of action a. Alkylating agents form highly reactive intermediate compounds that are able to transfer a reactive alkyl group to DNA, RNA, and proteins. Alkylation of DNA is the primary mode of antitumor activity. b. The 7-nitrogen atom of guanine appears most sensitive to alkylation. c.
Alkylation can result in: (1) Miscoding of DNA strands secondary to mispairing of bases. This is most likely to occur with monofunctional alkylator agents because these can each transfer only a single alkyl group. (2) Incomplete repair of an alkylated segment, leading to strand breaks or depurination, which is also most likely to occur with monofunctional alkylator agents (3) Excessive cross-linking of DNA and an inability for strand separation at mitosis, resulting in cell death, which occurs with polyfunctional alkylators because these can each transfer multiple alkyl groups (4) Alkylating agents are not cell-cycle phase-specific but are dependent on proliferation. They most often affect cells as the cells enter the S phase.
In a Nutshell Alkylation results in the cross-linking of DNA, which leads to cell death.
In a Nutshell
2. Side effects and toxicity
a. In general, toxicity involves sites of rapid cell turnover, such as bone marrow, testicles (spermatogenesis), gastrointestinal tract, and hair follicles (alopecia). b. Acute toxicity can cause nausea, vomiting, and phlebitis.
Side effects are seen mostly on cells with a rapid turnover, i.e., cells continuously involved in cell divsion.
c. Delayed toxicity is seen as bone marrow suppression and late secondary neoplasia, including leukemia. B. Nitrogen mustards (mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil) 1. Mechlorethamine a. Indications for use (1) Mechlorethamine is used as a chemotherapeutic agent. It is administered intra-
venously only. (2) It is used to treat Hodgkin disease as part of the MOPP regimen (i.e., mechlorethamine, vincristine, procarbazine, and prednisone), lymphosarcoma, chronic lymphoblastic leukemia (CLL), chronic myeloblastic leukemia (CML)" mycosis fungo ides, and polycythemia vera. Intracavitary infections are used to control pleural, peritoneal, or pericardial effusions. (3) It is directly cytotoxic and does not require metabolic conversion.
meClical
119
Pharmacology
b. Side effects and toxicity include gastrointestinal disturbances (e.g., nausea, vomiting), hematologic disorders (e.g., leukopenia, thrombocytopenia), and extravasation with tissue damage. 2. Cyclophosphamide a. Drug actions (1) Cyclophosphamide, a derivative of mechlorethamine, is a cyclic phosphamide. (2) It is a prodrug that requires metabolic activation by the cytochrome P-450 oxidation system in the liver, which forms phosphoramide mustard. b. Routes of administration. It is well absorbed orally and is administered orally, intravenously, or intramuscularly. c. Indications for use (1) Cyclophosphamide is used for lymphomas (Hodgkin and non-Hodgkin), multiple myeloma, Burkitt lymphoma, CLL, acute lymphoblastic leukemia (ALL), carcinomas (e.g., breast, lungs, cervix, ovary, small cell), mycosis fungoides, and neuroblastoma. It is one of the most commonly used chemotherapeutic agents. (2) It is used as an immunosuppressive agent for Wegener granulomatosis, rheumatoid arthritis, organ transplantation, and lupus. d. Side effects and toxicity include alopecia (common), nausea and vomiting, hemorrhagic cystitis, and interstitial pulmonary fibrosis. 3. Ifosfamide a. Mechanism of action. Ifosfamide is an analog of cyclophosphamide. Like cyclophosphamide, it is a prodrug that is metabolically activated in the liver. b. Routes of administration. Ifosfamide is usually infused intravenously over 30 minutes. c. Indications for use. Ifosfamide is approved for use with other drugs for testicular cancer. It is used to treat pediatric and adult sarcomas, carcinomas of the cervix and lung, and lymphomas.
Clinical Correlate Cyclophosphamide can cause hemorrhagic cystitis.
d. Side effects and toxicity (1) Ifosfamide it is coadministered with MESNA and adequate hydration to avoid severe urinary tract toxicity. MESNA is a sulfhydryl-releasing agent (2-mercaptoethanesulfonate) that conjugates toxic metabolites at acid pH in the urine to detoxify metabolites of ifosfamide that cause cystitis. (2) Ifosfamide may cause severe neurologic toxicity from its metabolite chloracetaldehyde. In addition to hemorrhagic cystitis, ifosfamide causes nausea, vomiting, anorexia, leukopenia, nephrotoxicity, and CNS disturbances. 4. Melphalan (L-phenylalanine mustard: L-PAM) a. L-phenylalanine mustard is a derivative of mechlorethamine. b. Routes of administration are intravenous or oral. c. Indications for use include multiple myeloma, ovanan carcinoma, malignant melanoma, and polycythemia vera. d. Side effects and toxicity include bone marrow suppression, especially of the platelets. Nausea, vomiting, and alopecia are rare.
120
iileClical
Antineoplastic Agents
5. Chlorambucil a. Pharmacokinetics. Chlorambucil is the slowest acting nitrogen mustard. b. Route of administration is oral. c. Indications for use include CLL, Waldenstro macroglobulinemia, cold agglutinin disease, vasculitis associated with rheumatoid arthritis, and polycythemia vera. d. Side effects and toxicity. There is less myelosuppression than with other nitrogen mustards. C. Alkyl sulfonate derivative (busulfan) l. Route of administration is oral.
2. Indications for use include selective bone marrow suppression, principally of granulocytes. It is used to treat CML, polycythemia vera, and myeloid metaplasia. 3. Side effects and toxicity include diarrhea, hyperpigmentation, pulmonary fibrosis, and gynecomastia. D. Nitrosoureas (carmustine, lomustine, semustine, streptozocin) 1. Drug actions a. Nitrosoureas are bifunctional alkylators, which require in vivo activation. b. Carmustine and lomustine can cross the blood-brain barrier and can therefore be used for CNS tumors.
In a Nutshell Side effects of busulfan include hyperpigmentation and pulmonary fibrosis.
c. Streptozocin has a sugar moiety attached to the nitrosourea. It is a naturally occurring
antibiotic with an affinity for beta cells of the pancreatic islets. 2. Routes of administration. Carmustine is administered intravenously. Lomustine and semustine are given orally. 3. Indications for use a. Carmustine is used for meningeal leukemia, primary brain tumors, and Hodgkin disease. b. Lomustine is used for Hodgkin disease, primary skin tumors, multiple myeloma, hypernephroma, and carcinoma of the breast. c. Streptozocin is used for pancreatic islet cell tumors (e.g., insulinomas, VIP-producing
tumors, gastrinomas), malignant carcinoid, and Hodgkin disease. 4. Side effects and toxicity a. Carmustine, lomustine, and semustine can cause delayed onset of leukopenia and thrombocytopenia, nausea and vomiting, and pulmonary fibrosis; CNS, renal, and hepatic toxicity have been noted. b. Streptozocin can cause nausea and vomiting, renal toxicity, and hepatic toxicity. E. Triazine derivative (dacarbazine) 1. Drug actions a. Dacarbazine requires activation by the P-450 system of the liver to an alkylating agent. b. It acts as an alkylator, inhibiting DNA, RNA, and protein synthesis. In addition, a metabolite inhibits purine incorporation into DNA. 2. Indications for use include malignant Hodgkin disease and sarcoma. KAPUlf I medlea
121
Pharmacology
3. Side effects and toxicity. Severe nausea and vomiting are very common, and there is moderate myelosuppression. F. The ethylenimine derivative thiotepa (triethylene thiophosphoramide) is given by bladder installation for recurrent bladder carcinoma.
G. The methylmelamine derivative altretamine (formerly known as hexamethylmelamine) is used to treat advanced ovarian cancer after the failure of first-line approaches. H. Cisplatin and carboplatin are platinum coordination compounds. 1. Mechanism of action. These cause inter- and intrastrand DNA cross-linking. They dis-
rupt the DNA double helix and interfere with DNA synthesis. 2. Pharmacokinetics. There is no cell-cycle specificity and no CSF penetration. 3. Route of administration. It is administered intravenously. 4. Indications for use a. Cisplatin is used for testicular carcinoma (in combination with bleomycin and vinblastine) and for carcinomas of the ovaries and bladder. b. Cisplatin is used for bronchogenic carcinoma of the lung, especially small cell carcinoma. c. Carboplatin is less reactive than cisplatin, but they are similar for treating specific cancers. Carboplatin is an alternative for patients unable to tolerate cisplatin. It is also used in high-dose therapy with bone marrow or peripheral stem cell rescue.
5. Side effects and toxicity a. Acute side effects include intense nausea, vomiting, and anaphylactic reaction. b. Delayed side effects (1) There is a cumulative dose-related renal tubular damage, which can be mini-
mized by the use of large volumes of intravenous fluids and diuresis. (2) Ototoxicity, mild-to-moderate bone marrow depression, peripheral neuropathy, renal potassium, and magnesium wasting are other possible side effects. c. Carboplatin is relatively well tolerated with less nausea, neurotoxicity, ototoxicity, and nephrotoxicity than with cisplatin. The dose-limiting toxicity of carboplatin is myelosuppression.
1. Procarbazine 1. Drug actions
a. Procarbazine is a methylhydrazine derivative. b. It auto-oxidizes and produces hydrogen peroxide, which can lead to denaturation of DNA. c. Broken chromatids are observed after its use. It inhibits DNA, RNA, and protein synthesis.
d. It functions as an MAO inhibitor and can cross the blood-brain barrier. 2. Indications for use a. It is most useful in Hodgkin disease (as a component of the MOPP regimen). b. It is useful in primary brain tumors and small cell carcinoma of the lung.
122
meClical
Antineoplastic Agents
3. Side effects and toxicity a. Acute side effects include a disulfiram-like effect with tricyclics, sympathomimetics, and alcohol. It causes hypertension with tyramine-containing foods (MAO inhibitor). b. Delayed side effects include bone marrow suppression, CNS depression, neuropathy, pneumonitis, stomatitis, and induction of second malignancies.
ANTIMETABOLITES Antimetabolites resemble normal metabolites. They interfere with normal metabolic pathways by competing for enzymatic active sites. The antimetabolites are cell-cycle specific. A. Methotrexate (MTX) 1. Drug actions a. MTX is a folic acid analog. It inhibits dihydrofolate reductase, thereby blocking the conversion of folic acid to tetrahydrofolate (the active cofactor). The result is an inability of the cell to convert deoxyuridylate to thymidylate.1t blocks DNA, RNA, and protein synthesis and kills cells during the S phase. b. Leucovorin (formyltetrahydrofolic acid) bypasses the metabolic block by MTX. It is used to rescue normal cells from MTX toxicity.
In a Nutshell Leucovorin is used to "rescue" normal cells from MTX.
c. MTX is approximately 35% protein bound and is displaced by salicylates, sulfa drugs, and phenytoin. d. It is excreted in urine; higher doses can precipitate in renal tubules. 2. Routes of administration a. It can be administered orally, intravenously, intramuscularly, and intrathecally. b. It has poor CNS penetration and, for central action, may require intrathecal use or high-dose intravenous administration (with leucovorin rescue). 3. Indications for use a. It is used for maintenance therapy of childhood ALL. b. MTX is used for choriocarcinoma and other trophoblastic tumors, lymphomas, mycosis fungoides, carcinomas (breast, ovary, bladder, head, neck), and osteogenic sarcoma in high doses.
Note MTX is being investigated as a treatment for ectopic pregnancy.
c. The non-neoplastic conditions for which it is used include psoriasis, rheumatoid arthritis, and Wegener granulomatosis. 4. Side effects and toxicity a. Acute side effects include nausea, vomiting, and diarrhea. There is also bone marrow suppression and gastrointestinal ulceration of the mucosa. Renal toxicity occurs with high doses, and it is contraindicated in patients with compromised renal function. b. Delayed side effects. Hepatotoxicity occurs with long-term administration and can lead to cirrhosis. B. 5-Fluorouracil (5-FU) and floxuridine (fluorodeoxyuridine, FUdR)
1. Drug actions a. 5-FU is a pyrimidine analog.
IAP~~. I mvulca
121
Pharmacology
b. FUdR is the deoxyribonudeoside of 5-FU. c. 5-FU is enzymatically converted to FUdR and then converted to the active form, 5-
fluoro-2' -deoxyuridine-5' -phosphate (F-dUMP), which forms a complex with tetrahydrofolate to inhibit thymidylate synthetase. d. F-dUMP blocks conversion of deoxyuridylate to thymidylate, which is the ratelimiting step in DNA synthesis. It also affects RNA synthesis. e. Resistance develops by decreased activation of the drug and by increased inactivation. 2. Route of administration. They are administered parenterally and metabolized in the liver. Administration may be preceded by leucovorin to enhance F-dUMP formation. 3. Indications for use a. 5-FU is used for carcinoma of the breast (usually in combination with other agents). b. 5-FU is less useful for carcinoma of the ovary, cervix, bladder, prostate, pancreas, and gastrointestinal tract. c. 5-FU has topical uses against superficial basal cell carcinoma, actinic keratosis,
and psoriasis. d. FUdR is primarily used for metastatic carcinoma of the colon. 4. Side effects and toxicity include gastrointestinal disturbances (e.g., anorexia, nausea, stomatitis, diarrhea), myelosuppression, alopecia, dermatitis, and cerebellar ataxia. Its use with leucovorin increases gastrointestinal toxicity. C. Cytarabine (cytosine arabinoside, Ara-C) 1. Drug actions
a. Ara-C is a pyrimidine nucleoside analog (ribose replaced by arabinose) and is converted to nucleotide triphosphate by deoxycytidine kinase. b. Ara-C interrupts DNA synthesis and functions by inhibiting DNA polymerase and incorporating into the DNA or RNA of the cell. c. It is cell-cycle specific for the S phase. d. Resistance results from insufficient activation or from increased inactivation. 2. Routes of administration. It can be administered intravenously, intramuscularly, subcutaneously, or intrathecally. It cannot be administered orally. It is given intrathecally for CNS disease. 3. Indications for use a. Induction therapy AML with daunorubicin is successful in up to 75% of cases. b. It is less useful for induction therapy of ALL. c. It is used in combination with other drugs for treatment of lymphomas.
4. Side effects and toxicity a. Acute side effects include nausea, vomiting, and diarrhea. b. Delayed side effects include bone marrow suppression with megaloblastic changes, gastrointestinal upset, stomatitis, alopecia, and hepatotoxicity.
124
meclical
Antineoplastic Agents
D. Gemcitabine 1. Gemcitabine is a pyrimidine analog which, when converted to its nucleotide diphosphate,
inhibits DNA synthetic enzymes. The triphosphate form is incorporated into DNA to cause misreading during DNA replication. 2. Route of administration. It must be administered by intravenous infusion. 3. Indications for use. It is used primarily for palliative therapy of pancreatic carcinoma. 4. Side effects and toxicity a. Acute side effects include gastrointestinal effects and flu-like symptoms. b. It can cause shortness of breath, hypertension, stroke, cardiac arrhythmias, and hemorrhage. c. Delayed side effects include bone marrow suppression, which is generally the dose-
limiting toxicity. E. 6-Mercaptopurine (6-MP) 1. Drug actions
a. It is a purine analog (sulfhydryl-substituted analog of hypoxanthine). b. It is converted by hypoxanthine-guanine phosphoribosyltransferase (HGPRT) to 6-thioinosineS -phosphate (T-IMP). c. The formed T-IMP results in:
(1) Blocked conversion of IMP to AMP (2) Blocked oxidation of IMP to xanthosine monophosphate (XMP), subsequently toGMP (3) Pseudo feedback inhibition on the first committed step of purine biosynthesis (4) Incorporation into nucleic acids as a false base (5) Inhibition of purine nucleotide synthesis and metabolism and altered synthesis and function of RNA and DNA d. 6-MP is metabolized by xanthine oxidase to 6-thiouric acid. The action of xanthine oxidase is blocked by allopurinol; thus, the dose of 6-MP must be decreased if given with allopurinol. 2. Route of administration. It may be administered orally. 3. Indications for use include maintenance of remission in childhood ALL, often used with MTX. It is less useful in AML and CML and is not useful in CLL, lymphomas, or carcinomas. 4. Side effects and toxicity a. Acute side effects include infrequent nausea, vomiting, and diarrhea. b. Delayed side effects involve gradual bone marrow suppression and cholestatic jaundice in one-third of patients. F. 6-thioguanine (6-TG; amino analog of mercaptopurine)
1. Drug actions a. This purine analog is a sulfhydryl-substituted analog of guanine. b. It is converted by HGPRT to 6-thioguanosine-5-monophosphate (6-thio GMP).
meClical
125
Pharmacology
c. 6-thio GMP is converted by guanylate kinase to a triphosphate nucleotide. It is then gradually incorporated as a false base into nucleic acids. (1) 6-thio GMP inhibits inosinate dehydrogenase, which converts IMP to XMP and then to GMP. (2) There is a pseudofeedback inhibition on the first committed step of the purine biosynthesis. d. 6-TG affects purine nucleotide synthesis and metabolism. It alters RNA and DNA synthesis and function. 2. Route of administration. It is administered orally. The metabolism depends little on xanthine oxidase, and there is no dose reduction needed if it is given with allopurinol. 3. Indications for use. It is useful in induction therapy of AML (with Ara-C). 4. Side effects and toxicity are similar to 6-MP, but it causes less gastrointestinal upset. Bone marrow suppression, hepatotoxicity, and stomatitis occur. G. Pentostatin (2' -deoxycoformycin) 1. Drug actions
a. Pentostatin is an adenosine analog that inhibits adenosine deaminase. The inhibition results in the accumulation of deoxy-ATP, which inhibits ribonucleotide reductase via feedback inhibition. b. Reduced reductase activity leads to a decrease of other deoxynucleotides; thus, DNA synthesis and repair are diminished. c. Pentostatin inhibits methylation in RNA transcription; therefore, it is active in dividing and nondividing cells. 2. Indications for use include hairy cell leukemia, indolent non-Hodgkin lymphomas, and CLL. 3. Side effects and toxicity. Pentostatin is highly immunosuppressive. a. Moderate-dose side effects include fever, mild nausea, and rashes. b. High-dose side effects include renal failure, hepatic enzyme elevation, confusion, and coma. H. Fludarabine 1. An analog of adenine, fludarabine resists inactivation by adenosine deaminase and requires
phosphorylation for activation. 2. Indications for use include hairy cell leukemia. 3. Side effects and toxicity include diarrhea, nausea, vomiting, pain, pneumonia, skin rash, and excessive tiredness. It also causes anemia, leukopenia, and thrombocytopenia. I. Cladribine 1. Cladribine is an adenosine analog that is incorporated into DNA and impairs DNA repair.
Unlike most antimetabolites, it is not cell-cycle specific, i.e., it does not require active cell division to be cytotoxic. 2. Indications for use include hairy cell leukemia 3. Side effects and toxicity include skin rashes, fever, anorexia, nausea, vomiting, headache, and excessive tiredness. It also causes anemia, neutropenia, and cytopenia and elevates uric acid levels.
126
meclieal
Antineoplastic Agents
J. Agents related to purine analogs 1. Azathioprine is a precursor of mercaptopurine.
a. Indications for use. It is used as an immunosuppressive agent in organ transplants, Wegener granulomatosis, and related vasculitides. It is used in the treatment of autoimmune diseases (e.g., SLE and ITP). It is not useful as an antineoplastic agent. b. Side effects and toxicity. Leukopenia occurs with its use. The dosage must be decreased if it is used with allopurinol. 2. Allopurinol
a. Allopurinol is a hypoxanthine analog and an inhibitor of xanthine oxidase, which converts hypoxanthine to xanthine and then to uric acid.
b. Indications for use (1) It is used in the treatment of hyperuricemia and gout, but it is not used in an
acute gouty attack.
Note Allopurinol is useful in "tumor lysis syndrome."
(2) It is used during leukemia induction therapy or treatment of other malignancies with high tumor burdens where rapid cell lysis is expected to release large quantities of intracellular purines, which would otherwise be converted to uric acid and cause renal stones or failure.
PLANT DERIVATIVES A. Vinca alkaloids (vincristine, vinblastine, and vinorelbine) 1. Drug actions
a. The structures of the vinca alkaloids are similar. The methyl group in vinblastine is replaced by the aldehyde group in vincristine. They are both derived from the periwinkle plant. b. They bind to tubulin, a component of cellular micro tubules. This leads to disruption of the mitotic spindle apparatus and prevents segregation of chromosomes lined up in metaphase, producing metaphase arrest. c. It is cell-cycle specific for the M phase.
d. Vinca alkaloids are eliminated via the liver. There is increased toxicity in the presence of obstructive jaundice. Dosages should be decreased in patients with hepatic insufficiency. 2. Indications for use
a. Vincristine (Oncovin) is used for Hodgkin disease (as part of the MOPP regimen), induction of childhood ALL (with prednisone, the remission rate is 90%), lymphoma, sarcoma, eNS tumors, and Wilms tumor. b. Vinblastine is used for metastatic testicular tumors (with bleomycin and cisplatin), Hodgkin disease, lymphomas, Kaposi sarcoma, and Letterer-Siwe disease (histiocytosis X). c. Vinorelbine is used to treat non-small-celliung carcinoma. 3. Side effects and toxicity
a. Vincristine
(1) Acute side effects involve local reaction if extravasated. KAPLA~. I meulca
127
Pharmacology
In a Nutshell • Vincristine ~ neurotoxicity, low bone marrow toxicity • Vinblastine ~ bone marrow toxicity
(2) Delayed side effects include the following: There may be dose-limiting neurologic toxicity. It may produce slowly progressive sensorimotor peripheral neuropathy with paresthesias, loss of deep tendon reflexes, and muscle weakness, which may be reversible. Severe constipation, adynamic ileus (probably secondary to the autonomic neuropathy) and alopecia are also caused by vincristine. It has a minimal effect on bone marrow, which is unusual for a chemotherapeutic agent. b. Vinblastine (1) Acute side effects include mild nausea, vomiting, and phlebitis. (2) Delayed side effects include dose-limiting bone marrow suppression, especially of white blood cells, and neurologic toxicity with high doses. c. Vinorelbine (1) Acute side effects include anorexia, nausea, and vomiting. (2) Delayed side effects include bone marrow suppression, leading to granulocytopenia, anemia, or leukopenia. B. Podophyllotoxins: etoposide (VP-16) and teniposide (VM-26)
1. Drug actions a. Podophyllotoxins are semisynthetic glycosides that block cells at the S-G2 interface. At high doses, this can cause G2 arrest. b. The proposed mechanism of action is that it stimulates topoisomerase II to cause DNA cleavage. 2. Indications for use a. Etoposide is used for refractory testicular tumors (with cisplatin and bleomycin); small cell (oat cell) lung carcinoma (with cisplatin); and breast carcinoma, lymphomas, and Kaposi sarcoma. b. Teniposide is used for refractory ALL in children. 3. Side effects and toxicity include leukopenia (dose-limiting), nausea, vomiting, alopecia, and hypersensitivity. C. Taxanes: paditaxel (Taxol) and docetaxel
1. Drug actions a. Paclitaxel is derived from the bark of the Pacific yew tree. b. Docetaxel is a more potent analog of paclitaxel produced through side chain modification. c. Taxanes stabilize the mitotic apparatus by promoting microtubule assembly and preventing microtubule depolymerization. 2. Indications for use a. They are active against cisplatin-resistant ovarian cancer, metastatic breast cancer, malignant melanoma, and AML. b. They are used alone for breast cancer, and the activity approaches that of doxorubicin. 3. Side effects and toxicity a. Primary toxicity involves dose-dependent neutropenia after about 1 week.
128
meclical
Antineoplastic Agents
b. Hypersensitivity reactions include urticaria, bronchospasm, and hypotension. c. Mild sensory neuropathy, myalgias, and arthralgias may also occur.
ANTIBIOTIC ANTINEOPLASTIC AGENTS These antineoplastic antibiotics are all products of Streptomyces fungi. Their cytotoxic effect is secondary to their disruption of DNA functions. With the exception of bleomycin, these agents are not cell-cycle specific. A. Dactinomycin (actinomycin D) 1. Drug actions a. Dactinomycin was the first antibiotic used in cancer chemotherapy. b. It binds with double-stranded DNA and blocks the action of RNA polymerase, thereby inhibiting DNA transcription. c. It inhibits rapidly proliferating cells but has no cell-cycle specificity. d. Resistance results from decreased cellular uptakes. 2. Route of administration is intravenous. 3. Indications for use a. It is used for childhood tumors such as Wilms tumor (with vinblastine), rhabdomyosarcoma, Ewing sarcoma, and Kaposi sarcoma. b. Other indications include MTX-resistant choriocarcinoma and testicular carcinoma. 4. Side effects and toxicity a. Acute side effects include nausea, vomiting, and phlebitis. b. Delayed side effects include bone marrow suppression, alopecia, stomatitis, proctitis, and skin changes in areas exposed to radiation therapy. B. Anthracydine antibiotics: daunorubicin, doxorubicin (adriamycin), idarubicin, and mitoxantrone
1. Drug actions a. The structure of anthracycline antibiotics is characterized by tetracycline ring structures attached by glycoside linkage to daunosamine (sugar). These intercalate and bind to DNA between base pairs on adjacent strands, which results in uncoiling of the DNA helix. This destroys the DNA template and inhibits DNA-directed RNA and DNA polymerases. b. The maximum effect occurs during the S phase, but it is not cell-cycle specific. c. The chemical structure of the two agents differs by a single hydroxyl group. 2. Route of administration. It is usually administered intravenously, but it does not enter the CNS. 3. Indications for use a. Daunorubicin is used in ALL and for the acute phase of CML. It is the treatment of choice with Ara-C for AML, but it is not useful for solid tumors in adults.
meclical
129
Pharmacology
b. Doxorubicin has a wide utility, including lymphoma, ALL, Hodgkin, sarcoma, breast carcinoma, bladder carcinoma, small-cell carcinoma of lung, gastric and pancreatic carcinomas, as well as ovarian and bronchogenic carcinomas. c. Idarubicin is similar to daunorubicin and doxorubicin; it is used to treat AML. 4. Side effects and toxicity
In a Nutshell Cardiotoxicity is an important side effect of the "rubicins."
a. Acute side effects (both agents) include nausea, vomiting, red urine (not hematuria), tissue necrosis with extravasation, transient EKG changes (ST-T wave changes), and arrhythmias. b. Delayed side effects include bone marrow depression, alopecia, stomatitis, gastrointestinal upset, and cardiotoxicity. Cardiotoxicity is characterized by the following: ( 1) It is dose related and unresponsive to digitalis. (2) The effect can be delayed for months after treatment is complete. (3) The risk factors include previous radiation to the mediastinum and previous use of other anthracyclines or cyclophosphamide. (4) There are decreased incidences with lower weekly dosages, rather than larger dosages every 3 weeks. (5) The mechanism of action involves binding to cardiac DNA (structural similarity to glycosides), which also may damage myocardial membranes by release of free radicals. (6) Pathology includes nonspecific decrease in fibrils and mitochondrial changes. 5. Mitoxantrone is a synthetic anthracenedione analog of doxorubicin. It is effective for the treatment in breast cancer, non-Hodgkin lymphoma, and acute nonlymphocytic leukemias. It produces less cardiotoxicity than daunorubicin and doxorubicin. C. Bleomycin
1. Drug actions a. Bleomycin is a mixture of polypeptides; some contain sulfur, and others are glycoproteins. b. It introduces DNA chain-breaks and fragmentation (possibly mediated via chelation with ferrous ion). It may inhibit enzymes involved in DNA repair.
c. It causes in vitro accumulation of cells in the G2 phase. It is cell-cycle specific with major effects at the G2 and M phases of the cell cycle, and it may cause synchronization of tumor cells into the same phase of the cycle. 2. Indications for use a. Bleomycin is used in combination with other agents. It is very effective against testicular tumors. There is approximately 75% complete remission rate when given with vinblastine and cisplatin. b. It is useful for squamous-cell carcinoma of the head and neck, esophageal and genitourinary carcinomas, Hodgkin disease, and lymphoma. 3. Side effects and toxicity a. Acute side effects include nausea, vomiting, fever, and allergic reactions (including anaphylaxis). b. Delayed side effects include the following:
130
meclical
(1) Mucocutaneous reactions, including alopecia, stomatitis, hyperpigmentation, skin ulceration, and Raynaud phenomenon
Antineoplastic Agents
(2) Minimal bone marrow toxicity (3) Pulmonary toxicity is the most serious side effect and is dose limiting. It begins as nonspecific pneumonitis and can progress to pulmonary fibrosis. Risk factors include age over 70 years, underlying lung disease, higher doses, high inspired concentrations of oxygen, and prior concomitant radiation therapy to the thorax. D. Plicamycin (mithramycin)
1. Drug actions
a. Plicamycin affects DNA-dependent RNA synthesis through a mechanism similar to that of dactinomycin. b. A specific effect is to inhibit osteoclasts, thereby lowering Ca2+ concentration. 2. Indications for use include embryonal cell testicular carcinoma, hypercalcemia of malignancy, and possibly Paget disease of bone. 3. Side effects and toxicity.
a. Acute side effects include nausea, vomiting, and phlebitis. b. Delayed side effects include marked bone marrow suppression (especially platelets), hepatic and renal damage, and hemorrhagic diathesis (possibly as a result of impaired synthesis of clotting factors). E. Mitomycin 1. Drug actions
a. Mitomycin contains a quinone group that undergoes enzymatic reduction and results in a bifunctional alkylating agent. b. It cross-links DNA and inhibits DNA synthesis (acts as alkylating agent). It is most active during the G] and S phases. 2. Indications for use include palliative therapy of gastric carcinoma (with 5-FU and doxorubicin). It is used occasionally to treat carcinoma of the cervix, colon, rectum, and bladder. 3. Side effects and toxicity
a. Acute side effects include nausea and vomiting. b. Delayed side effects involve bone marrow suppression, alopecia, pulmonary fibrosis, and infiltrates. Renal and hepatic damage may occur at high doses. 4. Drug interaction. It increases doxorubicin's cardiotoxic effects.
HORMONAL THERAPY A. Glucocorticoid: prednisone 1. Physiologic effects (relative to antitumor effects) are to suppress mitosis in lymphocytes. 2. Indications for use
a. Prednisone is used in remission induction in ALL, for Hodgkin disease (as one component of the MOPP combination), lymphoma, CLL, myeloma, and breast carcinoma (works by suppressing adrenal estrogen production).
KAPLldlf • me leaI
131
Pharmacology
---- ---- -----------------
b. It reduces edema associated with brain or spinal cord metastases, primary CNS tumors, and tumors causing bronchial or ureteral obstruction. c. It is used before the initiation of radiation therapy to areas where initial edema would
be harmful (e.g., CNS). It can aid in symptomatic improvement (e.g., increase appetite, suppress fever). 3. Side effects and toxicity a. Acute side effects. Psychiatric disturbances, peptic ulceration, glucose intolerance hypokalemia, sodium retention, hypertension, edema, and increased susceptibility to infection may occur early in treatment. b. Delayed side effects. Osteoporosis, cataracts, myopathy, and avascular necrosis are more likely to occur after long-term use. B. Progestins: hydroxyprogesterone, medroxyprogesterone, and megestrol
1. Physiologic effects. Some tumors are thought to have growth enhanced by certain hormonal agents. The goal of therapy is to block the action of these hormones and suppress tumor growth.
2. Indications for use include metastatic endometrial carcinoma, prostate, breast, renal cell, and ovarian carcinomas. 3. Side effects and toxicity a. Hydroxyprogesterone. Side effects include hypercalcemia and cholestatic jaundice. b. Medroxyprogesterone. Side effects include fluid retention and hypercalcemia. c. Megestrol. Side effects include fluid retention and thromboembolism.
C. Androgens: fluoxymesterone and testosterone 1. Indications for use
a. Androgens are useful in pre- and postmenopausal women with estrogen receptorpositive breast carcinoma. They may be more useful for bone metastases than for visceral disease. b. The effect is delayed for several weeks. 2. Side effects and toxicity include masculinization, hypercalcemia, and fluid retention. D. Antiandrogens 1. Flutamide and bicalutamide a. Flutamide and bicalutamide are nonsteroidal antiandrogens that bind to androgen receptors and inhibit the translocation of the androgen receptor to the nucleus. b. Indications for use (1) The principal use of these agents is for advanced and metastatic prostate cancer,
usually with GnRH blockade or an estrogen. (2) An antiandrogen combined with a GnRH agonist, such as leuprolide, facilitates androgen blockade by also blocking the action of androgens produced in the adrenals. c. Side effects and toxicity (1) Side effects and toxicity include diarrhea, nausea, vomiting, and reversible liver function abnormalities.
132
meClical
Antineoplastic Agents
(2) These drugs can produce loss of sexual function, decreased libido, hot flashes, gynecomastia, and mastodynia. 2. Leuprolide and goserelin a. Leuprolide and goserelin are synthetic analogs of LH -RH. They suppress secretion of gonadotropin-releasing hormone, which in turn reduces the synthesis and release of testosterone. b. Indications for use. They are used primarily for treating prostatic carcinoma. The LH -RH analogs are usually combined with flutamide (or bicalutamide), thereby providing two different mechanisms for eliminating androgens. c. Side effects and toxicity (1) These agents produce side effects associated with low testosterone levels. (2) They cause anorexia, breast tenderness, edema, nausea, and vomiting. (3) They may produce various cardiovascular effects. (4) Goserelin can cause an initial flare of the disease due to an initial transient increase of testosterone caused by the agent. (5) Leuprolide may produce blurred vision, dizziness, headache, insomnia, and numbness of the hands and feet. E. Estrogens: ethinyl estradiol, diethylstilbestrol (DES), and estramustine l. Indications for use
a. Estrogens are useful in the palliation of advanced prostate carcinoma. Orchiectomy, removal of the androgen stimulation of the tumor, is sometimes done. They compete with androgens for their receptors. b. They may be useful in postmenopausal women but are contraindicated in patients with estrogen-receptor-positive breast carcinoma. 2. Specific agents include: a. Ethinyl estradiol and diethylstilbestrol (DES) b. Estramustine combines estradiol with a nitrogen mustard. It concentrates in estrogensensitive tissue. Toxicity is mainly that of the estrogen component because blood concentrations of the nitrogen mustard are minimal. 3. Side effects and toxicity a. Side effects include hypertension, which is secondary to fluid retention and increased production of renin substrate by the liver. b. Accelerated cardiovascular disease (dose dependent) and gynecomastia may occur. F. Antiestrogens l. Tamoxifen binds to estrogen receptors and blocks estrogen's growth effects on estrogen-
dependent tumors. It is also translocated into the nucleus where it binds to nuclear chromatin in an atypical manner. It may take weeks to become effective, but the genome is left refractory to estrogen stimulation for a period of time.
IIAPLA~. I meulca
133
Pharmacology
a. Indications for use (1) For breast carcinomas, response is usually best in estrogen-receptor-positive patients. (2) It may have an effect on prostatic and endometrial carcinomas. b. Side effects and toxicity ( 1) Side effects and toxicity include nausea, vomiting (usually mild), and hot flashes. (2) Pain at tumor sites or local flare of the disease is associated with a good response to tamoxifen. (3) Infrequently, hypercalcemia, edema, headache, and mild decrease in platelets and leukocytes occur. 2. Anastrozole inhibits aromatase to produce lower circulating estrogen levels. a. Indications for use. Anastrozole is used for treating breast carcinoma in postmenopausal women, generally after it has not responded to tamoxifen. b. Side effects and toxicity include: (1) Nausea, chest pain, edema, shortness of breath (2) Gastrointestinal tract and nervous system effects (3) Possibility of thromboembolism G. Aminoglutethimide 1. Drug actions a. Aminoglutethimide inhibits the conversion of cholesterol to pregnenolone, which results in a medical adrenalectomy caused by blockage of adrenal steroid production. b. Corticosteroid replacement therapy must be given concomitantly. 2. Indications for use include female patients with estrogen-receptor-positive breast carcinoma. It is also used in the treatment of Cushing syndrome and adrenocortical carcinoma. 3. Side effects and toxicity a. Acute side effects include lethargy, visual disturbances, and ataxia. b. Delayed side effects include hypothyroidism, bone marrow suppression, and masculinization.
BIOLOGIC RESPONSE MODIFIERS A. Interferons (recombinant interferon a-2a, a-2b, a-nl, a-n3). Interferons are proteins that are part of the body's defense system and generally impede cell proliferation. 1. Route of administration. Intramuscularly or subcutaneously
2. Indications for use. Interferons are used for treating hairy cell leukemia, genital warts, and Karposi sarcoma in patients with acquired immunodeficiency syndrome. 3. Side effects and toxicity a. Side effects include a flu-like syndrome, CNS and peripheral neurotoxicity, loss of appetite, diarrhea, nausea, vomiting, skin rash, and tiredness.
134
meCtical
Antineoplastic Agents
b. At higher doses, toxicities include neurotoxicity, gastrointestinal toxicity, and cardiovascular toxicity. B. Aldesleukin is recombinant interleukin-2 (IL-2). Interleukins are regulatory glycoproteins produced by lymphocytes. IL-2 binds to specific receptors to induce proliferation and differentiation of T helper cells and T cytotoxic cells. 1. Route of administration. Intravenous infusion or subcutaneous injection
2. Indications for use. IL-2 is used for treating metastatic melanoma and renal-cell carcinoma. 3. Side effects and toxicity include: a. Severe hypotension with life-threatening cardiovascular toxicity b. Pulmonary edema secondary to capillary leak syndrome c. Renal toxicity, hematologic toxicity, central nervous system toxicity, and skin toxicity with local inflammation
MISCELLANEOUS AGENTS A. L-Asparaginase 1. Drug actions a. This enzyme is produced by Escherichia coli and catalyzes the hydrolysis of asparagine. b. It deprives neoplastic cells of exogenously supplied L-asparagine and thereby interferes with their protein synthesis. Some neoplastic tissues, such as ALL cells, require an exogenous supply of this amino acid.
Note L-Asparaginase takes advantage of the dependence of ALL cells on exogenous asparagine.
2. Route of administration. It is administered parenterally. 3. Indications for use include induction therapy of ALL with prednisone and vincristine. It spares bone marrow and gastrointestinal mucosa, which is rare for an antineoplastic agent. 4. Side effects and toxicity a. Acute side effects include nausea, vomiting, abdominal pain, and hypersensitivity reactions. b. Delayed side effects involve hepatic and renal toxicity, pancreatitis, CNS effects (e.g., depression to coma), and alterations in the clotting mechanism, which results in thrombosis and, later, hemorrhage. B. Hydroxyurea 1. Drug actions a. Hydroxyurea is a hydroxylated urea compound. b. It interferes with ribonucleoside diphosphate reductase, which is responsible for the generation of the deoxyribonucleotides needed for DNA synthesis. e. It is S-phase specific.
2. Indications for use a. It is an alternative to busulfan in the treatment of CML. It is used in polycythemia vera and essential thrombocytosis. b. There is a reduction of dangerously high WBC counts in AML or CML (blast crisis).
meClical
135
Pharmacology
3. Side effects and toxicity
a. Acute side effects include gastrointestinal upset. b. Delayed side effects include bone marrow suppression (reversible), alopecia, and hyperpigmentation. C. Mitotane
1. Mitotane, an analog of the insecticides DDT and DDD, causes a selective destruction of normal and neoplastic adrenal cortical cells.
2. Indications for use include palliation of adrenal cortical tumors (i.e., it shrinks the tumor) and relief of symptoms of excess corticosteroids. 3. Side effects and toxicity a. Acute side effects include nausea and anorexia. b. Delayed side effects involve somnolence, dermatitis, adrenal insufficiency, and hemorrhagic cystitis. D. Topoisomerase I inhibitors: topotecan and irinotecan 1. These agents inhibit topoisomerase I to produce DNA strand breaks. 2. Indications for use
a. Topotecan is primarily used to treat ovarian carcinoma after first-line therapy fails. b. Irinotecan is primarily used to treat colorectal carcinoma after first-line drug failure. 3. Side effects and toxicity
a. These drugs can produce gastrointestinal effects, loss of hair, neutropenia, and weakness. b. Topotecan may cause tingling of the hands or feet and sores in the mouth. Neutropenia may be dose limiting. c. Irinotecan frequently produces anemia, leukopenia, and breathing difficulty.
136
meClical
SECTION V
Behavioral Sciences
The Basics of Behavioral Sciences Before discussing the many topics that constitute the Behavioral Sciences, we must first address the importance of the subject for the field of medicine and review some of the terms, definitions, and foundations upon which the specialty is based. This introductory chapter reviews basic topics and axioms and discusses the issues of medical interviewing and patient education.
RATIONALE FOR THE BEHAVIORAL SCIENCES In 1997, 7 of the 10 leading causes of death in individuals of all ages were either directly caused or significantly compounded by self-destructive and controllable behavior. In children between 1 and 4 years of age, the leading cause of death is accidents, and the third is homicide. In youth between 5 and 14 years of age, accidents are the leading cause of death, homicide is the third leading cause, and suicide is the fifth. In individuals 15-24 years of age, accidents are first, homicide is second, and suicide is third. These age-related causes of death have not changed significantly for at least a decade. Many people approach human behavior as if it is isolated from the study of the human body. This derives from the concept of the Mind-Body dichotomy that grew out of religious history. It held that the mind was the seat of the soul, and because the soul could not be sick, the mind could not be sick. The "Mind-Body" split is not a medical reality. Today we recognize that mind functioning has its base in brain activity. Much of the study of the behavior of humans has proceeded on the basis of observational data and therefore is based in statistical correlation. Although it is very tempting to view a correlation as a "cause-effect" statistic, it is not. A correlation must always be interpreted in three ways. If a and b are the two variables that are covarying, they must be interpreted as 1) a causes b; 2) b causes a; or 3) both a and b are related through a third variable c. For example, for many years it was noted that mothers of autistic children (now called pervasive developmental disorder) were cold, aloof, and very protective of their offspring. This was interpreted as a cause-effect relationship, where the mother's behavior caused the child to be autistic. However, further research has clearly demonstrated that the mother's behavior actually develops after the child's autism becomes apparent. Her aloof, emotionally cold approach to the child is all the emotion the child can tolerate; the overprotectiveness develops after the child's inability to care for himself becomes evident. Many of the issues in behavioral health are associated with the concept of prevention. However, you must keep in mind that there are different types of prevention: 1) preventing the negative event from ever occurring; 2) if it does occur it should be prevented from becoming a permanent condition, and the person should be returned to the predisturbance state; and 3) if neither the first nor second option is available, then the disturbance should be prevented from deteriorating any further. KAPLA~.
meulca
I
139
Behavioral Sciences
BEHAVIORAL SCIENCES GENERALIZATIONS A. Past behavior is the best predictor of future behavior. If a person has done something once, he is very likely to do the same thing again unless there has been significant intervention into their behavior pattern.
B. Most human behavior is multiply determined. It is a product of biology, genetics, learning, environment, etc. The contribution of each varies for each individual. C. Most human behavior is familial (not necessarily genetic). Behavior tends to run in families, but it is not necessarily genetically determined. For example, all members of a given family usually speak the same basic language. That is an example of a learned familial behavior; however, the fact that virtually all humans can learn to speak any language is an example of a species' genetically determined behavior.
D. Being poor is hazardous to your health. Poverty places significant limitations on access to health information and health care. The overall health of individuals with limited financial resources is negatively affected; their children may be compromised by that limitation. These children may be equally restricted in earning power by the compromise transmitted by the family. They, in turn, are further limited in their health care, and the downward spiral continues. E. Changing human behavior. Human beings have the ability to learn new information very rapidly. This learning can modify basic genetically programmed behavior (e.g., sexual drive). There are two basic principles of changing human behavior: 1. If you want the behavior to reoccur, reward it. For example, if you want an obscene
telephone caller to continue to bother you, then yell, blow a whistle into the telephone receiver, slam the phone down, etc. You